var title_f3_62_4064="Med bronchogen cyst CT III";
var content_f3_62_4064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan displays a non-enhancing right paratracheal mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Spark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4064=[""].join("\n");
var outline_f3_62_4064=null;
var title_f3_62_4065="47 XXY in Klinefelter syndrome";
var content_f3_62_4065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chromosome analysis in Klinefelter syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A photograph of the 47 chromosomes of a man with Klinefelter syndrome. This patient has an extra X chromosome (47 XXY) (shaded area).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4065=[""].join("\n");
var outline_f3_62_4065=null;
var title_f3_62_4066="Insulin processing in beta cell";
var content_f3_62_4066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Processing of insulin within the beta cell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Insulin is synthesized as preproinsulin in the ribosomes of the rough endoplasmic reticulum. The preproinsulin is then cleaved to proinsulin, which is transported to the Golgi apparatus where it is packaged into secretory granules located close to the cell membrane. Most of the proinsulin is cleaved into equimolar amounts of insulin and C peptide in the secretory granules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David K McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4066=[""].join("\n");
var outline_f3_62_4066=null;
var title_f3_62_4067="Core components rehab A";
var content_f3_62_4067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60257%7ECARD%2F73513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60257%7ECARD%2F73513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Core components of cardiac rehabilitation/secondary prevention programs: Patient assessment, nutritional counseling, and weight management",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medical history: Review current and prior cardiovascular medical and surgical diagnoses and procedures (including assessment of left ventricular function); comorbidities (including peripheral arterial disease, cerebral vascular disease, pulmonary disease, kidney disease, diabetes mellitus, musculoskeletal and neuromuscular disorders, depression, and other pertinent diseases); symptoms of cardiovascular disease; medications (including dose, frequency, and compliance); date of most recent influenza vaccination; cardiovascular risk profile; and educational barriers and preferences. Refer to each core component of care for relevant assessment measures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Physical examination: Assess cardiopulmonary systems (including pulse rate and regularity, blood pressure, auscultation of heart and lungs, palpation and inspection of lower extremities for edema and presence of arterial pulses); post-cardiovascular procedure wound sites; orthopedic and neuromuscular status; and cognitive function. Refer to each core component for respective additional physical measures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Testing: Obtain resting 12-lead ECG; assess patient's perceived health-related quality of life or health status. Refer to each core component for additional specified tests.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Document the patient assessment information that reflects the patient's current status and guides the development and implementation of (1) a patient treatment plan that prioritizes goals and outlines intervention strategies for risk reduction, and (2) a discharge/follow-up plan that reflects progress toward goals and guides long-term secondary prevention plans.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interactively, communicate the treatment and follow-up plans with the patient and appropriate family members/domestic partners in collaboration with the primary healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In concert with the primary care provider and/or cardiologist, ensure that the patient is taking appropriate doses of aspirin, clopidogrel,",
"        <sub>",
"         &beta;",
"        </sub>",
"        -blockers, lipid-lowering agents, and ACE inhibitors or angiotensin receptor blockers as per the ACC/AHA, and that the patient has had an annual influenza vaccination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient treatment plan: Documented evidence of patient assessment and priority short-term (ie, weeks-months) goals within the core components of care that guide intervention strategies. Discussion and provision of the initial and follow-up plans to the patient in collaboration with the primary healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Outcome report: Documented evidence of patient outcomes within the core components of care that reflects progress toward goals, including whether the patient is taking appropriate doses of aspirin, clopidogrel,",
"        <sub>",
"         &beta;",
"        </sub>",
"        -blockers, and ACE inhibitors or angiotensin receptor blockers as per the ACC/AHA, and whether the patient has had an annual influenza vaccination (and if not, documented evidence for why not), and identifies specific areas that require further intervention and monitoring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discharge plan: Documented discharge plan summarizing long-term goals and strategies for success.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nutritional counseling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obtain estimates of total daily caloric intake and dietary content of saturated fat, trans fat, cholesterol, sodium, and nutrients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess eating habits, including fruit and vegetable, whole grain, and fish consumption; number of meals and snacks; frequency of dining out; and alcohol consumption.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Determine target areas for nutrition intervention as outlined in the core components of weight, hypertension, diabetes, as well as heart failure, kidney disease, and other comorbidities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prescribe specific dietary modifications aiming to at least attain the saturated fat and cholesterol content limits of the Therapeutic Lifestyle Change diet. Individualize diet plan according to specific target areas as outlined in the core components of weight, hypertension, and diabetes (as outlined in this table), as well as heart failure and other comorbidities. Recommendations should be sensitive and relevant to cultural preferences.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Educate and counsel patient (and appropriate family members/domestic partners) on dietary goals and how to attain them.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Incorporate behavior change models and compliance strategies into counseling sessions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient adheres to prescribed diet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient understands basic principles of dietary content, such as calories, fat, cholesterol, and nutrients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A plan has been provided to address eating behavior problems.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Weight management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measure weight, height, and waist circumference. Calculate body mass index (BMI).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        In patients with BMI &gt;25 kg/m",
"        <sup>",
"         2",
"        </sup>",
"        and/or waist &gt;40 inches in men (102 cm) and &gt;35 inches (88 cm) in women*:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Establish reasonable short-term and long-term weight goals individualized to the patient and his or her associated risk factors (eg, reduce body weight by at least 5 percent and preferably by &gt;10 percent at a rate of 1 to 2 lb/wk over a period of time up to sixmonths).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Develop a combined diet, physical activity/exercise, and behavioral program designed to reduce total caloric intake, maintain appropriate intake of nutrients and fiber, and increase energy expenditure. The exercise component should strive to include daily, longer distance/duration walking (eg, 60 to 90 minutes).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Aim for an energy deficit tailored to achieve weight goals (eg, 500 to 1000 kcal/day).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Short-term: Continue to assess and modify interventions until progressive weight loss is achieved. Provide referral to specialized, validated nutrition weight loss programs if weight goals are not achieved.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-term: Patient adheres to diet and physical activity/exercise program aimed toward attainment of established weight goal.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * BMI definitions for overweight and obesity may differ by race/ethnicity and region of the world. Relevant definitions, when available, should be respectively applied.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Balady GJ, Williams MA, Ades PA, et al.&nbsp;Circulation 2007;115:2675. Copyright 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Core components of cardiac rehabilitation/secondary prevention programs: Blood pressure management, lipid management, diabetes management, tobacco cessation, psychosocial management, physical activity counseling, and exercise training",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Blood pressure management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measure seated resting blood pressure on &ge;two visits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measure blood pressure in both arms at program entry.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        To rule out orthostatic hypotension, measure lying, seated, and standing blood pressure at program entry and after adjustments in antihypertensive drug therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess current treatment and compliance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess use of nonprescription drugs that may adversely affect blood pressure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide and/or monitor drug therapy in concert with primary healthcare provider as follows:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        If blood pressure is 120 to 139 mmHg systolic or 80 to 89 mmHg diastolic:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Provide lifestyle modifications, including regular physical activity/exercise; weight management; moderate sodium restriction and increased consumption of fresh fruits, vegetables, and low-fat dairy products; alcohol moderation; and smoking cessation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Provide drug therapy for patients with chronic kidney disease, heart failure, or diabetes if blood pressure is &ge;130 / &ge;80 mmHg after lifestyle modification.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        If blood pressure is &ge;140 mmHg systolic or &ge;90 mmHg diastolic:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Provide lifestyle modification and drug therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Short-term: Continue to assess and modify intervention until normalization of blood pressure in prehypertensive patients; &lt;140 mmHg systolic and &lt;90 mmHg diastolic in hypertensive patients; &lt;130 mmHg systolic and &lt;80 mmHg diastolic in hypertensive patients with diabetes, heart failure, or chronic kidney disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-term: Maintain blood pressure at goal levels.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lipid management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obtain fasting measures of total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. In those patients with abnormal levels, obtain a detailed history to determine whether diet, drug, and/or other conditions that may affect lipid levels can be altered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess current treatment and compliance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Repeat lipid profiles at&nbsp;four to six&nbsp;weeks after hospitalization and at two months after initiation or change in lipid-lowering medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess creatine kinase levels and liver function in patients taking lipid-lowering medications as recommended by NCEP.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide nutritional counseling consistent with the Therapeutic Lifestyle Change diet, such as the recommendation to add plant stanol/sterols and viscous fiber and the encouragement to consume more omega-3 fatty acids, as well as weight management counseling, as needed, in all patients. Add or intensify drug treatment in those with low-density lipoprotein &gt;100 mg/dL; consider adding drug treatment in those with low-density lipoprotein &gt;70 mg/dL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide interventions directed toward management of triglycerides to attain non-high-density lipoprotein cholesterol &lt;130 mg/dL. These include nutritional counseling and weight management, exercise, smoking cessation, alcohol moderation, and drug therapy as per NCEP and AHA/ACC.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide and/or monitor drug treatment in concert with primary healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Short-term: Continue to assess and modify intervention until low-density lipoprotein is &lt;100 mg/dL (further reduction to a goal &lt;70 mg/dL is considered reasonable) and non-high-density lipoprotein cholesterol &lt;130 mg/dL (further reduction to a goal of &lt;100 mg/dL is considered reasonable).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-term: Low-density lipoprotein cholesterol &lt;100 mg/dL (further reduction to a goal &lt;70 mg/dL is considered reasonable). Non-high-density lipoprotein cholesterol &lt;130 mg/dL (further reduction to a goal of &lt;100 mg/dL is considered reasonable).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diabetes management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        From medical record review:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Confirm presence or absence of diabetes in all patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; If a patient is known to be diabetic, identify history of complications such as findings related to heart disease; vascular disease; problems with eyes, kidneys, or feet; or autonomic or peripheral neuropathy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        From initial patient interview:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Obtain history of signs/symptoms related to above complications and/or reports of episodes of hypoglycemia or hyperglycemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Identify physician managing diabetic condition and prescribed treatment regimen, including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        - Medications and extent of compliance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        - Diet and extent of compliance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        - Blood sugar monitoring method and extent of compliance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Before starting exercise:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Obtain latest fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Consider stratifying patient to high-risk category because of the greater likelihood of exercise-induced complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Educate patient and staff to be alert for signs/symptoms of hypoglycemia or hyperglycemia and provide appropriate assessment and interventions as per the American Diabetes Association.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        In those taking insulin or insulin secretogogues:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Avoid exercise at peak insulin times.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Advise that insulin be injected in abdomen, not muscle to be exercised.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Test blood sugar levels pre- and post-exercise at each session: if blood sugar value is &lt;100 mg/dL, delay exercise and provide patient 15 g of carbohydrate; retest in 15 minutes; proceed if blood sugar value is &gt;100 mg/dL; if blood sugar value is &gt;300 mg/dL, patient may exercise if he or she feels well, is adequately hydrated, and blood and/or urine ketones are negative; otherwise, contact patient's physician for further treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Encourage adequate hydration to avoid effects of fluid shifts on blood sugar levels.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Caution patient that blood sugar may continue to drop for 24 to 48 hours after exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In those treated with diet, metformin, alpha glucosidase inhibitors, and/or thiozolidinediones, without insulin or insulin secretogogues, test blood sugar levels prior to exercise for first 6 to 10 sessions to assess glycemic control; exercise is generally unlikely to cause hypoglycemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Education recommendations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Teach and practice self-monitoring skills for use during unsupervised exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Refer to registered dietitian for medical nutrition therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Consider referral to certified diabetic educator for skill training, medication instruction, and support groups.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Short-term:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Communicate with primary physician or endocrinologist about signs/symptoms and medication adjustments.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Confirm patient's ability to recognize signs/symptoms, self-monitor blood sugar status, and self-manage activities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Long-term:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Attain FPG levels of 90 to 130 mg/dL and HbA1c &lt;7 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Minimize complications and reduce episodes of hypoglycemia or hyperglycemia at rest and/or with exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Maintain blood pressure at &lt;130 / &lt;80 mmHg.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tobacco cessation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Initial encounter:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Ask the patient about his or her smoking status and use of other tobacco products. Document status as never smoked, former smoker, current smoker (includes those who have quit in the last 12 months because of the high probability of relapse). Specify both amount of smoking (cigarettes per day) and duration of smoking (number of years). Quantify use and type of other tobacco products. Question exposure to second-hand smoke at home and at work.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Determine readiness to change by asking every smoker/tobacco user if he or she is now ready to quit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Assess for psychosocial factors that may impede success.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Ongoing contact: Update status at each visit during first&nbsp;two weeks of cessation, periodically thereafter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        When readiness to change is not expressed, provide a brief motivational message containing the \"5 Rs\": Relevance, Risks, Rewards, Roadblocks, and Repetition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        When readiness to change is confirmed, continue with the \"5 As\": Ask, Advise, Assess, Assist, and Arrange. Assist the smoker/tobacco user to set a quit date, and select appropriate treatment strategies (preparation):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        <em>",
"         Minimal (brief)",
"        </em>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Individual education and counseling by program staff supplemented by self-teaching materials.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Social support provided by physician, program staff, family and/or domestic partner; identify other smokers in the house; discuss how to engage them in the patient's cessation efforts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Relapse prevention: problem solving, anticipated threats, practice scenarios.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        <em>",
"         Optimal (intense)",
"        </em>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Longer individual counseling or group involvement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Pharmacological support (in concert with primary physician): nicotine replacement therapy, bupropion hydrochloride.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Supplemental strategies if desired (eg, acupuncture, hypnosis).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If patient has recently quit, emphasize relapse prevention skills.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urge avoidance of exposure to second-hand smoke at work and home.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Note: Patients who continue to smoke upon enrollment are subsequently more likely to drop out of cardiac rehabilitation/secondary prevention programs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Short-term: Patient will demonstrate readiness to change by initially expressing decision to quit and selecting a quit date. Subsequently, patient will quit smoking and all tobacco use and adhere to pharmacological therapy (if prescribed) while practicing relapse prevention strategies; patient will resume cessation plan as quickly as possible when temporary relapse occurs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-term: Complete abstinence from smoking and use of all tobacco products for at least 12 months (maintenance) from quit date. No exposure to environmental tobacco smoke at work and home.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychosocial management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Identify psychological distress as indicated by clinically significant levels of depression, anxiety, anger or hostility, social isolation, marital/family distress, sexual dysfunction/adjustment, and substance abuse (alcohol or other psychotropic agents), using interview and/or standardized measurement tools.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Identify use of psychotropic medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Offer individual and/or small group education and counseling on adjustment to heart disease, stress management, and health-related lifestyle change. When possible, include family members, domestic partners, and/or significant others in such sessions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Develop supportive rehabilitation environment and community resources to enhance the patient's and the family's level of social support.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Teach and support self-help strategies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In concert with primary healthcare provider, refer patients experiencing clinically significant psychosocial distress to appropriate mental health specialists for further evaluation and treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Emotional well-being is indicated by the absence of clinically significant psychological distress, social isolation, or drug dependency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient demonstrates responsibility for health-related behavior change, relaxation, and other stress management skills; ability to obtain effective social support; compliance with psychotropic medications if prescribed; and reduction or elimination of alcohol, tobacco, caffeine, or other nonprescription psychoactive drugs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrange for ongoing management if important psychosocial issues are present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical activity counseling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess current physical activity level (eg, questionnaire, pedometer) and determine domestic, occupational, and recreational needs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Evaluate activities relevant to age, gender, and daily life, such as driving, sexual activity, sports, gardening, and household tasks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess readiness to change behavior, self-confidence, barriers to increased physical activity, and social support in making positive changes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide advice, support, and counseling about physical activity needs on initial evaluation and in follow-up. Target exercise program to meet individual needs (see Exercise Training section of table). Provide educational materials as part of counseling efforts. Consider exercise tolerance or simulated work testing for patients with heavy labor jobs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Consistently encourage patients to accumulate 30 to 60 minutes per day of moderate-intensity physical activity on &ge;5 (preferably most) days of the week. Explore daily schedules to suggest how to incorporate increased activity into usual routine (eg, parking farther away from entrances, walking &ge;2 flights of stairs, and walking during lunch break).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Advise low-impact aerobic activity to minimize risk of musculoskeletal injury. Recommend gradual increases in the volume of physical activity over time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caution patients to avoid performing unaccustomed vigorous physical activity (eg, racquet sports and manual snow removal). Reassess the patient's ability to perform such activities as exercise training program progresses.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient shows increased participation in domestic, occupational, and recreational activities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient shows improved psychosocial well-being, reduction in stress, facilitation of functional independence, prevention of disability, and enhancement of opportunities for independent self-care to achieve recommended goals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient shows improved aerobic fitness and body composition and lessens coronary risk factors (particularly for the sedentary patient who has adopted a lifestyle approach to regular physical activity).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Exercise training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Symptom-limited exercise testing prior to participation in an exercise-based cardiac rehabilitation program is strongly recommended. The evaluation may be repeated as changes in clinical condition warrant. Test parameters should include assessment of heart rate and rhythm, signs, symptoms, ST-segment changes, hemodynamics, perceived exertion, and exercise capacity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        On the basis of patient assessment and the exercise test if performed, risk stratify the patient to determine the level of supervision and monitoring required during exercise training. Use risk stratification schema as recommended by the AHA and the AACVPR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Develop an individualized exercise prescription for aerobic and resistance training that is based on evaluation findings, risk stratification, comorbidities (eg, peripheral arterial disease and musculoskeletal conditions), and patient and program goals. The exercise regimen should be reviewed by the program medical director or referring physician, modified if necessary, and approved. Exercise prescription should specify frequency (F), intensity (I), duration (D), modalities (M), and progression (P).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; For aerobic exercise: F=3-5 days/wk; I=50-80 percent of exercise capacity; D=20-60 minutes; and M=walking, treadmill, cycling, rowing, stair climbing, arm/leg ergometry, and others using continuous or interval training as appropriate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; For resistance exercise: F=2-3 days/wk; I=10-15 repetitions per set to moderate fatigue; D=1-3 sets of 8-10 different upper and lower body exercises; and M=calisthenics, elastic bands, cuff/hand weights, dumbbells, free weights, wall pulleys, or weight machines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Include warm-up, cool-down, and flexibility exercises in each exercise session.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide progressive updates to the exercise prescription and modify further if clinical status changes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Supplement the formal exercise regimen with activity guidelines as outlined in the Physical Activity Counseling section of this table.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient understands safety issues during exercise, including warning signs/symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient achieves increased cardiorespiratory fitness and enhanced flexibility, muscular endurance, and strength.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient achieves reduced symptoms, attenuated physiologic responses to physical challenges, and improved psychosocial well-being.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient achieves reduced global cardiovascular risk and mortality resulting from an overall program of cardiac rehabilitation/secondary prevention that includes exercise training.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Balady GJ, Williams MA, Ades PA, et al. Circulation 2007;115:2675. Copyright 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4067=[""].join("\n");
var outline_f3_62_4067=null;
var title_f3_62_4068="Pyrantel pamoate: Drug information";
var content_f3_62_4068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyrantel pamoate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/4/3140?source=see_link\">",
"    see \"Pyrantel pamoate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/49/10003?source=see_link\">",
"    see \"Pyrantel pamoate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pin-X&reg; [OTC];",
"     </li>",
"     <li>",
"      Reese's Pinworm Medicine [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Combantrin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anthelmintic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose is expressed as pyrantel base; not preferred therapy since newer treatments are available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Enterobius vermicularis",
"      </i>",
"      (pinworm):",
"     </b>",
"     11 mg/kg administered as a single dose; maximum: 1 g/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Ancylostoma caninum",
"      </i>",
"      (hookworm) (unlabeled use):",
"     </b>",
"     11 mg/kg (maximum: 1 g/dose) administered once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Ancylostoma duodenale",
"      </i>",
"      (hookworm),",
"      <i>",
"       Ascariasis lumbricoides",
"      </i>",
"      (roundworm),",
"      <i>",
"       Necator americanus",
"      </i>",
"      (hookworm) (unlabeled use):",
"     </b>",
"     11 mg/kg (maximum: 1 g/dose) administered once daily for 3 days (Kappagoda, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Moniliformis",
"      </i>",
"      (unlabeled use):",
"     </b>",
"     11 mg/kg administered as a single dose; repeat twice 2 weeks apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Trichostrongylus",
"      </i>",
"      (unlabeled use):",
"     </b>",
"     11 mg/kg administered as a single dose; maximum: 1 g/dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/49/10003?source=see_link\">",
"      see \"Pyrantel pamoate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as pamoate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pin-X&reg;: 144 mg/mL (30 mL, 60 mL) [sugar free; contains sodium benzoate; caramel flavor; equivalent to pyrantel base 50 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reese's Pinworm Medicine: 144 mg/mL (30 mL, 60 mL, 240 mL) [equivalent to pyrantel base 50 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as pamoate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pin-X&reg;: 720.5 mg [scored; contains aspartame; equivalent to pyrantel base 250 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F215688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be mixed with milk or fruit juice. May be administered without regard to meals. Purgation is not required prior to, during, or after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Shake well before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Chewable tablet must be chewed thoroughly before swallowing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pinworms caused by",
"     <i>",
"      Enterobius vermicularis",
"     </i>",
"     (alternative agent; not preferred therapy)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F215723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hookworms caused by",
"     <i>",
"      Ancylostoma caninum, Ancylostoma duodenale,",
"     </i>",
"     and",
"     <i>",
"      Necator americanus",
"     </i>",
"     );",
"     <i>",
"      Moniliformis;",
"     </i>",
"     roundworms caused by",
"     <i>",
"      Ascaris lumbricoides",
"     </i>",
"     ;",
"     <i>",
"      Trichostrongylus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrantel pamoate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspartame: Some products may contain aspartame.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium benzoate: Some products may contain sodium benzoate; may cause allergic reactions in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Household contacts: Since pinworm infections are easily spread to others, treat all family members in close contact with the patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication, patients should be instructed to contact healthcare provider if symptoms or pinworm infection persists after treatment or if any worms other than pinworms are present before or after treatment. Patients should not repeat dose unless directed to do so by their  healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13761484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyrantel pamoate has minimal systemic absorption. Systemic absorption would be required in order for pyrantel pamoate to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13761493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Pin-X Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     720.5 mg (12): $13.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Pin-X Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (30 mL): $8.61",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F215684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stool for presence of eggs, worms, and occult blood",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anthel (AU, TW);",
"     </li>",
"     <li>",
"      Anthelmin (PK);",
"     </li>",
"     <li>",
"      Ascarical (BR);",
"     </li>",
"     <li>",
"      Aut (AR);",
"     </li>",
"     <li>",
"      Bearantel (SG);",
"     </li>",
"     <li>",
"      Bifantrel (CO);",
"     </li>",
"     <li>",
"      Combantril (CH);",
"     </li>",
"     <li>",
"      Combantrin (AT, BG, CN, CO, EC, FR, GB, GR, IT, NZ, PE, PH, PT, VE, ZA);",
"     </li>",
"     <li>",
"      Early Bird (AU);",
"     </li>",
"     <li>",
"      Finoxal (CO);",
"     </li>",
"     <li>",
"      Gelminthic (PH);",
"     </li>",
"     <li>",
"      Helmex (DE);",
"     </li>",
"     <li>",
"      Helmintox (FR, RU);",
"     </li>",
"     <li>",
"      Kontil (TR);",
"     </li>",
"     <li>",
"      Nemocid (IN);",
"     </li>",
"     <li>",
"      Pirantelina (PY);",
"     </li>",
"     <li>",
"      Pyrantelum (PL);",
"     </li>",
"     <li>",
"      Pyrapam (TH);",
"     </li>",
"     <li>",
"      Quantrel (VE);",
"     </li>",
"     <li>",
"      Trilombrin (EC, ES);",
"     </li>",
"     <li>",
"      Upixon (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes the release of acetylcholine and inhibits cholinesterase; acts as a depolarizing neuromuscular blocker, paralyzing the helminths",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (&gt;50% as unchanged drug); urine (7% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bethony J, Brooker S, Albonico M, et al, \"Soil-Transmitted Helminth Infections:",
"      <i>",
"       Ascariasis, Trichuriasis",
"      </i>",
"      , and Hookworm,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9521):1521-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/62/4068/abstract-text/16679166/pubmed\" id=\"16679166\" target=\"_blank\">",
"        16679166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1017):1-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/62/4068/abstract-text/9442765/pubmed\" id=\"9442765\" target=\"_blank\">",
"        9442765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kappagoda S, Singh U, and Blackburn BG, \"Antiparasitic Therapy,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      2011, 86(6):561-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/62/4068/abstract-text/21628620/pubmed\" id=\"21628620\" target=\"_blank\">",
"        21628620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keiser J and Utzinger J, \"Efficacy of Current Drugs Against Soil-Transmitted Helminth Infections: Systematic Review and Meta-Analysis,\" JAMA, 2008, 299(16):1937-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/62/4068/abstract-text/18430913/pubmed\" id=\"18430913\" target=\"_blank\">",
"        18430913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kunst H, Mack D, Kon OM, et al, \"Parasitic Infections of the Lung: A Guide for the Respiratory Physician,\"",
"      <i>",
"       Thorax",
"      </i>",
"      ,  2011, 66(6):528-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/62/4068/abstract-text/20880867/pubmed\" id=\"20880867\" target=\"_blank\">",
"        20880867",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9835 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-346F7DA307-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4068=[""].join("\n");
var outline_f3_62_4068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215700\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215726\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215703\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215714\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215704\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215686\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215671\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215688\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215687\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215723\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215724\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215691\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215675\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299963\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215680\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13761484\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13761493\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323760\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215684\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038792\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215674\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215690\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9835\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9835|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/4/3140?source=related_link\">",
"      Pyrantel pamoate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/49/10003?source=related_link\">",
"      Pyrantel pamoate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_62_4069="Sappinia trophozoites";
var content_f3_62_4069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sappinia trophozoites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 299px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAErASwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0lml2C7TNwSgEiKNwQ9h7dT+VJDJOrM0pkYyZTGwEkduaLOaJZJtxfa6gMvJ3Ht06Gr2ivBDdzZYKqjKPKxUEj0Pc9q+rk+VPQ+rlPli7IzLlDBawErJHIF5DqcHaeTmopFnW4ihixK+4Od3yt1GOD+dWNQnlvW24JaPcY442zgdT161BY3c1sG1D7s8MZ4deV9V/CtY83Lfr/VjWPO4XW+o/xgBbWzOkjuJ0k3uijMTHjb7Gvnjxxc38mt6Ha6NeeS0SBEYSYYBjn5iMdq9H8TXE93df8fE7xOQWWHJKuW447++a0fDvhuzinW51i3SS4cbyojVxCM9FzwTnnPYnHSt1BU6PK3qclWhVq/u27JdfL5EHw/spDHHMkS7II/s+8ZCtzkvz3zXe6tcJGFht2KPGoVw/JJxnP61AMRl4I5xLHyYty43egIHGarX1yRLIkqh9w+ZV5Y4HOAOTWUv3k0+x6FKly2XRDtHVhYhk2mR2JDAYLKBnr35qQSNdO0065mZC+zbxkDJ4/CoZoJbeG2SOH9w6KwKtyCx+6f7v0rQdRZTSCCRWl3FFbGRjuR/KlJq91uypSje8d2Z9pIkwi8t4RJu3Ljjn19vpU8+3zZDu3Eyb2dm6jvjP0q3aG322xz5SMxD7I8spHT6mocF2Cz/NhiT8v4Y+vNTze8T7X3n0sNnMxhaC2KNECWdZOSqnkAeuf0qWONAWGwRBcM6hvlAx09j9a0bGxdi5uP3bdFKLjg9frzSyQCDdaSgxIzq/UZXsecHPrzWLqr4Uckqy2RRsUWO1aeVSqK5dNvOV9PzrQecyNNIl5BHFMAqgLzICOc/Ss27DQyiPc7NFnhuC2e+ehpk2bSSKK58nzZV/c+YQhIAz8o7nHWiUVJ8ze/8AXUJxU/ebNOMQ2Uk8cTu5UjaXO1Bnpg+tMaCa5kKNuZ1OAy8rz71FDaNcQylWWcFg7bjtGO3NXrfTLt9PubuBmjuE5WNCPu+/r06VnKShq3qYTaprcozxFrnyZZAZpARhTwvoCfpUcFiYbZyXJSJcyHOSCKlmnDoyRwpcPISHYptVeQMH1NV7SdEeZJwEyCDtHyEDjnt26VoublNITk1ypk86edaQQXU23cuUyvQdcnHerSahKNImZHUmBdwd1wWXBz+mDVXUpfs+jL5SvLGVyG6c/wCH/wCqqthe77K5k24ZVwysM+YD39B6UuTnje2lxODkrtaEd1I9vI10wSLTTCoERBEkkvZ92eF7YqhceII7ZodksyTzhWljA+69cP4y1aZ7mO3t5j9kAAwsm4cc4NdlougG9sIdRiuPtTGHcIFUCSI+vv1ruVOlTjeqzCcnF8sX95k6ncz3UczOZlJcuzM2NxAxyfTpVqzW4VIZLtRPC0Y8xkjIIBGDgnqBxzWlOkWo2i2/k7LdAWkYjDOF4br3qSPz/tiqZ5FTy8Eb8oyZ4H1+laOrpZKx6FCm1uzNFx9otNpR5VCksS2QCONxq4j3K2vm7EkSMAEA9R0z6ipLwQRvN9h8uF0GyWZCTk55AB4J96r2FvcPB/aK4S2YtZqcgvMeu76dRx3rNyTV7WO1Vo2XS5ckv51twgdCu0qccj8PQiol32/kSqVEKKACTkqe+R+NQWRidyj5ONo2Ec9e/p0rRd0V3mRAOdoT0Hf61DtHRI0lGMHZIqFzLibzPlxt+QcH8f6U2QB45Q5yzYVVbgN/k1JuUuqKu2AH5U3YC/hUe/zCSy87tu4jrVotLQmjaZpWXf1A3qvQgfypu0zL56r5aqd+9R1PpTo4nVmRVJYjLLwCxpPLXHlrwD1UcY/Gp0voTZX0EZi/ykbVK8gHnmh5VigI3fID8vy8AH1qYZJJGNv97+9ikkixuk8vKnuPT0outguthyEoUXKo2D9BR9muz89qQIW5Urj5vfkU2Nd+6QDLKANxBFWPtc0oGJSu0bcY/wA+tS21sYz5r6FDM67JFkjZ2YeYUOMA9x6kVZR5Yywl/wBK4LOd23HGee3SqEN1GNqzrvG7ERRCXB+npjmpJWuihtI4hIFx5iKNp292Geo9cVpKL2ZhJR+FOws5lMahzbhZkykkbc4HGAR35oSRWjUSZdP4mB69M1FHNbDatxJG6AHyoYl+aTGeSeij6cmrDMZ2ihniFuoGNofcF/4F2+tFraW/r+vkbUnb3bfMsaVp0F3H9n01raM5+YzHBHc4Pfnr71pHw5qUM5W5ks/s0bDY5kKgg9+fzrAjikN0kNxAzW7Eq2HBL5NT6daxXF6kDSyFQeCxyYwOoGe+OKxmpatS09L/AI3MKtGrFNxkrb7DtXj2JKbF1uWT/l4iGURwODn0rqbnTNI0rw/DeT/Zv7UjhAW6xuLSkZ+UD73NZr2kUN7PbrEPK3BPmfaJGPTP+NZBtoUDhrdVmViWGDtye47Dp2rJ/vVFKTSWvr6nK4yxDiubRDtJ1SCM3XkjYryhpCynG8k/1p8d4st+0lwP3bk/IuD7f/XqpPEUtpMyRsrYOAeM+/pW9YvpNtZJu8t7jb5bQINzD3B9PetKnLG8km2ztq+zpLmir30G24aFQRbmQq4AkYYA98+tSTwtG0TJGxkkB2hsjg9Qf55pq3bxPhwrxRnO0v8AL0yOO31rDm8b2mrOLWK6Vih8tufLSMjsTWUadScrxWnU4JuTd+jO4CRskCS3QhdYd7RhssMHnb69eazozDLfOIHFyyPuWMsMZ9Ce2fSuB1zTLW2u0utI1a0nZyA0CS7gpIyR1PAretNQha4iRbiGR12syJkHP8WcdaPqnLHmjJu/lYxpU7xcmzpj5mJ5r540m8zZHiPdtIHQ46g+vvXLeJvD2o3d6bg2VvqcMyAzWV1KI9u0nDW0ow0Ug3HnODxyvWta9uzdu1rHL/o8YzlFPyDPqffvWpLdW0NnstGjlRUwxcfcORub+vHFefjMHDE0vY1VdS9Va2zTVmmnr6inSlJLszz7TdVvbeG4jspLnVrK3UrNbSxgajZZ4/eRj/Wp1w6ZJxwH5aql98TNM8NuGtbhbqJ1VttvKGibuc57jpit6606w1A2xR5kuLYt5V7bMY5Y2xnCsOQPUHIPcGvKNffw54tnuYvEDf2dqQby11+1h2RTHt9qiBxnI++vHHO0DFcVOWNym6xEXXoL7SXvx/xJfEvNe93T3MMXKrQioXWu1z2fStYtdY0yG+ijl+w3WZsBsgknt6AGuf8AEXi/TYNQtrK/1a3t7oEqkIA+U9OcdCeuTWH4auU8E2ml6LqUEsKS8W13HIJba5J5DRyjgg9dpAPsRzXmHxN8M6ncE+JYv31jrF/PDGyrzE8croqn2cR7lP1HcV6tPM8B+6qwmnGq7Qae7s3byenXW+hVTFunSUqaTl1XY95tbY31xHDczsI2+ZGYkd/1FT+N9Xh8GeHr661WWA2ToyxQjAkdj0C888/lXkvw/wDHU9pcaV4e1RxJLEmZZJG3EEH5QD/unpWR+1VNqNz4s0sSBzpcdoq2uB8oPVvx6V2Y3npLn3Vtvml94sRmHtKXPBW6WfRnHQePm+27pLRJLdnBMbsScZ5wRjmvp/w/qKrZQX+niFEntkZEH8IZclSfWvkfwR4M1XxXeyJp1vvjgAeViwGBn3717R4I/tGxvDpyAsk0w2JKOMDjcPQ4/lV4adXF0nKsrf5eZz5dVkp8k9Ys9Uuc3AL25lhmAwzY3r07+lQWC+bAZm2OVbG4/dGOpqIf6KziHzJAykylmI79s+vSkN3cxyETQRomcEBgd2ORj3wa1UXa0T6OT9nD3diacGOaYSTRwBhgneOCe5z0zV5NQmvYbYs9ubeFeEiAKbgCN3HUj8qxtR0601XSr6TUCzyM3mMVY854GfbjpWH4SjuIPDd/at80Jf8AdvuP3Rj5f8+tP2cZxv1X9aHE5N1Iwcd7/edBIIftWy3uUuInOQyDhCP5/SpJy0IwuxpuSilgu5uuAe1c/Jd2mm30VqlxNJcu7MIkhKLEvUdeuc8egrorbZdI0tvIJUIyof72adSFl5HqUKynCzeq0YyKabyUllTZMFDPCjbtjEcgHvjJ571bxwrfIzZ3bv5Y/wDrVWuruOC4jjuQys52qCRk/l/WnPc7ioj/AHuwhMDsTxzWfK7ItSUtESKwDZztRmyWPb/OaVxtDLL80ZUgMv8AIVKgUz4dAhXO8bc9On4mopFQtH9nAUDqCPu+49qV9RcybsSFiI1Zcqv3Qh7D1NVTIyz2aKqzQBiWRTwg9atJsMOS6MWbYMdQaJTGjSeVEjLJ/GRzn8KE7aEPVcqKFnqo1C+ubc2rRxwnHnEnH+FXoWQJ87BCTkA+lNuCoRVjGAx3MB0JqZPKuRvkUbxwcnGKJWtorIUIyhH3nc4D4jeOYfA+lwotvHcajdMTFBuIREH8TY569hjNcTJ8bLxvC0c0FisWpxXGwEktEBtzkZ5B7YzWf+0BGdR8T26wLsW1gEbkjgck5J/wrjtB1TSYfCF3pGo2H2l5rgTLMJPLaJguBtPf6Gsmq/tnGys1dX7nyuOx9VVpRjKyTtY9c+GnxIn8YaqdP1Oyg+2lTJG0ICZ2jJ//AFV6c0Xzco3luOQcfr+NeY/CfQNC8OaNa+J1mleW5jZR5+B5S5wSCOua19R+JPk3PkNabgGzt74/D2rohCryrmSut7bX8j18Bi3RoJ4iW+q72Oykt9pXGPlyhweqjsTVtFVIspsLn5hg9D369K4jT/GK6xOi2diZrYgeZyWUHr+ddlHLFcM0MbQq6AH5lzlscfjinOMranpxrQrRvF3RoWV3H+9ku/Mm+by0V/4D6+9LbzW7sPMaT7PnLorBn6cjHb+lVoo2+yKY5V3buCvBB9CD/Oq/9oSC5MkFjBhDygALf7X/AOqsPZpt8plKnzXcC3IYxLLFbIRCWDJngL6A+v1rIn8QLbuI7W1G8lXMrHgH6dSK07mazuwEs7GJInDiVIcq5bsTngYPPFZ0ditpbtcztEb3ymRyTvABHr/k1rTUbe+vkRJTlHkSszjPEN5f6rpi6nFJHPozsUuXtnYSWT947lDyoH94cc+mGNAWlveanbW9qhuA7JbqUfYJRjJwOvc85rQs7W6stTF7pFyLDU0YRs7KNlxGT0kTo6e2cjJIIPNatjDE2oRpYWMcF9GWlfQ2cBJf70thK2MHHPltgD0Tq3hTzPFZNNwzD36LelRK3LfpNLa3SS072PJcKinz1du5nWGkRJdm3sLSGG1iZmu7iQlpCynOAemMZ9K6rRBc2sVzPbOiiWIbQGBdh/vdBn0qjpssN5azLplwYYy5jmjljKurd0kU4KtkjIOK0LmaC2treRDb2wYhMkgLksBge5PFfQupGpG8XdP56bnp4aimr2RJaWs4gnSUsmOTuYuWOSevp7Vbg+0Q22HRRGxAEh7J14FEFw7ylYwu0ZYhz1HtUwuzOwVcIgGUdmygxwQfU1jJy2aO2d1pZFB5DCyTwS/xhiy8Eg+q14p8RbOfT73UUt08uJz5qoBgOD3H5mvaL2GGC0glSSFJLjK+QzklcHqeOOegNVr7R7TV9Ytmu5EAH7h5APlZfc9u4xzXTTqKGvTX8DysyoRxsOWn8UTyn4NP4p1a4Ol6RZRal4bkYLf22ormzQZySCfuyc5wuecEg9a+lJvCWkS+EG8NG3I0oxeUse8lk53Bgx53BsEHrkA14NfQ6DY6lJY+Fr6/0eeKRg8lnfSxRnHOdobHP0rX8M+K9VmlmsLDxjfzXcGP+PqCG4ic9xyivx67sV+U8U8EZvmWKeLwfJBXvZNxd19p9HLz0PFpclJqlzcz23/A8H8XeHdT8FePJdN1JneaCVZI5x/y3iJ+Vx9RwfQ5Havp/V/Dunaxo9nb6zp0s0cEaup3fvGduAi46e56VzeraJ4w8b3FnqWrWPhonQ7sFLwmWAzJ1aIqd4OeCOwI9zXfXN1CCqaWhYRqdshGNueuB3z619nkU8YsMqeOjaqn72t1e26a79t0deCw13ONrp2X9ehW0yytfDkSadoWnwQWsWCR95mkPdvXGe9WbZQ0mw4hWRWUiBVVck9SPf0rPjl2qfLj6AgKzAZPfFXEKlVLIFI5IYdf/wBVezKNj3Fg4QhZIq24RFgiVS9xlgYhnHHIDZHFSSkSXkUrW6bnXc0fQLzgVM4dbiNEkdZWGI5NmdwxyrH0zg5qjq15NDdKtzEPtu1WdA3ylSPlOKuPvS0MovlfJMSISWEcsMbwRoylXFypKqBzkVk29tPIkdzNcRafZ7SUWRCg2eoHZfr3q5JE+rTLNcLmNlz8xICD+verjW0ZeJmHnKqhNsrZUp3XHcGtb8u+73CpGcrVKStY8n+K/i660zVf7J0eUMIlVZ73YGkkJOQFY/w/zrl7XxlrNmsQkuZpyrbvLJwD7GvaPEXgvQdSt7m8u4WR0VSnktjbjsc/lxmvOLLQ7G5v2t9DsnurtyFO9zhCDzk9vSt6DU1dPRdz5bFfWadT2nNq+1/yPQQsetaPpV3DFJFNN88ibcbCO4Pf6VW0+e40J2OqWtzNZv8AvA6qSSOmOPSvMvF/xA1TQL610mAoJdP5OOUVic4Hr9axPFXj/X9dt4NSE9xbIh2MsLERB85OB2z1xWUq1JOUOa6V790b/wBozhZ6839Xue9T+Jrdik0STFAFIkZwFG7jr6/XpXSYjulE9qXKEAhMnIGOce/FeJ+CXPifwzJql3aYureTyvkyFkGM7tvrmvTfCV3cyabEzR7I1QIN42lj6jHaoqQg4KdM9nBYipWmm+qNlCjKoHy/MW4OcmpV3LEu3c5lchW46d6hjMbS+Y22IZ4VB0x/Q1ZxhS2Fdt2/cRjJNYSPXnpZIhZUJeN2wUP3R6UhDS/NGNo6EdOlJclVaXlm+br/AEqGZJGfIkCDAwu/tVRRcdFeTGahpGl6hfwwXNuJ5LfJaSRvlyP5188+LPhfe6JqEsj3duNIeVngl35ZxnoEHUivoaGBrlyd4EErfLI3CKP7wHcdsVy3i3TrnUfskkZeaO3yE3LtAJ4bp19foar2UZtKTvb+v6R4OLw0cSlJLU8+sLu8u4LTTbZvsViVVFVRkhQSefQnrXdeG/C1vDAs2qWrS31yuEjLHgHP5nB/CorHw15USyrPI1xkbvJyxUdfwArrdBid47KRgrztExVtxy3OMe2BjmuutP3W0GCoKD/eq7X3EGhaKtvALIi3s7eIfu0QHLlSDz6n/GrUNtJZagXeMpE48ssDk/55/CuJ8f8AjTUPDGoSLJcLbrFtCwvGHLnrkE9e30FS+E/ijYeLdSt7D7FJFfTqRM7PhZG9QO2cVyu97XTutuv9febLNKPtfZTVlsu3/A+Z6PPdqgiZI9xZWQkjBAH86x/t0lrJfIUcOcCEsuFBPfP0qeVzY28zyTfPBlykgClR32kdcVA0p1BkiZmYP1+TJXPQe/1pQgkr2uv6Z3Q5amkWcZrfiXWdN1x7T+07G7jCKf3EZDR8/dyOvFdqly0tnDdgff2yIrrwueOfzqhZeFtO0+dWitQty27dKWyVHbg1q6aQzNEs4MByGBTAI6cfzzWs5QcVyrYwwsKtKUnVldPZGe1o8/mSBYxJESXWQZCkcsQO2azpzFcxLb38L3ILK0LoTGykdGDD5gwPQjmuu+wv5Zuord1gt38yRmPX1+vWs3V7WPUGISQWwU7FkiUYx2JHfrWalCreE1ddf8jSrUcrqnr3MDV5ES9R9Xu2trlQsdv4iEY2tgcRXqDAZR0Egxj1XkldYtbnxZr+m+FNesZLRbhvNmML5jaJEZzJDIOGUuIwOhG7kCsPXb270O7WwuIfNt5jt+2NBKbeHsWcorHHsB9SBzXqfwmi0Sx0MWekeJbfW23GTbHKhWDPVI4wS0a/7JJr8w4sxX+rFGVLL5vlqJrks7QuvihLaP8Ah27WPFlNwbhHRPozD8Jfa/s2o6TqSh9Z0txa3EpGBJGeVm+jqVb67h2rRvLb7Tp9uy25+zxylN23ALAdR7VL8ULCXT3h8U2JdfsyfZtSROPMtS2d5x/zzb5v90v60/Ub1o4dLt7edLsyxlhIhAjOTjIx16D86+i4Tz7+2sDCs3+8Wkl5pb/PdHo4SvOo0pO7/wCBuVoFt9StmQQoJWyC3K8fjVJ0t7aN1nMsZztYrnOezcdK0LiBrdhIIJGX7pl6DPXFVZoybpFEsnnsCQiBiGHqcDP419XF9tj0I+ypt1NkeH+Lvhz4mj8RTS6Lm8trh8JiQBwD6j8eteg/Dr4cf8I5DHqN/L9s1fOWXcdsHH5NWePB3iRPF6y3usxHT1csWWQhnzztwOnOB+FdqtrLcX8KQT3H2VvkaItnYw9D6Z61o9FdT3PBwmFp+0dVwcbPS7NfUbjz9N0y3J3KFldkj+63zH5j79sVganqU2n2wlaFnZ8A54AP+Na97AifabeKXzBG4QzHhBkZIHdqz9RittUVkLyRgjflhjaQMZb09azgko6ef46ns4SacWoru/xG+H78albG3uIY0MS7mXPHJzwfX2rWjcqhyu1ScjPVe35Vl6BosNhaYkd7iSX77Dn8PpWqxt55cLIXZMq8I4ZeM0m1c3uo6MmhmWG11S7fpBat5fOTliAOvTvXnelXMmueOLl5TIscaxqVJOcKOOvf+lbvjy4uLHwnYW/leTd6vOZChPPkxY2j2JJrN8E2cyNO1xlpZDudnGSM8YJ9eK1opRjKa8192n53PI5vb4qy2/yOyt4k8gGFozCvCrHjA9qW4jcbdix7nIzuJPy47AdD0p0zxQ2skis0ccSluDgEAdK86m8QXWqjdcTqkT7mWOMhSccYODniue+p6sE2zu76Ey24jf7nXpnv0NQ2kfl3kU3+j28YRshFwWLcbvc1i+ELq4F7JZvumj2lssCSO2K3bqJ7jc8ajYVGVJwcd8VqnpZ/1cUowerR5F8SPhnqHiDXje6O1urLCqPHK20sRxnPv711fhj4d2Wi/DuXSNaSC9vNSm8wlDnyWUEDbnqR3+tdW8v2ZmSNGIkQMshOeOvJNNnuPNuYpd3m+QoSEoPUZJHv2NKNFc7nFb7+f9M8qWW0pVObv/Wxk+DfDg8Lq0UE4nZ0/wCWqgKvtt/HrUvivxdo/hW3hOrzeXPLyqIuX6YOB6Vu+XvZNvzrKuQf514F+0fplxbeKrO7aNvs0tqqqRyFYE5Hse9Z4mu4Rc7XaOjGShl9BewWux7HpHiWx1XRBqujMtxGrgMr8MPXcOxNbOm6it3A7rlAj7CJOG/zzXlv7POkGLQ7++l2yRXLpGkTnuDyw96m+I3xDk8NeJBYQFHkhiH2pdvBY8gDnrtxW9otWlZP1OOnmrUY1K2z7I9WVCGySG2gNzxgU5U8hRG7TZXsIycVg+CPiL4Y8R6hBBo815b3hAlmj1BVWOQADIXBOSO1d/c6NE07Stc3Mhm/eEqwUDPbHtXHKsotc2z/AK9Do/tBVknT2OFfUGhsYQs9u5jVF8sLgpg84PrULRveSosZ8uAOWbzBgMfb1+tZniLUvDXhHSIL3X/tt0WcokcTD96wH3eeQB61l+CfiP4Q1meSxkgubSaTPlm5kBHXIAPb3rs9rCLajv8AK/3bieMpRkqLdn/Xy/E7WGNbe2VbmSOMA4PlHO786sWpiLNJHAIVYbWCYUEg479MimadHbLdrcGEPAI2JRh94EY4P65rkPGfjFPCfhq5a2jjm1R5miBblVx3/DtmhrmukbV5U8O3N/15epxn7Szw3eoaFYwIEuo0kdy33ipIC7j/AMBNcFoHhvUtL0aLxLPcR2Fu7FIGZiJHHdlH6ZNbvw6tYPGeuaxfeITc3C2GnzXrxKWb7Qy42occquT2+lZPi7xle3V1Z29zaQrJDEiPbsv7pVxwoXtwRz1rH2WHpyWIb2suvyPk6lT2spTatfb/AIJ2fgf4p2f2s6f4gs5JoZRsiu9wZ42PALDuPXvXtU9n9lnjKklmCyloz0I//XXgXwu8H6Pr81xc3aXkMkEqYt4jmMgnruPIwa+i5Y08sRoYpjCV2I5wBt7N6/WtKspRa593vbbyPbyipUjC8tU9u5WWETXShro2553PkHJxxnNeY638Rrax8Q/ZFsnOnw3D201w5/fK3cqnp/Ou8ur37NqCz26Dys4l34C7j2GeoGOteLeN/DFxeeOtS1GeJmt7yYyQSKeD8uACB7jBq6cJ6WV7m+Y4mrGzoP1PctFvYdRto7xLuQpcKsik5wYmHJ29jx0qxaaY4mOGxCvEchPzSZ6fL6YHfpXnPgDWrtNFtodSItrOGYRJM/yoUB+6GPZTXV+LfFMGl6XDc2l9BJBO7ATZzH07EfWlUozjPlj1IpY2mqTqKWtrtdf6ubKxTOoa7SPbFneAc/l3xWX4i8N6ZfXAfVNLtpHJUhvKAZCehDDnP0Nc3YfEXQb7Sre61PUJra6jmAZYMsrjsfbiu0tJYLi0juLOSe6sJhvWUsHGPbv+HWs6lJrSa0/A6MPjYYh20fkYcWmXtjbSxaXr+r2wJKi2mkF5A0ZHQrNuIB5GARTfCGn3Gj6FbQXF6L1LUsIJVi25ixlUYZOMdOvQCtVkEUvnQyzIhkzhgXLewHrU1/BCLY2zSMLicKoRRjyUJ+bcRxnGeOtcmHy3CYWq6tCmouW9la/rbsdKlQpPmpr3vL+rCw3jS2Mc9y3k5wVDyYB7bsdx/OrEt3dCFLHTHaLTpJFDyx5MkpPLF3/hHYKK8r+JutXcvilrGXda2UZVYIEGzdGeB07nAp+javqWhNLZ2UqNIAskiM+QzFfzAHQkV0KUZO1v8v6RLg6jTmtun/APRLS2ba6W0E5kjkKLLIwDMfX0GK0bHz2itHk8pZXBWQN8jl+x2noMVk6fBfajHbWdoqJezRB3ERLRxHGS+484ye/NeEfHnxCW8Rw6Tpl032awjCyNG5/eTfxOT3/pRXqQpwcpvby1107nHjsY8PypavsfRsdvLLpBMTRxz21y4mZ+I1U9w3c4/WqCHbFcyQxsY4v9a6JncvXJH414l8MfHlzqKab4b1WIywM+yOUMSXOeBIO4569q9hj0nVpJoHWeXT5o2aGBEXEbAjJB7tk9zxWtPkcefm0evb+v08zLC4+q4uVNX127f10L9vdRyXFtpsURe4lTzGWEn7p6cnGOOas6n9g0C3lk1BJJNSuXVILOAq8rf7TFT8q/WuE8Stovh9Rd+ItTuri/nAlWBCYzJnjp2XisHw38UfC9remG50n+z0lBQXCt5rAnoxz6Vc6KspRen3Xfk29vkc1TMKjbp1ZqN+1215bWOjtLXV/EfiK41DxFNveECK2hXGyFBkbR/PPc119narZReVGeSRks/LY9/WqsSCO5S5idbiG4iEnmxegAx9cjmrpmQScj95Iu7Bx0/DvSqSvpHbse1gadOlDljuNv7ZbjT7i1bhZAVJH8Jx0rzmPwnrH9pxxfYkSEOGedGBUjr+FejNKFwW/eK3TBz9akD5yFfb3UKen1rFxejO6UeZWKVvZ2+mM7W+5ZpGy0jfMWJHf0HFSz+YWcQ/LKo5Y4C4OOf/rVA0svm4nG8M3zgJj/AD/Wp7SOCb94XdIlUFy2QV7ZNabasc4+zjzeRh/EO6v9M8NahJph8zUba2DncPlwOrBfUBq8O+GviPWpPEDy3N9czqVLN5jFhntj069K9D1P4q2kviTUbDTrKWWB2MCXJbJZlG3OOw/nW14B8ACWRYrn/Q7PJmZVPz7j0X27fnScXFKq5aJf1ofOuaxFZTpydo7+v/BK3h/W7uDVYJkytuXx5Rb72T05q9qcSeINZu7TVYdzs7MYymQpB4GPpXQXvhrSdOLNcLNaqhACycsD2Jx0/pT7WytHvlu4/MMOeCGJJYd8+hArWFWLTk1rbc6qmGlW5Zxd1fW/YqeHdDjsFW1tTu+fcsMSbERfX/PpXh/jjQxqfxG1C+nlhaCWTcI5JMByBgDI6ZxX0XaFI5JmCyOr52fNzuJ9fTFeaeIPh1c3+rz3FvcIYHJcseoJ9RU2hWdqvS1rmGZ4abhCNGN0mcd8N/h/rMXimwv9QtJrW0gmyMOMkDPCjuP6V9CRXs0KlIYkdMkgs+D1qDR7E2WnRxSy+e0SghhxuHUgVVuvOvGSdRFsZRtG4gqPQ+9ZWjJ8vRHZgsLChDkit9Xc8S+NyXHiHw3oGuafbzyWQVvMIBYIWwf5gjNcF4G8C6v4n1CHyYWtbJXHm3cq4RB/U8dK7jS/HOtaVo2k6PBHDDbpEqKzgvvyckkV6J4P19taguNtzDG9sCSgBII9V9P6VlVy6FWt7Zvbp+R5dKjSxlRSqSabtdW3dujOn0PTftP2LT2u1aO3VId7fKJXA4+nriuX8Q+GbfxBZ3aXOREquTKeGBU8sQO/au0sLsxWxCRxyMwO1mQDAPX8c9+tY2u6lZWCiK1gjRrWDEkkjbjID1A9812U3Jza/r+mejilyL2U17trI5v4eS+Fvh2NRmtp7nUZ54vJOFwJCRnHsAcZzXK+KFsfF80cl/ZWVjLkgz20YWTHXLnue1RajtklkSOTJTLOiJj5j259D3qtcOY98bbNjty5wQo610KhSUnJo8SolZxtodVpd7YaHp8FrBOlnZRIGy7Ydh/ebPJJ9q7rw1JDe6db6hbYlsJwTG5OQ5H3vxyM4r588RQtZWNvrGqqLhrpmFunm/fVf7w7CoPDvj/UNOvbW6eedIoziK1gcLGq+w7D+dRVqU2/ZuVm/wCt/UmGYToNJw0X9L8A+K+qaqvj3U4b+6nREcGFUYhQnG04+lej/AzxXBdaBqVrrN0pitfnHnMC20/3c/Sk8Z28HxR8HpdafHbN4nSVPLUjymkQ5ygJ4J5yPpXmFv4G8VaFIt3qmkXFpZpJ5crSEKPp1rzuevTxHsJr3X+Hp5L8jJz9nU9vT1uvz6P0PSPHfjLTvGNjPaQQSW00LH7M0fCgdAAg/nXnP2yODRZ9MuLs3i5Dqgf93Ee+Ae/biuq8N+Dp77Wre5WCSawlJWRV+UsuDkj6DvW7a/CTw8ZWWTU7+dzLtWGNFBCZ4y3bivSb5EoxWnzJWGr1l7R2X4dDxnWbG+hMElwrR2c677d+iMvsfbpX0d8H4L6X4YaRdC1Z7dJrg+ci/dAYD5iOc57ntVnxJ4asr7w1ZaXYWFs1tYIY0EgLlh+nPuO9HhRtX8JRW8kKsbKEgSWkbbY3jI+ZSvc89exrkjRa5pwer6P8vI7cNQqYaqqjXT5fedBDPd3V6RZPO0SqdxQt19yOh5+tWJLC/lRWltnAb5nLuWx9axbjVr2e2RtIih0rT0zsidyXkyeCQB29elWNF1O5h1O1S61K+vJHlTeAVCOO4+mOK0dOok2klb+umh639pJLmjGy7lq6tbRrmNprSGWUY2MyKzKB1wx6Vj23h3RI9ZknjtnN1MRsQSEoST6f413GqaCkBuHfUoLCwHzb59o8tc5br1+tcddeMvBulzNeabBrOsSDOzCJHDOV4zuPIHvisITjNc1NN+n6vb8Qr5pQWj+I3Yb2603TvE160E0D6dps0qqx2gnacAY7d6+J7qe41C7kllLyzOSx4ya+opvibqOoeZHrCxHT7pDHJZ20IULHn7gcjJP1rN0O28OQ6kV0LQIrVbjgTXJ3yKCRzk9Bx2rKvl9TEaSdl1trsvO3meNVU8XVUpaX/rocH8BPD97/AMJA2sXVu8WnwwuqyuvVj/d9/cV7T4putV1LwXqj6KXXU1titvHGzBguedue+PTmtF7NTHBGhiW3VvlQDAXHVSB0/wDr0+K4McguVZ2PLKi/dRegOPStKdGNOmqcOh9Bh8ujToOle7d9flY+Nr6/1CWYG7uriSaP5f3rkke3PSqk8zzybmHPWvfPi94MF5cza5pttCWZCbhF+Unn7/1NeSWEdgbq1hureQbTiVUbG4fXtXPPAVKmjqaPufI4ilLDVHCa1/TufRvwkmlk+GlhHd5BETKFPePJxz2raeCJIBC8s0gyCjwtlgPx59qXQr2yvfCdjFp0RtbRUEKLtyU9ie9LLIkc7RLKrugA7dD0+p4Nd6TTa2PssBRi6Mbu7tYLpZot7QuiAKCyuxzjGePTv1qKK6ysTHdtYgg9B6ZY/wBKtfankkWxJIIBDBxkjn/69RarqumaDaW81+09wWYqbULku2DznsvenzaWtdlT/cJznLRDBqlvNrMGlmdBfvD50cLj76g4LKfUEdPrWiw3rPCwAmm/dAY+79ce4+lc34Z0lPHDa9rekH7Jf6e1va6Vcvz5c0StK+cdUY3G1h6fSui8L6lHq9ik88T2tzFKYbuEpzBOpwyNjng9+4IPevn8FntDGYvEYKPx0Xa3fzXz0OKljPa35np09Dn7D4Y+HrHVG1xoJpFibe1vI37tX7uMdfp616bZyWXkJJ+7cbA0jxKVYegOO/1qvqFq0bRtArm267Wbgn+nXvSQm10y1mm3lE3bNjnDTsR0Vfb1rtqT9rHd/wBf1/VjHlp29xWuzO1WQ6jbizkOZVQus8jnAOe4/THtWcszwWMcESoQjZY/dLH29vaud+IHjfSfB6KdRlnnvZ1yltbMpP1Zj0x+ftUHw+8daZ4wukFmjxz2+N1vORnGeobv/OuqHLH3fnY7qNehF+w5td7HRi6ka9iiijLAjcxBAwwPCgfjVuOXzLuNXVWVchlDD5Wrlvid40t/DLrBCbNr+bl41B2RrnOT6ntXD2XxAvZ5Gm+zxSeayhTHxzjpW8Ie0V9ipY+inyPf8j1iV1aZ/mLIZvkAbk0x4Jrd2S5VwxJKmJwoKk8cevb8KytG1lNRtIzHE0c4XkkjkiqV9468P2109vJeNcSxHY7GM8HrgHuBnrVxhJuyReIxFKEIylKyZ4JaXcz2BTyC8y4ZZsnD4HAGO9e5/DHwrc2tp9qmkiW4eENHgYDE8lcDkDpzWpo3h2zt7mSVNNtoTO4m2Rw7SuBx9Kl8R6k2lNDFGv76SNhgdWz0H0quaT9yL1Z5kcuWHiqtSexn+OtWvbOGBLJ0N85/fOoz5QIxhfT15ry0rqUSPcxybbjLkpJl2dcctz+mK6Zp7m2uZo/NWNlBd1Yk7zj+eKZerdXVooneGBZAAvlgliOuMdjXfSpKnGx42LrzrVb3t+hi6I/9o3DyT580EMfOILH8O9dfN4Wt5LJzeRAW3ktLJs4aMAcHjoe+KzdH1XTNOsJDf2TtqM7KLWTy8FIx1Y46Z966268UGeG3Nqkao4XdI2ArjOPm9T2rCamnaKOzCyhKCU3t954FrnjaPV59M0+90+A6FpzlY4ohtldCeSX6knH0rnfE7aeuu3Y0MOunb8wB2ywXHAJ716jrfwgF9qc91ot9DDbO5cwSg5jzzgY6j0qSz+B11eX9nDa6kvluAJpJI9o3eiDvn3rwatLFTjKNRrffstzjngq6XNKN0cxoXiKa28KNO4VZrWceVPnBzjIBHfkVS8LprvjLXJIoru7nnkJllLyEg89TmtTXtD+zST6a1jPBHYybQmM7mHBZj6mve/AsXneGNNTT7KCzDERNMkYCggbizY6gDk5716tT20eWU5aJff5/8MYYWhCvVcJOyX9W9SfQdNPh/QYYZEVJSuFfd1Yfex7VoQqY7OUQoke5cHjGT3x7UsWyUD7FbxwwvlRLLHvml92Pv12jpmnMEh/1vlxsBgGMbVx7Vi5NvXc+ro0tErWKzieWUCBQwQbH7EgDP5028t4b9oYbiDzEdi2TwQVqdHw6nJGeRgfz9sfnTrZUkJVhIY2yQ6j7vpz25p81tex6E4RcbPY5q5+0wqWVW8qENgqOFXPAIPb2rE80IkE115oiVtu6L7zEHJ+mK72GWJHcMDuDZL9QQO/6Vnanp39qXrRQRbLeJeZupfPORjqe3510wrdJK3meNi8J7O3Lt2OTttN1TxHZTid7h7bdvCyMZAVzwDxyaVvDVtvV7tDHM7bWDNtwPTA7V36XVjosrRTSRpaTQKh8z5DuXscds8msHVLy0ubthZSC4fbhdmBjP6e2KunWnN2S93ozxfZQpu3XsYEnhyyEg8pmRc/MOoH+HNTaf4bCalFDK6mLnzAh5Q+mexxitaS4ZIYoyEhmZhtGSFj+vr3q7oUNonz+b5xiXcASAS3Tcvrg0Tk4pyPSpUudWirf1sWXgi0iyuWjkaa6C7HJPRc4BX1+tP09HGo2rRRMiJEVfHzZC+v1zmozMkkcbSOWkzj5z83UA4A7e9ZXxB1bUtE8MLdQpGN0oUSBsEHPcDtXLZy917s9mrNYWg5S1Mn4ueO7bwULa1trCK9vr9GlcTZ2LFnA6evp7Vg+C9C8P/EXRzqS2b6fc2jiO4WBgI+ckYzzXmOr+LJPFus2tr4ohWaGN9izWyBZUBPY9x7GvpCx0ew8CeCT9hgjFikTSh5JQXDlfvN3J6DHauelUqKTUZJp6Le91vufO0qixdZzqfCuj/r9S3bw6boWmtZabc25+yqW8mSQAysFJ7nr7CvmxvEWp3eoTXt5M7XByUAO0Ag9MelZ18r61dvd/aXJafMjEn5ffFeheD7PTr74caxPqJQS2Mu+DKAMw6YZupBrvhHlb1ve2pxzx067UUrJJv8Ar7j0fQ7kX9nbSOSHlVQQT0OBnk9OelZvxE8NapqxtLjS1802SvE8OecHkOPXjivPYfEQi2bNgeMDDbvurxxXrxubi/8AByXOlK7X1xayQ26lguZNpAJPYZx+FFdOilOOp7FPGRzCnKlLdam98A7D7B8MNNll2rLfSS3bHoDvc7P/ABwJVLx3DBpmot4u0iSG5sH2waykLhwoU4S44PVPut/s4P8ABWAbG70/wvZXmp3byyeHxbPBFbkpbQRwMhfA/jYxqwLt2JwFHFWR4X0O6vNds73T7c3NvqE6PNt2u0cp84DcuGwFmUYz0FfieXcOZhhs++tTqqFWfNUta6a5tYvVdGtr287EUqVRTUNmdjLcyxPm1myZkzJMGEhII+7npjHSuA+J2vtbeFZrq18wzRyeQrkYMfGCPyPUfnXQLDb6TaW2nadHIfs8YiSLexEY7DcxJ/WuAuZ3jnvp/E0oGnrGP9HY5UID296/YsPS2k9ztrJUqTUd2t+x4Imm6nrd9tt0lubiQkhScsfzrvvgEr2/jO80+8syyywMspbgxFeeT25q54e8d+FdJ8Rzm00iRInfENwz5257lT2r3S3S2UteWemw77gB2eOMbZVbkFvU1zrDUlV9vCV5a3162PIy/DxnKM1PVPaz/rU+eviTYyv4jnt5Xkcxudsh+ZWU4wQe/WqNjp7wrHCoZwVBzmvcviP4Oi1WxW9u7mG1eEcSTYVWGPuk9gK4Lwv4JF1b/bItRt3giU4aB9/zehA5x9a7YuMvfRVTBzeIcVq359DX0CKZdJ1UWz5la1YRu3TJGDn/AOtXljSiELHFBHdlFCvIDjDen5Yr6G8O6M+mIfMiLSqnXOfoR7YPeq8nhTRbiWSV7GBZHbLl+rN61aq8rPTxOVSxUIJO1jzrxV4z8R+Hfhd4Tit5pY7y+ieWS+zl/LzhYyT3xzz2qGz+JlnL4ctbjxTJJNrQfbGIUDEx8fM4PA59Ote2a14b0o6da6XcWtvqOmIRs3oSI+M49Rwe3SvDvib8MNQvdZiufDEIvbZ1EexGVfKxwBg9sVwyq1Yp1aOvZNef3/I8udKtSipU5XVrW+W9ja0PW7HVLJrqdo5lVm8pmXDMuckH356VDqkIitFiVnWCQDYwYbc+h4z+Xeul8D+Bl0jweml6jsmu3lM0rRkHym4+UHuPX3p1z4Mumgmihk+XqyytjcB2X0NerTxSlBc+j6gstrKPO1utjm1hiu7KF4oJvPAChs7VPPIYDqKn0vTfOe9basBjkWOGBZAfNfIB4PRQPSrtv4X1q3nltVtpbcocBySQ6Htnpn3FdQ/hm2S4s/sUYiQII2YfeJHUj3pzqw0aY8LhqlSTTiaWjWYtrMPtBkZssDxtArUFytsXkZZ5ZAd67AERAB0JPf6VXt4JmluIovLaC32qPmBdh3B9KkurkMhWFAAGzsPTaPf9a8+b55a6nt+yukonN+OfGei+HLpI9ZgMl5cp5rRogbyweRuJ9x09K1fDuv6drWkSXGg3VsENv5KWpba8Yb/WHb64xzXhfxptrGW/m1C31yO6u3YM9o5y6jGMA9wK4nwP4kl0PxfpupKcpE4WUEZ/dtw36E1nVq06bjSlu7f16dPQ+cni6sKkozs4p9P8z660y5SUAKvlyAkY46dOKmdoYpTuKiNgVLONx57D3rEtFhtkCWMgmRvmQdJI0Iyu4HnPpjrV6G7ged4QQGXquOQ3v6GtJ09W1sfR0atOol7xYuS8gWeaMyQIVRoQOOnU+/NU5JFtrgJGsm+UFflGASOmamdGhRmimDLlTgknvxn3qjLcQvc7VkSFIpPLeRjnkdRjr604RvtsdinCj8T0LsAaRDFPKrSxrvYCTYijOBnjJ+lVrzWodOhiMaRvc/dEW/KqO7fTvXMap4wmuLuSy8PWSSq8u6R+pA6fgOOgpYtDu1CT6ncxxxyfN9nXmRh6t6Anjito0VvU+48apiJYqfJBXXcqXzXGuXk096rICQikcA+/sK3dI8O3UFpDJptpeXsjPhBGowyjuSe2K5nVvHmkeGb2yt1t3n8qUrIoxkHPf19OK8+8bfFHWm8XXl34e1K7062dgNsUhUEADjHpTrV3Sj2X9aHDWq4bD/AlKf5HdfEHx/beEtQ+ynThdX5OZElUxonYjaR1+nFRad8U9Bn05WQx2MkriNoJMny89SCP4a4rxt4k0zxz4WsbrVENrrtrujW5j+cXA4O1x1B6kGvKGXaxHXFeXjMZWwslJxTg9tf6/IyWaVVNyptW9P61Pqrxh4t07Q7WxutOWO6e9QyW8atlZAvBOf6Vw8PxMS/P2fXLG2/sm7k23QXcfKznJHo3tTfhX4R03xn4RuDP9ruLvTo2aJIX2PvIPyBjxg4rx6/lvIBLptwTGkUzM0J6q445Pc9q6a2Ohh4Xtf8A4Nmrv9RYrHYmtytyXK+n53PQdd13whoRFx4P025l1Nm3JcakoZY17Mq5659a734V+Lbnx1bahpviyGK7RYflmCbTt6YOPTrmvnR2Zn5bceg+lfT/AMJvDlr4W0CC7Jmk1O6jR2yuEG5QdmPbpmubC4qeJqzaVopaeve4sBSqVaq5Nuva3p1PI/E3hy88L+K5bewSRrSQl7cyjiRP616p4R8KaVP4RvobN7t7+/iXzfNI8tSOdqAdOe55NdVr+jW2urZzSQeVJEWQ7+ffj0q3oVmmmRSrbpuYDO44G7HtXopqMNNz0YZR77lL4e3qeGzeEr+PUJYEhm+VhvZwFRMddx7Yr3Dw/ZLb6DaRabc291DAuxzC275gezZ4/GvHPjjp2txa4Jg10dIuwD8vC7u+4Dv9a6D9n3z7SbUITIWtpI/mjycKR3q6k3Ui+Rba+p5uDcsHiXTtvp8j1TVpEm0rULSUyAzRNbCMgbUQqQx+pFYWl38klzaTyxK8mp6Ra3D5OAJ4w0U3PtiMZrptSt44JZZ51SSEL5iknC5xXBPKslhp0sQdvsurXunER8ELcoLoY9sgAflXyuZqNPHYLEpaczg3/jjp/wCTJHtYhxpzhVgad5rItmlYoryOdrx4yAM/ePrXG6jpja8ZD5eIJ08t1SPBUnoFB69q6ODSg10ZJQ4DEAbycr9QK9BsdHigwZIQTK/yIz4CKP4vc19TWnTorXqKrKVaznsfM8Hwa1OXUir3kEdijfvJTyyexHrivoHTAljZ2lrZO7iCJViJOSQvA+nANa97BZwaVfwxJAbpgpiEchDe/Pqais08yFGESI5BAy2Onp64rhpRpU4twjZN/oPDUaNJycE1fucD+0fbC68Gwro/meSswlueM5wMD9TXhnwz8SXHhTV5pZLcTWjLieNm28A5496+h/iA9z/ZlzZWsO6aZFLbxhh3Jx2rwS+8Ny3+oCC3mRVYAyyOpG316d61jhrKNVN3S+9PueTi1OnXVSjvp956Bd+Lr7XdQZbaVrO0TLwxIxBZcZy3qfatbStU1W4tckoNjFOT+Pc+9ZVvo3lCFYsyyJGEUDrGv9PWu20vQoILQfaI5vMkPmYHI5rsaULXPVwDrVJtts8Tl+Ofjlr2SeLUookdi3lJboFGe3SvZvBPxAt/E2kWl7fT2ljqj5j8gSLGhfoZMep9K+dLz4d+LLS8+zS6DetJu2jy03An2I7e9WdJ8EeJboGBdKeL51HnzMI1j9sk49/XivAwNSq5tVoO3pb9NjwKU6lCfPFffc+uEBg8sSLOfO+YuQAC/qT3GKddNDM00uozFbeTkOrjaoHqfrXJeFvEWnXV1F4fg1Jr65srbbLKDmIsgGRk9fqKf44u7VfBerPdSeTYm08lFVwMOx+UEjqc9a9L2T5lf+tT2pYhcjqJ7L9Dzv43fENjDBY+FrvZZMmHkgIGWzyMjpXm+gfEnxRpOlz6fbag5hm4WSX52hOckoT0NZ+k6PqGqavDpixfPOQq9AgJ6HPpXtGo/BSFtHsLEXMcF7Z/vLmdD5iybiMgD2xxUVISck4S5Yro+uur/wCCeHSVavKU47/1oa3wq1q91jwrHe6jL5t6s5iMz8lgOckevNdtq1m9zp1z5cL/AGWWJoFeHIYvjHGPu8n8qqeHtE07wto5iDKtnbQyStI5PzFR1JHU9sV5b4b8U+JvEviAG0uJrWDAOyObZEATjJz7ZrqjH2jvF7HsSxlSkqdFq8rWZxuvfDPxUfEU1l5Ed0UIP21JQItvrk46dPWvR7Xwh4R062smuLeC7vbS2TL25OJ5B1Ljock966HxVpkWsQG2UXH2e1kBBtpG3u3HccAdeKzIPDenWFtLFm4heL5ZZpTvMf5dSR+tOlRhGfO93/X9dSVgYxv7ON0+rf6W/UpeNQbuFdQ1W9ltY0IwsQ4Ru3ze3twKbo39p6FHDqy3f2u3uNpWaRDIFA/2uvIOM1yPxe8Z6TqWh2uk6K8sxDl5Hf8AgA7D1J61B4CsdUh0Ca81HUHSzWPEFux3Bh14FXGsqlT2UVol8vQ5J16UKrcVfTdd+r8+x7HH4kikVZ4bHNznKPcS5VGJPRAPmA681zeo2GhwzwxalrCQXZy00jyDcmeuEHc+tang2a9vfC8d7d+WhYPbxhhuI/uufYZ5zXzx4x0fVtO1m5/taN2naQ/vQdwlyeGU9xWc5eyvyq/odmIxNOnSjUS53Lv0/roe+6R4o0Cya307w9El2QFJeLkNz0cnv9K6I3lml/JLdTW0V0YzFFZiZfnlIyFyewz0rzf4Y+Ef7M8F3d/fwvHqd0DLGHJQxxqMgcjq3X1xXi3iDUrm51CYSyOCshJBPRqzr4inQo+1mrPscs8dWjHlkrX+Vkdv4+8IalY6g+tajdRxWt3KXjdnyS245AX2qnqvhOG91OabSLqS+tDjbNHESCxHQ+nNZd4Na1HwJZXd01xPp1tdPDG7kkISoJFen/Bq9OmaRqWprGY4oUAjhLf6xzgf1rSk6VfmbhvZ/f8AfseXGk5TjCLsn82V/CPwqjl8Cane63c/ZC22S1kcgBSDg8dTnpXKa18O4tPsn1FtWSa0TBcRxEP+ANdpr2salq0/nancER5+SKP5UUDOBgfz60Wd5ctC8dtCZ96FcMNwIPceo+tW8NCUeSSuui7eR3xw9Lqnt8797Hidxqk8LyQadcXNvadBGspwfc44Oak8MWUupeILO2jtzdPNKoKEE5ye/tXsl78IbC6uYdsktpNIwD+SA0Z4yeD90/pWn4tsbbwJ4HaXQdONvcLIkDX8iAyN6nPY/SvKhl9T2qqVp3Sd0un/AACHhZQu56Jf1p/wRupeF/h7p2uW7atIIrobA8Ebfumbp26CvSpZEikXYVMTR/K6nKkD+XGK+UIdN1jxMl5eWEUt49th5Qgy209/f+dfRvw+j1CPwXp8WsIyXirtKsPm29gw7HHFd8ZxlJqKdu/R3PYyfEc9VrkST108u5t+RNcXSRwyBUAO5jzgHH5+lbMOnxuGlunkhtLT5JvIUb1/ug571XtykQJSESTM6hFDYPHep7q5udQ82aPcdpJcp8uc8cr0NROUm7LRHp4iU3Lkjpcu61otj4w0x7SCVpIdgkaPy/nBHUbzwR/KuW0azsPDkd0lpHtkUY3dGZc84PbGOtYfin4mJoEs8Ul3NdzKm2SJJNqDOMjA6CsWz8d6Jr3hnUbwzCK7giYG2kYKw3cAqf4h/KnRpOH7uUtHsuv6HlqdGlOUZyTa/rct+I/iF/amqnRbaJTbMwWWbADNjtmtO3tZYWu7W0iLNcy2F1CwdeJ4ZT52cnODFtAIBrwnwjK+pa5HFM24IQwZM54/ma+mdJQwxia0OEbGdrDcnHPUVnjsFQxmHjTkrJSUlbTWLTX5fNXOfAc2ITcn1LUVoDCglP71HOJAMM3cCtKWQkmS4jK4AcB8c5HNJshYJHFuWdwRIjjGPcfWtW6+ynRZbe+k2w7AQXTIUAfpwOprKpV1V0d8ppO7WhghkXbIpwu3dwvHYYNF5ew2rz3dzJFFBtyA3QYHcf0rkNL1W/uHay0VmuEZ/kLLwvPTcewrVn8OGSbzLuaO4uQdsjK+9Ym78dOPfmul04xdpM6Zct7I57UZJtZWZ443jUtuG4HLj1GegrzfxnJceEL21mZ0nacN+55wBjrnua930jQfMk3SP5zeVhs5AA/ug1wfxs8GTSC11S3QXNvZH94iEkhD7dwD3rVVo83s4vU8zMIc0Lw3RyHg/wAbvpFpJLq6LcLMd5i8vDADp15xXqGneMbDV7VbiCWJox8g3sARjsfzr5/1eWTUbq0eZcyRo0TMndeoU+w9T2rHW9NjJLDauZIw+d6MQCcCtZcvMvaI86jmNSjeKfNHofQt/d+KLScwpr8lvaSHdGIVDBgw55POc9q838XaI0bLJBNcSu7+ZJ5j48wnqcdzmvbrZomugPs8crquNsg5GTjP9ahk0TTVLPcRx4UmWV5GwkajqxJ6DNV7aCTTVn5WO3E5ZOneV9PM8V8JaZfwTzSwD7MzqIVH3QN3v2rf1/w7rV94M1PT2YTEypLCHYBt6nkHnuD1rZ1S48L3he50HXY/Mkz56PNgFlGQyr9R2rN/tNpYpYbGSRiw3SOzbt2PbtyK10nT5ej7o8n2MudKLTXrc5n4b+AdZtfEFre6sVhW3O/yDIGZvbAzxXv1xewlyz+TFheY04ycc7vUdqwtFthY2NzcXUU51J/k2427BjIYZ4zWrJZJEzK8sUkcLCV5PK3FjtHDeo+nFcPJCFodF/wD3MJShh01bVnNa/q1xFeQ248v7I6/6vbxt9MVDoGh20SXk1nAfLmByo4CHHAwe3Xmta/0pbiKO9t4pDNuYxbRwRn+JfpjitDw8uyC88yaRUdgrxlBjOQMMe3TtWrqcsbx6HTKnBe9PW+xoWupLp+jrZpCscDH5ZRgFuOh/nmqU1pJqIKX7JDZ9C5XcxI65HuOc1He39vo2k3t3qmy1sFcF2aP75LYAX0+grmNX+JvhzQruaxt9RklguYU8zYhZVJ7/gKw5N3Hvv8A11D28MNHlTSf6ehJF8L/AIe2azXcLahNcxvnzpsGIN1wF6kfWte60Wzu7C107bZoR++G3O057DsDWjpktprCiQzwSwXSqYbwlWUbQOW9OvSjXZrS3u5bTQncYjEMsluOLiY87UJ+nalS/dy5I3vv5fkc9KguX2cUtb69LepW8+C30aHwxoiy+dcyZEYQMwB4Zs9lzzzUl8q/b4TCIpLe2jWFC6Bw20cnkckkdRUiQjS7VtPtZVWXA+2SJ99m6+WW6nGeQOO1PZS6gIYfND55UhB78deKtW3XX8b9f6/U7cNhIRV7e50X+ZNBeXZiMojsy38UixcMoPGQciuc1rwx4b1rUmn1nwpYz3ko3PLbytbF/wDawvGa6O4jmtrGJEmARuhHBwe4H+NSlMBvMeECTaA+PlA6fN6Vk4werX5jq0KEleSOam0bSmtTpkVmLbSQuwWgJZUz1YkHk1zdx4RbQtOaTR7h57RXWG4ikjAdSehHqp/MV3iqkM2BAFbG0sFznnOM9MVPA6pHcSAHzJ5khTA48teWP49Aa39o47GWIwVKEVOG72/4B5PDYC6uU3iUFGwwQ8EehrrrG0u7ZIzawwRbFJjAHMmDnn8K1JrRLjWbydBCFmJRSF4yMY6elTrKLKB3uCRKGKBtoGF9V9cn1rT2j7GtLCRgnKRdtFE2oHyriN5SglkmP3S3B2n8eOO1J4k0uDWvDsuj6sB9kkDeZKrZKt1Uqo6fjWPpuoeXbCHcnkRvkliMu7Hv6/UdKsyTlpLc4SNdwJQggsxB4znn15rCVNt69BOh7VeWxg/DzwZaeBra7jgvGvb65wTKEwkYB6Y71q6trMNiwJndmKsVEbBef7x9+aXUtX8gLFDFiVk3AEABV9vrXIX0kksjyyKZZc5bCg4x16dKqFO2ljVQp4anyU0dHZ+IYV06IIjzXzEyEfdA7g5/wrq7G5s57NCzMLyVMsqHAU/1H615bp5Wa9WOJgoZgx3DhQOtdJplwv8AakcTSkZYEsD/AC9jVSpKcb9TFOU9ZM+bPFcElvql7GblJv3rKW6E89awIo8k7s4welek/EzwFrNt4mmk021m1CyvZGkt5bdfMJyclWx0IrgvN/s6XyZ7VDcxShm3knp/CQO1eLjFCWI56miXXofK1aMqUnFq2p7J8JPCM+m2g1C9hjaS6jDRq33kU559q9l0mH7DaqGMW/YWd14BPHGPoOtZHgrV21vw/pt9CkUU06KJFHCpjjiuquLF4XhMaW1wWYtvTkKvcn3r1JOMIqktEfVYalRpUoqPVXNOxligsvtV6DLHI23A5YDvjFc9reoxaxMbBmuDauGIRhgyY7fl0qaG4WT5TbG4ZmDKqNhgOn40zU7BZrskysNjhQF4dcDoB34rKnTjCd5b/kY1F7KTk9TNtL22t4I4IGjtoEGxYG+V9/Q8f1rVu0crCxRw0ZDtGmVVm6EnH171gXAha/aewjZTH92WfAldh3I7Z9ua2EnQPJ/pDPK0YQj6/wA+a6akLWaNYVPrBrySJB85L7SeVjHQngD3/CopLZre5FzJkzRrgo7ZGPTjg57imxyiKxjaYh42Qfux1Lg+/Sp2dFZVeQsGTzEyDzk4PHtXFZx2M+W0tTj4/hz4b1C5a8uLaW2csXaCFyschPY/4VkXfwp8P3VzJJFBfQx5+WNDwo9OK72MTGGWUtM9vI4EKCPBUg8fN35q1Be29rGItQZFuB94s+C3vitnWqJuzv5HPLDUKiuoqxz8du8tyVMIDjnzJOBwM8VyHxoOrN4IvbPSFmmEjr9rKHkoOu0dSM4rszCs0oWSWTAXduVjyKajLE6D5biYhtrDheeu78ulayXOreR62JpuvB05dT4tgeSKdfLLLIG4A65zX014K0K50/WIFvCQmxWnCrySVDYPcAnjNdTBo2kNqtzqB0PSru64dpZoMPB/eKgYBPp6Vq2L2661Bc2o85kLYXzgHOOV354xg4xXNhKEsLCUL37eWnqeLhsC6M5SnutrF12n1iS78p1+2ttySwKlRkLgnp6HFLcpfSBLEQW0N5ay/ZvN34PTjJzgrj1p9ldWtlcT3KK6/aQfNgZd67gxOUI6c8YHFVpkiv4tRupFnjnMiuyMoAQt1UHOT/hVK6e1ktvXb7jV3lK2yRc1G3TTdRSNYsG2t9v25ZN2+c88j25wPpVLxLpx0y7sUuNgM8BllnOQocHr6FiPT8qI7260d7W482C9uGTzH/uKueF6fexx/KuK+O2umZbG/hu4ljSIrDbF/mDk5JCn06U6amqkbv3bO7/rz17GDUo++9Yrc8++POuwanLbR22rPPb2oEYgBIDY7+56814zJP57fOTkn7zHJxXbeH/Cl34yuLy7xcpZwLulm25APoPX6Vg6z4Wu9OnkAaN4VPEjHYT9Qeh9q5MbHEzs6Ubw7f1t8jyardSTqyVrnrf7Ot6rw6jp7I0pO2UKy7gO3HYZ/WvYInNvLEwKRoATFLnAh3HBP1xxntXzb8MrrXNOvGutKuTDbphJzb8ljg7c49+9e1+EVvrq3mu/EE7mMk5WQgg8en49BXpxjz01N9kvwPSy6vKUVSs7a+m5vXVykUE0yIUiwxBYffI6t7jPeuL8PeIbqS+kudSvnksY1ZWj45bHYV3kseV8yZnlyuz5sYx6Yrkdd8OW2oqn9kTR2swILIV49yf0qWr6o+ijflVtWb2kavbanp80tqzhEkCt5nDccjbnsRWxIFkO2AhvMjOcHhuOn1rD8P6UdGs1ieXz7hnDFguABg4GK05WjaFG3BVbBYKuCxxyP60NX1HKknqxl08ixqs8MqzuoDRDscZ/yajjyFYiRCzcBl4jQ47evYZNKpkkWN90kaIAplZgxmHO4KeqkAd/WkvpbO3hLtMv2dUbchXkKQexq12Mo1vaP3laxmXGq29ojnzcSqSMqPukfTqT6jiqlybu4f7TcWs1zGgzy/Ke5HasjQLaTX70x2KN5DHZEWwOB7f0rB+JPju70OUadpmC0I8qSRxw2OOneuiyp79N/Q8jF5heDn06ebOittRinuLcSptSdwjgYyO2fw9q6TSPs0ulLa6hCSvnEx3KZJJHbHavnzw144Z9ftm1kqIPMy0qjHl+4HtXv+gbLyVWs5oriC9UpFJEwaJj1z7MMfrWXtqVaPPSei/QMDivaJxqS16Ik121iUyJa27yOqgqzfeRccYNcOklw08gjOwngqgxz/OvZIpIvJeK6hDPFGAGVwd+fvce1ZgsbRtZkubSNF52Ozj5Xz/WsY1r6NbHowfO2nsjyPxRqUPgu4s0mbz7yVPNEMY+6D3Y9j7VqeB/E9j4hluVaEWV3GgkCS8ocHtWn8WPBVlrE66qs81tLbgQyGFPMJB6NgVneFvh9okOmXM1pc3d1fSoyJJcLsUEDptzzW9Ofu872Z5TnivrDULWXTuvzO0jVL3THksrlUkSMo4RsYZh94D096+UL7wzrMWuPp72NwbkyFR8hw3PUH0r6B8G6Rq+na9LJdWzvH5eJFj+YBT/APX/ACr0mQP9lisprQJMknmiQqC5JHQg/dPWuLHYaFZqMnob1KUsZTh7Vcsk39xznw70seG/CGm6dcRmWZwskkuMryeQPQjIrtooSlszQKhjJ8vBX5QPUnqc+lZjqIJJInVmWbHptP8AnParmlLumeKPeIZWUHbkbD6//rqKlrcyOqpTjCmktkR311aR3NvvwUBP74Hb5YGMfU1m67qlvImpNaMzKWjkRhwu3ox+mKNe+zwRzNd3scUcRIZ2wEK55JJ6HFcZffErwjvWzspJp1KlC0NszceueMj61rShHR6t/wBMxqqEEm5Wv3/rUu6lqlobm31A+YyoVaTOSgA4wP5VR1rxO9pcxtBCgaWTzA6MPlXt/k0lh4i8O6xJcWWm3Uc9zaKZkimhaPJHXg9cVympxXDG3GoIEaRyImjUbdueRx2Fd0XF6MyqO0eei7p9Uek6VrMd7EY5o1kkVSUzx1PU/wCFbFxd3m2IlMrGfv5zx67a8lj1mfQZpljk84zE7DnPyg+9dlpl3qurQfaspDDt2lnYKAB1qZ0ot30t5mVOcql6etzux4yW5tVsryFoXGCegVvoO3Ncbr3g291/VJryS6mAz5aBCcbR9PqaaLaW5ubf7OSUZvMaX1x2GetddFcoDJi+kQFs4Cew6+9c/IsK70FZv5mrw6ceSaKsjlI4pY0VfNVvl++CT2JHSi6a2uLdJLa3eBwgQhG3K79yT2NSSCK3uVfTAyfOC6M2UkyPm69Me1VWkV3kt47iNZlIcquAME+3t61MVezX9ep2czfvN/iReUslyIUuIIr2WP5BKNq56fN6nvVcX1hBavbuttdzrgsYVOX29QQfzz2rRVVX7QsM9vOzKOhDvHnv6j0qvpckUOgXWL2RXimEUMUMQDSk9dzEcjjt6Vd7r7v62KliYxje+hTTUXs7PzlXbp44Vd+ZUDdfw4zitCS50+3tb27a5+0xh1FoiSEGQMOT/wABORUL6NPNaRajcWTfZ5cgSAgFj0wPyz7iq9rZRbiWgiDL9zrlB0P0/ChpS2frYpOjWvyPYnaKfUbZPNDtC52iJGAZeOAccds818u+Ozear8QbuCGQzyef5MOw8DHHH419a3KyQ2vlLZ5UbQ1zFwB7Y7ZHrWFZeFdI03V31awsYkmmBMhK7mBH3sehNc9WEa0VFuyv062OHFxWIShF2Sep4vbjX/h/4XuJr2aIYulUW/nbvMyPmIHavOPFHiO88Q3izXRCogwiDsP6mvp7xr4N0rxfb29jdG5tG2M9tdDDDPUBvwyP1rxDX/g74l02ZvsMcWpW+4APA2G59VPI61z5h9ZnFU6Pw9e55VfDyveCbijN+FvjGLwdrr3VxALu3mTynib7uD3I7mvoa51bS4dHs9QaSNrC/KyW8AyzzEjlUQfMzdsAV5TpnwO1TynM+o2S3IAKxrGZcHGTnGOleu/DGW08P6pZ6ddeGXTUriJ1OqpdLcHy4x8zPvCNFGOBhV2glR1NeRnGb4rJcA60KPtGuzSSXm27+ll5HXhfb4VPmWj7lrS9A8R69al9T2+GtHVjIASHvduOcZJSIY7ncw9FrlfA7W0Wgxrbyu/9oTSXhWRjJJsdiUDMeSwjCg59K9M+LGtRWvw2v5rS4U/2lGlpbyxtnInIXep9kZmz7VyGnDTdQtLO90iWP7OjiMRrwY2UdPdTwK8XgPMsfnc6+Y45+6nyxS0Se7077avXzNYtTk7y97oaUM6tHJ8hKn5VDMN2exz6c0jSysDEUdCEDbJBgjn1qHLRHPlbFDMrRS5BU556fXNcf8SPFc3hvS40t42Z5gcS7wQn+Le1fotluepLFKlSc5PRHbi3nuEkEAkXI8xz2GOKxtXubI2t0mr3kQiWJpVJbG44xiuD+DHxC1TWdev9G1W7mktru1bZLty0LKc7uMden41hfH3Tbyzu7GcFxZuuwKWyQ3uPesHiYRg6i1S2seZ9cnPDzqwj169j37SobDQvD1ncJcb1mjSeOeCPMZJ4wD1J+lcr43+Gtl4veS5WWWK+DhzLtyGz2bPf6V434L+JuqaP4KutAlu5WgMqPEXAfyUByyoT0yewr3DwL4vt/Efh0XiNKkglCywliVbAxlvTPr2qYOU4e1i7uX5ea/A4qFSFf91ON2fLfiPw1qGkeIbrTGtJzJG+FAQksvY1658HbK8sCtpPcSW7x5lCZyA+B+HT0r1/UNHg1mwQ7VDxgxnnlgx4we/41lWnhq2sZI4rRNmckyb8Mu08k+mRSwmHoUJSmnq+nYujg5xqqUdl951FpPJDFcSwE7pY8RzAAKmfTPeufvNSi09hHNLtaTcyuV+8f730qwbuC3uJXuVCWuCFXsc/z+tc1q0c+savD9njKwyREo8oKrjOM4/StYw5Wz6RR9mm+rFbxVdMAsJHlD5GDdGx1J/+vW3pM2patuFwy29q7ZIWPDEY9e1ZFppyR3i20drkwgGSQpuDt1713RtI7uSN44tkDoQM9AfrRUahqzFOENWaXh/T9Ms7Cea9Z5YDICI9/O0evc+uKw547i8jvkm8xWlfzUVjhioPA3f54qxH9lgvdl2hDo+zdGucMRwW9a3LSzsltZ7G85vT8yzxLu2jGQfbjIwa4nN0pObu27f1/mcE5ujNybvcxReN9ji/drHt+Xf99uvPHcY71NYr9ivmvbc4ZcFY52J8wEenY/WotTtrqBmV4woVwxx02np09R2xWjfWL2NrBfKUMLr5sioM+UpAxnNOUo2svtDq1Y8t+58/ftRXt4W0iOOTdZXKm4mKLgecT90/Qdq8ctPEl9blU3rJHlQdw5KjjbnsK+x9Y02x1y1udN1C3Eli42eW6cA4+8G7HnPtXy74y+HGseFb2e1awa/tZ3C2t5Bk45/iA6HHBBrlrRrQnzUn/S6fM87GUJp+0jd/oWfhZpN5qHjjSxYRSAuzvO0nIWHHOfwr2S48L3l7qQhZo/3LbIZP9hQACwHsM+tWPCnheTwt4N0WASWf9pygx3LpzIMkttJ64GcY6V2OmwrHE0rEsR0jH3lYdh655Oa9SFTkhdf0zvw2G9lh+aT31t/XoeSa5oRl1+OCwaGQqpGXyA2D8x+nPavT7A2lt4ejS7gjEVlBmXb0fnNP1yKzMTzsPIcukisq/vEyCPoCSen41S1fT5rvQtQspmkhdU5O4BeEyoz3FW5Rmk9v6/4JpGPJTlOL97/gF7TNW0/VLX7dp10HhhfbuQfdbsPeuns5bS4tImuGKSgYYBQe/fPfmvm39nuXVbi/1ayYr9mgj85t7HKndj5R3r3O2RI483KCSVzuLKwwfT9BXNVpxmrxuvzOGjiva01KXxeR5L8VdQ1W1FhcRqYdPtsKZkXhHzkA+oIrh7/xtfahqAd/MLAbXZOBtA74r3fWbOLUrG6t4k8y0vIykkTjIzjg89CMV4H4p+Hl/Yp51vJ5sIbaVjU529mx3ruVWSj7qKzLA1Y1PbUrtM9G+El7/a015e2DJABD9mkdsthjzu9jjge9ei6mqadbWtvYsfs8wDi+xlUVvvYHY9ev515X8IPDkmgi41K+abyrmMRGHyyvGeHI7gYzXq9+LEahcW1u73UcsSDzQDGgb0x0IHtWcpSc05f1/wAMOnTqRopONnr/AMOU/F3iy30PS30m+1SVdOj+WJmiw0u0ZBGO3+FeSat47vJ9Qtp9FcfZYnThAR57buc555r0vxz4GtfFTSpFcQ+bDHj5ZwQqAdTk8c9q5Twf4Gt7bVrR4/KeysZQwYnLSuBnjPYGnQcIxvH1fr/wTnnSrX5aekX956OVtrrTIL+F5oluv3qWpkZ2Zh1bn0PY9qsQSeU8zfNMGZS6gFREvVhjvnpmopVvbG8jRg0hcb4ym0FQB8xPHGelQ/ap4k8uS+VjfZ3BI8BAp4Unse2Kx5XJaO6/r8rfM9SVFyjb+rDXvEvL2PyLVbeBvmwrHD5B/pU0d6kbK0zHzduzDLnd3Bz2Iqneq7tHAhRXUeYzbsDaenPoM1HfyiOCWa8mhgt7dCzySElcDgsD6YFaOMba7HVHCx5VZ9yfVLi40q4ivnxI7sFhW2Ks91IxwqqvTcT+A5J4BNc94inury4v7Lek1xPIo1y6hHyMR92yiOP9WgPznuSc8swBBFdw3MctvGIfEV7ATaow50u1bgzMO08nIUH7o6/dYNuHS7PTIbawD/ZxDGVZxkh+Mk89T1yepNfJ04rP8Wq0tcNSfu6fxJL7XnGL27y12SOWnGGIq809l+J5tqx1aW60jwS1vK+mWFxLeQzgceUykIn/AADfKBz90p6V6Bovhu00qS3sPDUE81w6F2V2AUL3yff9a0rC3kuLAXbyItq75EpXBODxn0HuK2NC06X+01hiukjgmjM9xLGPlWMHP3j27V72Gw9DLqc4YdWTcpNdLvV/8MKpClh25R1f5GTMt0mnmWzEF2Y+PLnU/e9MnnivnX4yya5qOsxwai0QhtVOyKJNiqW5P1PTk19FatrVxf31+LS7kKeeY4rfYApUD5VB/DPuTXCtoF9qV/ez6myOkrbXMkeGTP0712qlGtTcKul/v/Q5sThataEXFat7dPVnJfAXwne6ctz4m1BTDAyta28TcNIx/i9gMV3ni7w0vivS7nT5pzC+BLFL5YIOOnHX1rei+SKCzM4jtLRdi5XLN7kd/r2qpeXv2Jru5kJaUQ7vL25EeBxUUqEacPZx2R6uGwkaFD2NTW+587+OPAmoeHrSG6CNcWhIjkmUcK/v9a7n4F3MWmadqEGozpB9qKshbJK44zj8uKxNck1TXrloryea4cESxwgEK/XsPSobWzvdE1jTYNSVYYJ2BkIyNqnofYZraGGjCbqLrofN3hSxHPSXurv56H0jBexjyXcSu7RmUAsBx/CMDqTjNRWrJNfub5JF8xN824jCrx8oP0/lVDTLcLbKpO5gqIkqHd265/rXiPxl8dSyajLomktJHDA2Jp9xDyOOvToKxqOFJOTeh72JnSwlP2j3f5nst/p8+rakblDE8EOAsRbesadsgcMe5qx5NwgljW/eZ8YVguPK/wB2sH4Xie38C6fK4m8+4iMjEkndngZ/AdK6S1Ba9ggt2KyyyEnau5lPX+QrW9ttkbYf3qaqT6pMkhma1uI2biNhllAyQSMde/Tt0q0mqyGJbO7maS2J+WMRgbx1AJ7/AFqPUoi8yxxrn5imfug+9UY2lt7pGl2ZDblQvu+XpxUcsZq7R0KhSqwNhbm1juI1lYqs4JjhQZKt02knp9aNLu4hPN5zSM6P8mWOWfGNo9u/P1FVYnzc+c0Jl6qZGGMgdQPr2qO7u2tF8uNQs5YSrNknG30HY9qj2d/d7nJPDrVWNqa8/dPJGr74wHZs7iHx90nuKzrPVJ7e2ntC8sv2qJfnd8gY/wBnHHPFWoctplxeLbx29pLKhkwpUl/p3znqKrLDtZsRu7ry3p+FZwjCzi1/X/DmdGnTk3GS2JY76/aLy5pQ6SzCNotgyf8AawB+FadzpyNZXaN+9SGYKZNm1kLYyv0561h6arI6G28wXSMWDZ4IHUmtm9u7iV3imkZQ5VjIgyp/DvyRyamrFqSUNDLEJwmuTQybiFI9+/YvkEDeD29RUk3lwW0UsBWWON1dPlw0hI5Ge1WgZ5wRMsU6w8SSOdvQ8Y9agacRsi3MUQlZnRYzwM5znI45J789KpSb0/r+v8y/aSno9SkJzeNcW/lrvkZJNv3WcjgDJ6dM1P4ot2n0ZnZJFuLe2ZXyCwZsdT2x9ax5JFk1fexMXl5UNjndn+XpWvcTDUrUzwiZL0wmCbqFl3DAJHT+tayTUotaI0xVBxs4o+S/CXjSfwx4ui1WOL7QkRZTHvKbgeDyK+ltI1geINKtNU0wz29vcx79kgBIOSDz+FfL3jrwnd+FtZmtZ2WSDeRHMvRvb6ivo/4RpN/wgGlBYnjjCYQvkbxn7w9s5/KuXCVa8pT9v0ta/Z3/AAPFyuhBYhwn2/yOiaN3eMoWAizG0gGCqj19Rior6O3SGG4s2cqSY5QemBjHXp+FeReAfinqOseKbaw8RxxSQzt5REYKYOOpx717npViNUsr6yNsyvakusjzYUA9mP8AKuv2keVVL6f138z26WZQqx54p2W5jzLtJ8lvOVV5KqQAM9CemKrRSTFGt4g0RTDCKRflHuM8c1LcwGz1GaGxdggQCTDAR7sevbirkd3PPmO4G10UMA4zznAwR1rTzO6NZNLQgkaKazeacBLiOT5VZAdw45o06UQ6qBK6+XKwlfdxk5+bDepPatW3hMrRQshnM+FO0AY7E+2M1kXCCOeSEBJIzIxG87s4OOD/AFNSmpXiRCcZ3gzoHcXpnljx5zzs0bMMll6gH0Bxjisu2S4vDcKJoreUuR9n3ck5DEewx0P4U5541GyJmMgGTsOOnQe5qGzuXs7oNLEsoJZRLt+fceeT+FRGDinymf1dwjaJELqP+07kXe1IpiI2dDwqk459PpWFe3EMLpezut9pNtcmHR7ZmO3UblT/AK1v+mEZ5zzkjIzhd0mqyR38l4l5dzxaNbBH1WdfvMxxst48cmV8gccgEdCymr2nSxv515qCQ2t7PCILKFY1aKyiX7sCdgeAWI6n2CgfO5jVnmuIeWYZtQVvayXb+RP+Zr4u0fNnHXqSnJ0oPTqN0mWOJpftUj3s9xm5u7rbtMjnALMOygBQqjoAB2rRu3eecSF0eIgJHtX5hxnI9c4qjOX8+GWRIt6KBOoxjJ4Ax64/DNLcGNpiYI3iiUb4s8gn0we2fSvpaOHp0YRp0laKVklsjopy5H7iNGzupZdNeOP94VcsBjPBPcH/ACKi1iSc2HkWN1LLoskaJMTA3yv1AJ/T0NR6ZKptyY0khOwqxT7xbHzde1Osbd7iCKzBeMKQ7/MfnJ+6Djtj8qGknfp/X9I3dKDtPoiGCyPktaW8W4bwclsbFx2/HNXF+2XEaeYvmFT5LKGGSg4z9aztc1my8PSRpLJI01ySkcT9QFOCT68nr7VN4b1Q6hdlVQiSMbkYDIPrnP1quSXI5paEVMbSjPkT94tXdp5Vmhux5IX7jk7m9cY7k1lTFxdrIUR7dsR7Rgqobjr/AErb1NZJ7S7AImuIMSsqgg4HXP1HQ1lxSxXeniF9sbNzG3YEc4/EcZpU5X3LhUc6ba3MnUNCtdJurbVUmYbC0aI/G1j3I7Lg5rE8RynVPDbyXDRxwF1WW4KA7V7EetdDqOLiwniaE+ayrGH67MDAyT2xWTrPh68k8KSaZLK8MpUBTGQC2BnDema64StHXVnh4rC1JN8q6NlBfHWl6RYWNl4bjaZkb55JxjIPb8aqxfC5V12TUdQkiu0nP2iNHBI55IPqRWb4R8BahNrkEGpAQwI4YnqNo5/GtzxV8Xk0G8a20uKG7gtH8pCxyOBjge9TWcVG6S7u/wCGp5tObi+fGr0X56dj1Xw7byG3UXkA8gQmNVj+TpxuX3HHtivJPih8SLLSUutL0a4b+0B8ks0f3o2HVVI/nXPa98YddvY459Da3tgq5ZI06k9eCex9K5Lw58MvEPilpLxmhgSR9zySk5JY9cCvMxHtoe9Sjdv7l89jd4+piG6eHuk/vPW/gh4tuvFOiXljr1288lhgxSSnczIRwPoCK7ma2E8UHlbmjZsxttzsI6/Qe1cp8OPA83hCynhaUXU8zhJHQcFR2A6iu3ZmXYyQRQBDnCMTkHjp2reN0lfeyv62/wAz2MCqtGioy3/4L/zHW5hQ+SoxKTwSM/J3P1zjFQiIXE0cEI2OqHPmdTg/yp6rH5nDCPI2qXBznsSc9QBV6zt4r2e0a4IEiDahRseYnqePWplLk1OmpUlRfMZS/u42yZdvIjTJIXPpngD6VYs1uzbme6DR2qoEjYS5MmexTqa2LmzjEAlQSSQW6tvUjAQ5zt9+cV55rni7StC1W3try423V0SDL1WFOw9jn8adOXtk7f1/X9XOWeJjyc2iOuhvHiaaCdfLlljB4/5bKRyAPVe4rdkmZY97lI2yESPf0Qjng9+tY0N6b7SNLGkW4mEdqI7meUgvFg9VHUknv6VRM0qoj7v3x3BHfLHPoD/Ks5UvaPs/6+7YmNF1/e2Zq/bAzEyONjn/AFmziPHqPWqUltthmnSVmdnbEZO4sc54HbgdRT4o5jFHHK6SPdKoaROSM8Fc+v8AKnPaSzTvbKu9w2wITtJx3b34qlaL0ZouWMrxexgXax/bYWRHeJ12spG0ggHnPrzV2FZE0hbZvNlZpPOiVFAYAj5mY/pUNurXmtvbtCsSx7VMmM5OcZ/Csn4weJLvwR4Rii0d5G1KefcXkjDIIRnBUj1Pb3q6k1C33nRjMTGnTTfqL4j13QdHnWw1eGFpFUShJ4xIwJHOfTJqyfGujR21osN9AsfkrhEYqE5Py4r5j0STUPFHilBfXM1xPcvmR2O4mvQW+HviJHZIbYSRqcKykEY+uarDVKWJgptWXmzwaeJxGtSnFNbdX+Wpv/CfwBDpNiNW12Fxqs+4xI+QYR05HqSetX9f8bW8VzLaXO9IYGKuUkI3Ad2H1rv0BmKjymYMpXap75zn2rwv4k2Nx/bd3u2xyiQbpF+63/1+1aUaaguWK2O/HJYHDqNPa+vn6lzxb8V7q206C08PrGpkGZZnAY4Bxt2/Tv6V2/w58S2/i7Rz/aemyW17blVje1PyyDuCD931rg9F+Gov9MtL6+l824lfH2VOvl9SfY816poegad4dj+zeH/MmCphxKTnBOSAfalySU25P/h+phhKeJqVVOcmovz3NiGFYdXH2EyJpIBZw8nIIHOMeuK1pLXS5LCMWrsrMAw353K3fJ75rJglhV/3RKSMSrDoUGOCeOtXLGZpD5nnFBGnlhGOcse59xjNZ1IvRptW/rU9apTcffT1MDxdqll4f0tp76dldRlY1UlnbPQY46etZnh74gaBrhhsYJriG/kcbIp49oPU4BFcb8dfFJ1Gzt9M0iyeYRt5lxdhCSrA4wD6fWvO/htomsax4pt5bSKQR2snnzTt8qIq9ck8Z9ql1lGapSi7/gjxKmaYmVZKm7ra3f5n0bcaTBvicPOtlDNJPFZHb5aTufmkOBkk5OMk43HAHa4DGIXilOFXJ9di47D3NWFkjluYTJ+8hmztyOc460y9miuL2OSExxyPEuAxUFSDy2en50UKFOheNOPKm23bTV7v1fVntTtHSC3MqFIwY0KZEknmPxj889xVWOa7ubjzLqaSVYmO1SeABkgfyqxcCB4X8jAncp8+4bc4wePWpbeCOJQlwoWNpMMp+8uCP511t3epMYdTTj0+VN0jvtTAP3sk7snt0H1qzav5O1Y0VRwHLNtGwc5x3P8AKp7qxW3WeaOKG3SSdUcyzclCNoO3suc8HvVSaGNZpA5fChdzN1AXjj2OK5VJVNzSlUdWLi9jyX9oJNSsBo2u2khktsyWruyj5ZM7x+BU5H0rnfhJ4wvreZxeyC4VnAUSYOOcn8K9k8c+E7jxr4O1TRrAqL5dl1ZRP8nmyJkFRnqSp69K+UbmHVvDd/LZ3ttcWN4hw0U8ZRh+B+lcM8W8PiFztuFtj5rGp08Q5R3Ps+3nM7RSozMs+IixGMZHTisqVYWv7mORAtnEpCb8jcR1Jx2z+lYPwk1PXj4Ca/1iJ7lriRY7beu3yVHAbHf/AArYf/Ugxt+9kP71ifkLHrkn9K7oaNtf1/Wx9FgW6sFN6JlyBXWZE8xH3Rl9pQFSCp/Wo3t4xmS4bzP3ahVZstknjPvUdrqAs5xFKEi8tCm9eclh9047YP51E8yfKASzMxCKjAlT/Dn8q1V29Dq5eVtlvVGmbR7yzjdo71oZIIUUgNJIy5G31PavkXxFo19pRj/tC2uIHYspEsZXkH3619FeMH+0TWlz5k0csOJNm/DA4A3jB61zmuTX19AZL54ryxwrul3Hu5B5A9OvalVwX1ik6d7X/M+XzFSnWv2/rU8a8KW7yXhnV0XycFQ54LHp9a+y/C2nLZ+DrCaXYj3OHjAHLgjDH3PcV49ZwaNCGfTNOsrIXGGJA3mHHBOD2z2r1jw9exjSNPWWXzUVVRN0m8qOwXHTPXmsFh5UcNGkns9S8Nh3C9nq/wAjV+zRnUJXtj+7X5ljYfPJkdh6Z71JqVvbxIY0t8zoyqOcB2bkn2x1p638dnbXUqtInzqWMnzNGN3G32yc0y9vmYiO38lkMvnO04wxkxgkeqj17Vzrncl2R0upNSv0MzUIXjjiWdcRsxRn+9g54xjqf5U9HglsL+GUtHcCZVROhZVH3fYGoLthbE+ZKrW7fvGjxykh4OD+tc74h8U2mgQyXUjvPKD+6TkORtGOeg7811xg5JWO6pKPs+aq9EdJcXNzdpcXgm+zJG4lMNuT5WwDJz78V82+MBF4h8TmeSWOKGWXBZeignqferuqfGjVprx0jiiTTpEaKW1QYV1IIznrmvPLa+luNQg2qWUSjah5J5/WlDEUIv2V03tZHzmLxKrWjBe6nf1Pq3w1pb6JoVuls73FtDHsd92C4Ix19PrV2BkUxhcLCQNsQbdtGOfoac87WemRFFMJfYrqy8529Md8ZqveSppelXLu6Rbl/dE/MQSev0rVXZ9dHlhBy6L/ACNm0ltoFQzSxxywjdbxxnDKx4A9z3qpqM7Q7EjDPK6BlzJnd3Jz269K810x7x/Eqz+bJ5UiYJzyAfTqOtegKBlTPGuxWBaQnkdhjFJ0lF3vc5cJFVZOo11tYbHcfZbtWniId+GBbPB54PYfSl1m3ttUtWTUkeW2ZDFFGX3DDdGT0A5qtNnUpCLOXyzb8M7nHy/T9feptMurY/ZFIje5k/dO0mAWYfdYDsMVXLpzdS8TUip8kkZPhPwJovh6SaSxt2F1JwXkO4j0A44znoK61YrV1BkVRL/HmTbz9MVcFx9gunniWJ5FcgM3T5uhFZU80jys/nAsxLOUXjP41hG89tEZ0IuMeWC5V5f8EeGW6cpG8qQhlQyouM/h+NZV1YadMp+12kV1eibgTL/CCeePTr71pRxkRM9m6LvYFAGxgjrmnwrE126OERXfZLOzZCDqdo7k1ony7HZUit3qQ6VHbxDKKY5pBhWX5cZ9jWpFpksAmPlQyykA+ccgAN/e9T9PSs24Et4oKXBVbaQ7DJFlZU7dOelP3/ap4YIncqyphAcLgcf0+tTNSet/U5qnNOSS91E8rRSGBIS7hMxMXUjdjoQe/wCNUQjGK4JUR/IV3Lyc49/rVg20il443dJN5I3c/LjHX1PtVq3sR8+4hpzFucISQPTOejcdBS5owW5spqlBKRzeiaHY20ckgt2mllVo3ctw3tg+taEty/8AZrWckMdtbyMuxI0CqDnHQdT3qdLdjIkv2dhCw3KOrR8fXqaYxy1vM7fKoztjwOhwTg9/rWjlzSu9R06NLS0V5D5DOkhaUQKkUmxByWyR19hjvWffWm1mjkgaO33HLSOCHXGeB/jWnaERXD5WPfOGctPkg88DI6DH61XXa52oVY4GX3bhg9FOfTFEW0ybNvlsV7OyiilVwDG+NwKpwQMnr2p9wVuHV5SXBdXCrw4z/Op0DyFIyvzPlUx8iEjnH1OMUs8Md8sckJMcZx8mSMH0+nX+lNy1uzWKUE0VPE99a6Zpl1d3apLkgt8+SE7H8CK5Ow8aS74ZWhD2zqA+TmRVzxj0rr9c0tp9Kvra8skmhkhAjZeCpH8hmvMbXT5pF8gW7boX2qQMlj6MaqmlKNjirVKimlB6HqLXsUiI1o8isCbiC4L7ZIh0z7mukudP0TXvDKXms38dzf6eC3n30CBwBzgrjkehrnNOiSz0+2jkAa9SNcsRuAHQjior2aWbbBNsZflVwydF649xx0rnqUvaW5Xaz3Kq4P27Uo6P+roLrUJL1ZIm3Jbq5aFU+VcAcHI/lVa2dZb+CJ1meMxsZWUcJjv6fTNT6pOs13tZPs5UAuxyCq4+6B39au2Ej6RO2mXogls9StnFpMVO+GRRld3fB5NW3ZLlX9df8zonNUKXuq77C3Wg3HiLwxYapplkYms0ZHiA2tcYP3vc45HvxmvPbm8kivolmKyQeZtRkOOWH5gjv6V7FpviKDTfDN3b+Us1smY0Nq5UBiBwoPJAOcntXHato0WtSx6jDpPl38GXnkL4LjscfXvWVGU+eXMrRvp/wbnmYfEVJxcJLS+j/wAzg/FNy114kWD5lhQCJlHX3HHX60t5eu/hueLTLfa0pNvwR26nB/lWn4uhNvZ21xuWGVtwVUGDkYyAfTjrUtnpCzwW7tFvtQ5kJbAO44zj1r0VLlRnKk6lWcUzA8BaI9rHGt+SLt3IYyjco47Dsa9M0nTzpkYe1EdyNvlsyZ+Vew96rQrFDZGGGMmULkygdsjv0HHatG3ljt7XaWK2sa5Rl5AY+oHXmuabbWh6dLDqjSUFsVJ74XD4nEiQxkp5ZByuBxn1z71HHey6o7hWLZXOWAGzkdx3wDxU+sxedBbPpsqzeSC0+PlP19zWFZT3CXDo48mKVlUqTlWbPUHt6048rWi1IdGNRp206nQTKFtnKpG0YR8lstv+v+FeO/FHwtr2qXtsuiRNNb+TvMYwrfT3Fepy2lwLswRrvjiw0hjfH3Tg/Kev171esBDexvc6pBfQW9sG2CP5GmyOAQR047c1ErcrTDGYelXpW7dj5hHwx8Suts39ny/vwW+VdwTnHzHtXsPwx+H2m+FYRd6zNZ3uptIoJjQyfZPdezH3rsbjUJJIgZXQQXOIii5+5yRgdQRnmryQCOBLiG3Mfz4ZXG0FfXBrGnhKVGXNFWb8/wDM5aWWUoPmb9L2I76d5J2EZdrYSAhpVzI3PYHoO1UPEmlTaxDKsEkcTodoEn8QB4x/jWm8ZkuFmLKjMxBBGcj2P4VBclIoA7MyIHBOBnGDx06it4vltY9aVGM6fIzF0nRpLDykcSvIhWRgBgY5B/AVvCVYIwQgkgcEGEn5856gU9biKwjnugBHEUy7E5xkdPpWVBqVjqumEaPcI9zAS29DhuDyuDziqu5vVaHLKX1eHJDV72vZlq4nHlQxXESQwxlpQB8rO2OB7gV51Lfs88uxVWVWJCgkYyeldHrdrdXUALMzyv8A6vB+7nqfY8VwOnwSm7kEryecMqSqg8jv+VdKXItDw5TnVq80la57D4cmlv7KHz0ikG0h/wCAgjt+VbuFAC2qQmFflXAJrl/hxJOy25YIiI5DRsMiQkY/A13NvbyI022TdukLFeuw4Hyg9+lefiZck2mej7bRa9Dm5fLjd23eXJuOSvBLenv260gDSbVAVHA3SeYo+o/Gr5stPunhC6xFptw52ohPngt/telZ91DJaTm1ubm1u5UAfzbdjtIOcd+PoaqM1J8q3/r5fierSrwqS5Y6MmkeSWRPmVRjLsMBQP7v8+lXbJhKWcIBG6gRl1GFx2+uao2qwyRSksWjxsAfs5qe1bEQCmRAMHB559cVM1pZE1Kd00i1MgEZ2SqzFAN+3BAz0b3OetSwN5ds8CS7JX6gjovsaqeZL5rPEYgVzkSjcBj+ee1WZbfMMaLJI3TLNghhnnp3HSsmtkzkcOX3WRXU371pyVzJGI08sY4HViB3NVLmOK2YSQlBLuVPLRc8f3j7VLcKqsjZ+8xZSBgkD0/+v60pc7MoV39iRjBPr/nitIq1rHRCKjaxVheWzvHntIhK67gqSkkBW6/hxn2FU55LeC+u57VQ0ShUWKLJViRyR69OtXmKp5bKqmYEnYc7WU5x+FKXmtbeQI32YugP7sYBNaJ6jlo+aKI5Y75oo4rq3t4XmAltwxA6DkA9z1PFPtIHhEM8UTbMgOshxwTyc+351x/x48Yy6JpGk2umpFa3twTE96w3PsUAbwOgz7c1876j4z1yVDDHrWotGchiZ2AYfT0rnqYmFKnzVNH2/pnjVs0cH7Nw1+7/ADPrvTrq01G+lSzvYJmVSQA4Y7h1JweBzVSQwRsLxYVRpEOSMBvT/Jr5j+ENrfar8QNLaCeZEtpBcXM277kanLc+/T8a+plvYlit7mdbe7EcjmC0ZTjGOCQfz9KqhVVWPPBOxtgsVUrJtxKyNHc4NvgREEZx8x/2fWmSlY7RmjVQzkhY1ySxx909+3WobMZBLsDI0mfMPC5PJUfy+lT2KSXEdzfMsRt1dovLRsHeOp/z1zXQ9Nz15T5Vck0e2tbVEub4sZ4ozmFzkH0wT1NJaalaatcuZlNs8LExs7DLEjGPYYq0s7tMjPBK0e0PhgMoo6njjFZs72+YkisLKWIMfJbeVYDvz6c9Kizbbe/rsY8rqa6l67t5LHSYCLO3eRYzElzA2ULE/wAIHCkDj3rlvGOpPpMiLJ5zzhEaNiCCSB39cZq9rOrzWulmLy/s8MTCQhY9ysc8DH6Zridc1eVxIJFeS6iYAAqXx7fWt6EZXu/M4MUvY03Hqx0K6tql0qSyrcQzRAgEFiik9R9enFdscWOmxxmO4byeI/l3ZyRwB3OeOa5vwzbajMVuJIZbYxMACp3KD2II6denSuvtbeeaRHSeSeZDvaRgVGR3HvWlWUb+Rpl1KUKfPNavuaQ0iDRoVub24e9uZeI7JGCqrHk7m6kCoZfISCNLjA3BncRAnjtj2+taUN5DqU2y4sJpZo0x5hn2xu3TkAde/FUdqxGTz9wijBQo/wAn8uo/xzXDBy+3v/WxrCpOz5r3/D5FN7dppIobBN6z/IDnaDuxyxx/kCu+0H4f2tlG0mquNRuZWOSfkSJSP4R3I9a4O5vBJPbSyt5EDcEJh2hUEAlfXGM11aateXesQxWV1P5UkiCEXDc4IOHAHY4PBrHGKu4pU5cq1v8A8OcOZVa0bRTsjC8aaK3hnUYrm5dp9Jcny3LEMjY+43scDmuWj12611ZIwRIIMSJaJKDlMkMmT1YDnFe0eOvD9rr+gJp+o3aqNwZJHwGaQdCPfrwK8qfwLPozR31hdxXMdvvEpcbXwecAjr3+tLA4yNWmvaNcy02/H1ZlhMU6iipP3kx+jzRwsrgbo2TajBf9WnsPX3q1rct0+liJ53uYY2DIzkbxk/y7c1kabcRtbWk7AsEy5IHznk8YrXcxyWLLak+Y2Jfm4BXOcexHpXZJWknY96cYuXO1qV2EWbYlHaNAeDyBk+n61I0Tu8WyQeZtYoz8JjOVB/KlsnMd2Il3Fm+Uy54PGeh9cYquHW4jJPzlGIZApAQHsPXFPU1i+Z6FPxZYT3Xhe4WCQBx85SPnfn0rwLQ9RudN8WWwt2kjkWURmNMgn1BHpX0jHHKmG3DyQNzIBwvbjviqf9jaTNqa6i+mwtMql3kQAMT2/E/nVRny/wBfgeZjsA8RONSLs1uS3EVn5atdONuC4JkKckc9PrT9O8O6dYwlb4b/ADcFHiUtvHXJx3H601WeIrPs3ooZTEQSzHGADjvWqj2Eelw3HnTF1h2iJSWcOT0Yfwgc89+tROc4qyb17DxtOMbNLV+Q+OwSysGu7S5s7kG43kqNjhsYK49O9JJcfNxJI467lAA9a1rW/swY2tIomRML5rcyE46AduBjNZkNk18HuImGHYk5l2c57AVyxm226n4nJGU7WenyOct762/taOez+yXMsIdE86PjcR1OORj+dbGr2EWleH9Ds5hBFqDM90qhSAY242k9SRkcnvXjPgzWxq3iWymtVnH2g4fcQM4BPQds17PquoR6nqh1GeJQTHH5aN86RhfT2yc111INTi47b/ovzZ10qrxco1obLf8AD/Mr2zp9n8tgC0KgMoHQjpx2qaOJ/KTcUdivzKDjHqfpTkjUXl3cNcQq8581hAcBn24/pn3p0ixvbfNJskjIYSAdvp61m32O51Xv1I2YIUkXcFlPzKBwQOhPoeKLaVsKBKxWH+DgHr0H19aequjCVTuUqMMwxx9BTLtdzo6AKN3IOMkdKNHoVZPQsSNHkpCpRCSMEdB1x+uai/dvGyOGDMOD25//AFVZt/sktpMgWSC4AV4lPKuDwRnsfeq0/kq6QuSCw2vsbOAB3qYvWxgn9lIwPHFvqY8NXkekMEvwivCRkgBeSPrxXgvhnxd4pHivT/MvJLmSWZYvKlbKMpOOn0NfQGqeS2k3C3lxttYgUlcvycjge9fNPjK60y2uI7fRGlSaGUkyk85+vat3NU4c0pbdO9zwc4U6dWMoy/HsfRfxG8CS+OPDz29uYBe2TDyZXBUjOMg9eK8Jj+DHi0SM00NnFajOLhpwUbHpjJz7Yr0X4aePtXuFsYrsJeQMGSTzQdx2rgEkdRXqjSefZ21vCkbxl3mUiTgbsZyO3Hb2rlxGBUpxdTVdH5FUo0sc/aWfn/X4HGfC/wAFReENDuI7iX7RdXjBpXgj6joqjPOByc11UbGW8R0CEn5cAYcL078Z4x71I8hIdIwqQRqFYkY3qBwPrmovO2OEtYHDleWzjaT6+o5raEOVWij26FFUo8sVZEU0LNK8Hl7ki4OPvdehx3960ZJItOhtbCwilggZ/tEsZGQSRg845HA/Gq0Bls7gPg+Zj5C/zZyOT7kAd6sgyy+XcXDyrDnargcK3HHPNEtWr7fqKtG8kpFG7nPl4uLt4IIgwVZeNw9hj5h7dKrqLe4ht7yBS0G8Hyg2OM8/iT6Vn/EfQrnWdVtJLK6C21ug8xc4DHufpVzSrEwaZa2xJk2ZyeoPHH61qlF01JPcjDzrTqSTjaPR/cactpataXSFYpJrg58wxkBVBGRz9KyUsbEbJDbCaMkqzgAHcP8AGr1zcSQWcUkKLA0eVKhc5PQ/gabJDJLLC00zwQoPMCrwjHHVvepjdKzejN4UvtdTN1DxFpmg6LePLp++8heORIYD99OjA56Y659Kq+EPEc2uXF0GEkSiMFVfGNp5K5FcP4ns4ta1Rrqx16K3u2k2C2dGImJYAAew9+K9V8KeEZtJW5sZm87USokaXZt8/vhe2BitaqpUoNvd/wDAPBwuLrzxLc37iLUbeXp0MgbczuHTy36diT7ZpslvDHcW5iubDUGOJGikLA7hnkn05x+FRiZNsjRxhFkLSq5+6q/3uPocCrCJaNG6sixJsDZVuWPUYHqc1g7r+v6/A9iavqxUtZbi4tyfneAO4jReBz09h161at9Rc30ptZiJIyinfgDdngqR2ycYpul3U0U+pL5M4FxB+8lHXBwQfqcYxWHcb7bU1LIJYpY9wi3fNGoHTA6Ennmo5edtS/rqY+yWIvGfyPQb27trnUUt5YlhuDJuiBywXPUnqBk8etW2s7abTruwuY/KaUYdScbMcr07GuY0CXSL66tooQ6XQKyMd2CWz0Hf8qd8QtcS51COxsH89beYNdIFILOBlQSOw9K872EnUjShdW1v2t1/rqeYsPL2ypxWv5HNwbtPjNlKImnVgS8Y4zzhR6nHekELTJ5smQiSAk5x827J6dMVJBE8srmTd5khDSOc4XJ4C+mMVbXyUaVSQzNEAsanb65Iz3Nes5W16n0VuWPKxPFNxHJrM+qRIYkmAjCTAgfKMEIRxluuTTLYYggi6IctGGPJ49O55pLaOVrCeKadWZSp2tzjByPwxxT980hQQwj7RGhdBxz6qPTtUqKjFQXTT/ImjB04cvYZbyiKZ5WO8MdjnJ4wP/r0kk6rLPmNVgdtwO7gf/W+lSTW4J3SBsJJypHTjkZ/TNVltJPOkEcYlUpwj8DOe5/Sq0epslT+JkS3EbylArlVj3rs43EHjn17YrRjj8q8Lakv7q4RTMiSZZSOgx6EVBNaXLafctDcRrdFNkdrgLsXOC5Pp1xWh4diih+3/an852jMUSlMybiBtG7+XrUVJJRbRyYmqnG66bjJ7yJri4Zji3UkBQOg9R6Yz1qrc21pLJ8sK4Ubc7z83v8ArWskM0EFrGcoyRhxFIvU9CCKxb62vpLl/IkgZF+XLdfXBx6ZxSpNN2i7fM44cs1ornkvwZ8N3FvA+qaqhgZx5cBbO4g9SR29u9evkiVVeFijQoyeXkZdOMED6/pVCxVZLpo3VWjIdipHeo5riVQxVyCI8j2PSt1BytG+x6lHAQwtNUovbqasy+SwZAHZQWLHAz6AD1p6LK75y+xQCAFyef8APNVpwBc22AOcg/h0p6SOk29WIZQCCPqays7GjTUS9I/lRhHASViAvPPPOAD2qpJFOkiT2AhlQscjPAz/ADpmhzy3HiXQ/OcvmcZz3wWxUmnSMTPDn93uZto453nmpcXTdv61uv0OaLd+Vf1cj8n94SfM3HJyTwMHp9KdcSYXzsAEsuFA6g+lJc/LqmoOoAZSADjoNtQo7SCSNzuTYpwfpWiV7N+Ruvea8y7eNprWk8GoSRSW7KN0IX5wxU42nGOCa+VdY+HfiKLVZfK0+SS2YlxMzBVCk/xEnANep/Ei+uYpZVjmdFQllCnGCBwa8H1HXtVvFK3Wo3UqseQ8hINc+Np0qNJOrd9dPK3+Z8nmFdTrODje3W9v0Z7r8Pvh2kdvHqE+pxPFGNsSWkofD9yW7GvULG0XSdPjihZTJEAgXP8ArAT0Y+teafs2uz+CtW3HOy+Urnt8lepuikW2QDvIZvc+taKt7ZJrZ2dvlc9LLFBUotLXX8yrKWSSSFCBMFPA5G3/ABpLpJP3EMEksay/IquBlSTjj39c0+7Zm1lIWOYtpO31xVOZ2eQFjklmz+tbRjex7TvJXL1vdf2Xe2sU5lWyhkf7S5UfK+MdT7c1W16Ge/0i7t9I1JS8rDbOT8yoTnPHen6MBcwSLP8AvF8hmw3qW5qlp0jJHe26ELDE42KAOOWH9Knl5Z36o5auGjVi+Z7o07eE22nSyXs/myqgEeMDdgY59ah05VvJjGH+zW8SbpLnurY4UE9WPNVrniOZlCqUZFXaoGARWrokEV1omqJOgdRFFNjp8/mYz+XFKfurmfW342Rcl7Ki3Dy/yD7K1pYoJ/NzKWYG427+n3VHf1PpWYqYXDKytu2AHLbs9vrx1q/Zk6rFqE2oYnlgVjEzDBTKjOMfSsy3JWNSDgxsQp9MrzTgnqnuPBXqIzH0Owt4f7dliGPP8rzCv+rU5GSRwOeK6bwZNK99Jq32+RtP0xgPLLF/OYjAC+2PwrX+HcrMbtWwyuqKysAQRuIxg8d66fxZp1nBotzbwW0UUPls2xF2jI5B471xVsUozeHa36+Wl9O/Q4MViLVHh2uu5xOpXsc+prd29lLaqfl2cELk8Mv17iqpkke+VY5C0cqlWfj5iD/D6elZ8F5cJHE4kJYKpywB9PWqrzytqlqGckfaSv4HqK7o0eVWOmnBKOmyRqyTTMgZVKmc7Yk3k+Xjqze/60iWQiVdimbKcEtjZ/ifrT/FxMfijVAmFEMYMYA4U4B6VUsp5fs0hLniRse3FTC8oKa6nRR1gmuoDTzJNlVeCQsAjxMVYY57dBjj61aSAxTNKzNPIvyhm43HPOfU+9JcEmOEnrtIyODjBqccTIB0ZQT74Xim7mkoNO4PgPOkyq6qNrLu5J9PYc0+INElxDbT4eUYlmLAkADjB9O2RUumsWsXY4LbVOcc89aZYoksEqyKpUZXGO2BxWbe9+hjycz16FdbRDEjSEAOGWPa2dxz1z34ohYQ3izL5nyLs2OQPm45FUddmkgvIUhdkUkjCnHervhr/SChnCybHULuAOK0knyObNJxaps2Jrdlt8+U4jQc7jgnJ7DvzVZdOF2piM89ukTHMhboB2I68Vfbm71WY8yxIAjf3cjnFZ1zdTJZQush3NGQTjnmuWHO/hf9WPLU57Ef2eVbdVtRIbhm2RyMOWHbA/Hp1NTyS/Zd0d/B5EchBZ0T94SB0Udhn16dqfcOyujqxDx4ZWHUHB5+tWtOijk1SJZFDCO1Lru5+bPX3NOUtLyIb5rpmZdyNK0n2WRvtMisygcxgjtjI546VDaR6DHZ24kgfUrhkDz3FxM0bGQ8kY9BnFPaeRdbikUgM8O5vlHJxjOPXBqpDM6wrgg5yTkA9yO/0rdQdrX+52/IfJdeR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four trophozoites (yellow arrows) of",
"    <em>",
"     Sappinia diploidea",
"    </em>",
"    in brain tissue, stained with hematoxylin and eosin (H&amp;E). In three of the amebae, the two nuclei can easily be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Free-living amebic infections. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/FreeLivingAmebic_il.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/FreeLivingAmebic_il.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4069=[""].join("\n");
var outline_f3_62_4069=null;
var title_f3_62_4070="Hypersensitivity vasculitis in children";
var content_f3_62_4070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypersensitivity vasculitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4070/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4070/contributors\">",
"     Karyl S Barron, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4070/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4070/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4070/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4070/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/62/4070/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"hypersensitivity vasculitis\" refers to a vasculitis of small blood vessels of the skin (especially arterioles and venules), which is secondary to an immune response or hypersensitivity reaction to an exogenous substance. Other terms to describe these disorders include \"predominantly cutaneous vasculitis\" or \"cutaneous leukocytoclastic vasculitis\". In most cases, the inciting antigen is never identified and the disease remains idiopathic. In others, it may be caused by a specific drug or occur in association with an infection.",
"   </p>",
"   <p>",
"    Hypersensitivity vasculitis in children including the clinical features, diagnosis, and treatment will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major finding of hypersensitivity vasculitis is the skin findings of palpable petechiae or purpura of the skin (",
"    <a class=\"graphic graphic_picture graphicRef78697 graphicRef60323 \" href=\"UTD.htm?38/42/39587\">",
"     picture 1A-B",
"    </a>",
"    ). Biopsy of the lesions reveals prominent inflammation of the small blood vessels, typically with neutrophilic or mononuclear infiltration of the vessel wall and perivascular region called leukocytoclastic vasculitis (",
"    <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"UTD.htm?7/58/8106\">",
"     picture 2A-B",
"    </a>",
"    ). The term leukocytoclastic refers to the residual nuclear debris from the infiltrated neutrophils. In general, postcapillary venules are the most prominently involved vessels followed by less frequent involvement by the capillaries and arterioles. Erythrocytes often extravasate from the invaded vessels leading to palpable purpura.",
"   </p>",
"   <p>",
"    Two histologic patterns have been described, which can be either necrotizing or nonnecrotizing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mononuclear cell predominant",
"     </li>",
"     <li>",
"      Polymorphonuclear cell predominant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histologic pattern is highly sensitive to the age of the lesion. Lesions that are less than 24 hours old are more likely to be predominantly polymorphonuclear and have leukocytoclastic changes, while older lesions show an increase in mononuclear predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little correlation between the clinical manifestations and the specific histologic pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity vasculitis is thought to represent an immune complex process. Evidence for circulating immune complex formation includes the detection of soluble complexes and the deposition of immune reactants in vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/4\">",
"     4",
"    </a>",
"    ]. Immune complexes are detected more frequently in early, rather than late, lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity vasculitis was first reported after the administration of heterologous antisera and was initially called serum sickness. In the past, serum sickness was the most frequent form of vasculitis because of the use of therapeutic antisera.",
"   </p>",
"   <p>",
"    As discussed above, hypersensitivity vasculitis is caused by agents that act as haptens, which stimulate an immune response. In most cases, the exciting antigen is never identified and the disease remains idiopathic. In others, it may be caused by a specific drug or occur in association with an infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medications can cause hypersensitivity vasculitis, but antibiotics, nonsteroidal antiinflammatory agents, diuretics and anticonvulsants are most often implicated as the cause in drug-mediated hypersensitivity vasculitis (",
"    <a class=\"graphic graphic_table graphicRef81148 \" href=\"UTD.htm?2/22/2414\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ]. In addition to drugs, foods and food additives may be responsible for the reaction in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although drugs are the most common cause, drug-induced vasculitis is a poorly defined disorder, since proving causality is difficult. As a result, classification of all suspected cases of drug-induced vasculitis is based upon the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The precipitating agent",
"     </li>",
"     <li>",
"      The involved organs (eg, isolated to the skin, gastrointestinal tract, etc)",
"     </li>",
"     <li>",
"      The pathologic description",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Food",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although controversial, it has been proposed that foods and food additives may be responsible for hypersensitivity vasculitis in some children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As an example, in two reported cases, symptoms resolved after elimination of the suspected food antigen and recurred with reintroduction of the specific food (rechallenge) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/8\">",
"     8",
"    </a>",
"    ]. In one child, the offending agent was cow's milk and in the other, chocolate and other cocoa-containing products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several infectious agents have been associated with hypersensitivity vasculitis including hepatitis B or C infection, streptococcal agents, Mycobacterium tuberculosis, and HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ]. Hypersensitivity vasculitis has been reported in children with endocarditis and infected shunts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of hypersensitivity vasculitis are the skin findings of palpable purpura",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    petechiae (",
"    <a class=\"graphic graphic_picture graphicRef78697 graphicRef60323 \" href=\"UTD.htm?38/42/39587\">",
"     picture 1A-B",
"    </a>",
"    ). Lesions most commonly occur in the lower extremities or other dependent areas. Edema may accompany some lesions. Other cutaneous manifestations of the vasculitis may occur including macules, papules, vesicles, bullae, subcutaneous nodules and urticaria.",
"   </p>",
"   <p>",
"    In most patients, symptoms begin 7 to 10 days after antigen exposure, the time required to produce a sufficient quantity of antibody to form antigen-antibody complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. However, the latent period may be as short as two to seven days with a secondary antigen exposure, or longer than two weeks with a long-acting drug such as benzathine penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/6\">",
"     6",
"    </a>",
"    ]. Manifestations usually appear abruptly. Skin lesions generally are at the same stage of development and generally resolve after a period of days to weeks.",
"   </p>",
"   <p>",
"    Additional findings may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Malaise",
"     </li>",
"     <li>",
"      Myalgia",
"     </li>",
"     <li>",
"      Urticaria",
"     </li>",
"     <li>",
"      Arthralgia",
"     </li>",
"     <li>",
"      Lymphadenopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the fact that skin lesions predominate, other organ systems may be involved to varying degrees. However, it is difficult to ascertain the frequency of noncutaneous organ involvement because of the lack of detailed description of internal organ involvement in most cases, and a bias for reporting isolated cases with serious end organ damage. In adult series, glomerulonephritis, interstitial nephritis, and varying degrees of hepatocellular injury have all been described. Lung, heart, and central nervous system involvement has been rarely reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal involvement that is usually mild can be seen in some children, and is manifest by hematuria, proteinuria, and cellular casts. Acute renal failure is rare, but can occur with heavy or prolonged antigen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/13\">",
"     13",
"    </a>",
"    ]. Renal biopsy, if performed, typically reveals a proliferative glomerulonephritis with immunoglobulin (primarily IgG) and complement deposition along the glomerular capillary wall.",
"   </p>",
"   <p>",
"    Although hypersensitivity vasculitis is usually acute and abates once the antigen has been cleared, chronic disease has been observed in some patients with persistent hepatitis B or C virus infection and occasionally among those with idiopathic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypersensitivity vasculitis is based upon clinical findings of palpable purpura, a history of an offending agent, such as a drug (",
"    <a class=\"graphic graphic_table graphicRef81148 \" href=\"UTD.htm?2/22/2414\">",
"     table 1",
"    </a>",
"    ) or infection, and a biopsied skin lesion that is characterized by a leukocytoclastic vasculitis (",
"    <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"UTD.htm?7/58/8106\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, additional clinical criteria may be necessary to distinguish hypersensitivity vasculitis from the more commonly seen Henoch-Sch&ouml;nlein purpura (HSP), such as IgA deposition that is seen in patients with HSP but not in those with hypersensitivity vasculitis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although no specific laboratory test is diagnostic of hypersensitivity vasculitis, the following non-specific laboratory findings are often seen in affected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild leukocytosis.",
"     </li>",
"     <li>",
"      Low serum complement levels particularly C3 and C4, although there is no definitive pattern of complement findings suggestive of the diagnosis.",
"     </li>",
"     <li>",
"      Elevated inflammatory markers such as erythrocyte sedimentation and C reactive protein.",
"     </li>",
"     <li>",
"      Positive culture or serology (eg, hepatitis C virus) of an infectious agent associated with hypersensitivity vasculitis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity vasculitis may be difficult to distinguish from other forms of vasculitis, particularly when findings are only confined to the skin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura &mdash; In children, Henoch-Sch&ouml;nlein purpura (HSP) is the most common disorder in the differential diagnosis of hypersensitivity vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/15\">",
"       15",
"      </a>",
"      ]. Palpable purpura and arthralgia are prominent features of HSP, which also may be associated with bowel angina, gastrointestinal bleeding,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematuria. In contrast to patients with hypersensitivity vasculitis, patients with HSP usually have normal complement levels and the deposition of IgA-containing immune complexes on skin or renal biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignancy-associated vasculitis &mdash; Malignancy-associated vasculitis is uncommon in children. The malignancies associated with vasculitis tend to be chronic and are most frequently due to a lymphoproliferative disease. Patients present with palpable purpura and generally have other signs or symptoms of their malignancy.",
"     </li>",
"     <li>",
"      Systemic vasculitides (eg, granulomatosis with polyangiitis [Wegener&rsquo;s], polyarteritis nodosa, and microscopic polyarteritis), although uncommon in children, may occasionally present with predominantly cutaneous involvement, such as palpable purpura. The presence of systemic signs and symptoms, evidence of internal visceral target organ involvement, and ANCA positivity in combination with the lack of evidence of immune deposits are helpful in identifying these syndromes and distinguishing them from hypersensitivity vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/7,16,17\">",
"       7,16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=see_link\">",
"       \"Classification and incidence of childhood vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with hypersensitivity vasculitis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of the inciting agent &mdash; Removal of the inciting antigen (eg, discontinuation of the implicated drug) should lead to resolution of the lesions. Resolution of symptoms within a period of days to a few weeks after elimination of the suspected antigen is supportive of the diagnosis.",
"      <br/>",
"      <br/>",
"      In patients with infection-associated hypersensitivity vasculitis, treatment should be aimed at the underlying infection, such as the administration of interferon with hepatitis C virus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic treatment &mdash; In patients with severe or persistent cutaneous disease, drugs such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14118?source=see_link\">",
"       colchicine",
"      </a>",
"      , antihistamines, nonsteroidal antiinflammatory drugs, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"       dapsone",
"      </a>",
"      may be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/18\">",
"       18",
"      </a>",
"      ]. Immunosuppressive therapy with glucocorticoids or cytotoxic agents should be reserved for the infrequent patient with fulminant or progressive disease, or other organ involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4070/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9657?source=see_link\">",
"       \"Overview of the management of vasculitis in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypersensitivity vasculitis refers to a vasculitis of small blood vessels of the skin, especially arterioles and venules, which is secondary to an immune response or hypersensitivity reaction to an exogenous substance.",
"     </li>",
"     <li>",
"      Hypersensitivity vasculitis is thought to be caused by agents that act as haptens, which stimulate an immune response. In most cases, the inciting antigen is never identified and the disease remains idiopathic. In others, it may be caused by a specific drug (",
"      <a class=\"graphic graphic_table graphicRef81148 \" href=\"UTD.htm?2/22/2414\">",
"       table 1",
"      </a>",
"      ) or occur in association with an infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical finding is the skin findings of palpable purpura",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      petechiae (",
"      <a class=\"graphic graphic_picture graphicRef78697 graphicRef60323 \" href=\"UTD.htm?38/42/39587\">",
"       picture 1A-B",
"      </a>",
"      ). Biopsy of the lesions reveals prominent inflammation of the small blood vessels, typically with neutrophilic or mononuclear infiltration of the vessel wall and perivascular region called leukocytoclastic vasculitis. Additional findings include fever, malaise, myalgia, urticaria, arthralgia, and lymphadenopathy. Other organ involvement may include renal and liver disease, and rarely the lung, heart, and central nervous system. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of hypersensitivity vasculitis is based upon clinical findings of palpable purpura",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      petechiae, the history of an inciting agent, such as a drug (",
"      <a class=\"graphic graphic_table graphicRef81148 \" href=\"UTD.htm?2/22/2414\">",
"       table 1",
"      </a>",
"      ) or infection, and a skin biopsy that demonstrates a leukocytoclastic vasculitis (",
"      <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"UTD.htm?7/58/8106\">",
"       picture 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, Henoch-Sch&ouml;nlein purpura (HSP) is the main disease that is difficult to distinguish from hypersensitivity vasculitis. Normal complement levels and IgA deposition distinguished HSP from hypersensitivity vasculitis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The major intervention in the treatment of children with hypersensitivity vasculitis is removal of the inciting agent. Symptomatic therapy used in severe or persistent skin lesions includes",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14118?source=see_link\">",
"       colchicine",
"      </a>",
"      , antihistamines, nonsteroidal antiinflammatory drugs, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"       dapsone",
"      </a>",
"      . Immunosuppressive therapy with corticosteroids or cytotoxic agents should be reserved for the infrequent patient with fulminant or progressive disease, or other organ involvement.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/1\">",
"      Soter NA, Mihm MC Jr, Gigli I, et al. Two distinct cellular patterns in cutaneous necrotizing angiitis. J Invest Dermatol 1976; 66:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/2\">",
"      Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis. Serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate. Arch Dermatol 1990; 126:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/3\">",
"      Mullick FG, McAllister HA Jr, Wagner BM, Fenoglio JJ Jr. Drug related vasculitis. Clinicopathologic correlations in 30 patients. Hum Pathol 1979; 10:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/4\">",
"      Tosca N, Stratigos JD. Possible pathogenetic mechanisms in allergic cutaneous vasculitis. Int J Dermatol 1988; 27:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/5\">",
"      Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol 1996; 8:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/6\">",
"      Parker CW. Allergic reactions in man. Pharmacol Rev 1982; 34:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/7\">",
"      Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997; 102:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/8\">",
"      Businco L, Falconieri P, Bellioni-Businco B, Bahna SL. Severe food-induced vasculitis in two children. Pediatr Allergy Immunol 2002; 13:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/9\">",
"      Lunardi C, Bambara LM, Biasi D, et al. Elimination diet in the treatment of selected patients with hypersensitivity vasculitis. Clin Exp Rheumatol 1992; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/10\">",
"      Sais G, Vidaller A, Jucgl&agrave; A, et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 1995; 131:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/11\">",
"      Blanco R, Mart&iacute;nez-Taboada VM, Rodr&iacute;guez-Valverde V, Garc&iacute;a-Fuentes M. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore) 1998; 77:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/12\">",
"      Leavitt RY, Fauci AS. Polyangiitis overlap syndrome. Classification and prospective clinical experience. Am J Med 1986; 81:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/13\">",
"      de La Pava, Nigogosyan G, Pickren JW. Fatal glomerulonephritis after receiving horse anti-human-cancer serum. Report of three cases. Arch Intern Med 1962; 109:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/14\">",
"      Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/15\">",
"      Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Sch&ouml;nlein purpura: a comparison between the 2 disorders. J Rheumatol 1992; 19:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/16\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/17\">",
"      Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4070/abstract/18\">",
"      Bodemer C. [Allergic vasculitis in children]. Ann Pediatr (Paris) 1992; 39:426.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6404 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4070=[""].join("\n");
var outline_f3_62_4070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6404|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9794\" title=\"picture 1A\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/50/37677\" title=\"picture 1B\">",
"      Drug induced skin vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/20/43333\" title=\"picture 2A\">",
"      Leukocytoclastic vasculitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/37/23126\" title=\"picture 2B\">",
"      Leukocytoclastic vasculitis II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6404|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/22/2414\" title=\"table 1\">",
"      Drugs cutaneous vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9657?source=related_link\">",
"      Overview of the management of vasculitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_62_4071="Treatment of narcolepsy";
var content_f3_62_4071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of narcolepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4071/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4071/contributors\">",
"     Thomas E Scammell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4071/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4071/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4071/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/62/4071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly half of patients with narcolepsy report that their sleepiness and cataplexy substantially interfere with their daily lives, including jobs, marriages, or social lives [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/1\">",
"     1",
"    </a>",
"    ]. The mainstays of therapy are brief daytime naps and pharmacologic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to realize that patients with narcolepsy often have concomitant obstructive sleep apnea, periodic limb movements of sleep, fragmented sleep,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rapid eye movement (REM) sleep behavior disorder that contribute to their daytime sleepiness. It is often helpful to treat these disorders first and then to focus on improving the sleepiness that is caused by the narcolepsy. This topic assumes that coexisting sleep disorders have been treated and reviews the treatment of narcolepsy and its symptoms. The diagnosis and neurobiology of narcolepsy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25913?source=see_link\">",
"     \"Clinical features and diagnosis of narcolepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several nonpharmacologic interventions that may benefit the patient with narcolepsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoiding certain drugs &ndash; Some drugs should be avoided by patients with narcolepsy. Drugs that can worsen daytime sleepiness include benzodiazepines, opiates, antipsychotics, and alcohol. Other medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      or excessive caffeine can cause insomnia, which can worsen daytime sleepiness. In addition,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      and other alpha-1 antagonists can worsen cataplexy.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Napping/sleep",
"      </span>",
"      hygiene &ndash; Behavioral interventions are often helpful for optimal control of narcolepsy. One or two well-timed 20 minute naps will often improve sleepiness for one to three hours though some patients only benefit from long naps [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/3\">",
"       3",
"      </a>",
"      ]. If it can be arranged, a brief nap at work or school is often helpful. Sleep deprivation may worsen narcolepsy symptoms and therefore patients should be counseled to maintain a regular and adequate sleep schedule [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Psychosocial support &ndash; Patients with narcolepsy face various psychosocial and work-related problems throughout their lives; as a result, they may have difficulty meeting economic and social responsibilities [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/5\">",
"       5",
"      </a>",
"      ]. They also have the additional burden of coping with misperceptions about the causes and the involuntary nature of their symptoms. Common misconceptions, even among medical caregivers, are that sleep attacks and cataplexy (emotionally triggered muscle paralysis resulting in partial or complete collapse) are manifestations of poor motivation, denial, or avoidance. Thus, patients often benefit from participation in support groups that focus on coping skills and identification of community resources to assist with administrative and medical issues.",
"      <br/>",
"      <br/>",
"      Narcolepsy often begins during early adolescence and its symptoms can severely disrupt school performance and social development. Many clinicians find it helpful to work closely with the school guidance counselor to ensure that the child has an opportunity for a brief nap. Schools can sometimes make other accommodations to improve the child&rsquo;s alertness, such as sitting at the front of the class or allowing a break midway through a long test. Some teens find cataplexy very embarrassing and counseling or support from other teens or young adults with narcolepsy can be helpful. Sudden obesity is common in children with narcolepsy and regular exercise and a thoughtful diet are often necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients will benefit from these nonpharmacologic approaches, but most also require medications that reduce sleepiness and cataplexy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Daytime sleepiness",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with narcolepsy have some degree of daytime sleepiness. Although a few manage this successfully with only an afternoon nap, most patients require a medication that promotes wakefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/6\">",
"     6",
"    </a>",
"    ]. Such agents improve performance (measured by reaction time and simulated driving tasks), but performance rarely exceeds 70 to 80 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of therapy are to obtain \"normal\" alertness during conventional waking hours or to maximize alertness at important times of the day (eg, during work, school, or while driving). Once therapy has been optimized, the severity of residual sleepiness should be assessed with the Epworth Sleepiness Score or the Maintenance of Wakefulness Test, and persistently sleepy patients should be counseled to avoid potentially dangerous activities, such as driving. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link\">",
"     \"Quantifying sleepiness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Modafinil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    has become a first line pharmacologic therapy because it provides good control of sleepiness, is generally well tolerated, and illicit use is rare. A non-amphetamine \"wakefulness promoting agent,\" its mechanism of action is not well understood, but it may increase dopaminergic signaling (",
"    <a class=\"graphic graphic_figure graphicRef73012 \" href=\"UTD.htm?7/57/8086\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trial randomly assigned 283 patients with narcolepsy to receive 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    , 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of modafinil, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/12\">",
"     12",
"    </a>",
"    ]. After nine weeks, patients treated with modafinil at either dose had significant improvements in their Maintenance of Wakefulness Tests and Epworth Sleepiness Scale measurements, without evidence of tolerance to the drug. Similar results were found in a second clinical trial involving 271 patients with narcolepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link\">",
"     \"Quantifying sleepiness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    given once in the morning typically promotes wakefulness into the early evening without disrupting nighttime sleep. It is generally started at a dose of 200 mg each morning and then titrated up to 300 or 400 mg as needed. Patients with persistent afternoon sleepiness may benefit from divided dosing with 200 mg in the morning and 200 mg in the mid-afternoon (",
"    <a class=\"graphic graphic_table graphicRef73910 \" href=\"UTD.htm?37/3/37949\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects are uncommon but include headache, nausea, dry mouth, anorexia, and diarrhea.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    may have fewer sympathomimetic effects than amphetamines and is often a good choice for older patients. Still, modafinil may increase blood pressure (especially at high doses), and it should be used cautiously in people with a history of arrhythmias or heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Rarely, modafinil can cause a serious rash, including Stevens-Johnson Syndrome.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    reaches peak bioavailability in about two hours. The drug is hepatically metabolized and induces several cytochrome P450 enzymes, thus decreasing the effectiveness of oral contraceptives and perhaps other medications; women of childbearing age who use modafinil should use an alternative method of contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Methylphenidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    is a central nervous system stimulant and a potent wakefulness-promoting drug. Although effective, it is considered a second-line agent because its sympathomimetic side effects can be problematic.",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    (10 mg) is typically administered twice per day, with the last dose given no later than about 3 pm. Therapy is often initiated with immediate release formulations and then converted to a sustained release formulation once a stable daily dose has been reached. Methylphenidate dosages are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef73910 \" href=\"UTD.htm?37/3/37949\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Typical doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    increase systolic blood pressure about 5 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/19\">",
"     19",
"    </a>",
"    ], which may have long term consequences. In addition, regulatory authorities reviewed several cases of sudden death in patients taking methylphenidate and issued a warning regarding serious cardiovascular events in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Some of these deaths were associated with hypertrophic obstructive cardiomyopathy, while others may have been related to arrhythmias. Patients taking high doses for daytime sleepiness also can develop psychosis, anorexia, or require psychiatric hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/22\">",
"     22",
"    </a>",
"    ]. Methylphenidate and other stimulants can also lower the threshold for seizures. The potential for methylphenidate dependency exists. Patients prescribed methylphenidate should be carefully informed about these risks, and their blood pressure, pulse, and weight should be monitored regularly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Amphetamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , amphetamines are central nervous system stimulants.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     Dextroamphetamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/25/42390?source=see_link\">",
"     methamphetamine",
"    </a>",
"    may be the most potent wakefulness-promoting drugs, although some patients require relatively high doses. Other amphetamines include mixed amphetamine salts (Adderall) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/53/23382?source=see_link\">",
"     lisdexamfetamine",
"    </a>",
"    . The amphetamines are considered second-line agents because their sympathomimetic side effects can be problematic. By increasing aminergic signaling, these drugs can also improve cataplexy, hypnagogic hallucinations, and sleep paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/6,23,24\">",
"     6,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    (5 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/25/42390?source=see_link\">",
"     methamphetamine",
"    </a>",
"    (5 mg) are typically administered twice per day, with the last dose given no later than about 3 pm (",
"    <a class=\"graphic graphic_table graphicRef73910 \" href=\"UTD.htm?37/3/37949\">",
"     table 1",
"    </a>",
"    ). Therapy is usually initiated with immediate release formulations and then converted to a sustained release formulation once a stable daily dose has been reached.",
"   </p>",
"   <p>",
"    Amphetamines can produce adverse effects similar to those seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    . These include cardiovascular events (eg, hypertension, sudden death) and psychiatric events (eg, psychosis, anorexia, addiction) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. Patients prescribed amphetamines should be carefully informed about these risks and monitored regularly. These concerns are highlighted in new patient medication guides provided by the manufacturers of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/25/42390?source=see_link\">",
"     methamphetamine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cataplexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 30 percent of people with narcolepsy have cataplexy that is substantial enough to warrant treatment. Although hypnagogic hallucinations and sleep paralysis usually do not require specific treatment, these symptoms are often improved by medications that suppress cataplexy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     REM sleep-suppressing drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brainstem circuits that generate REM sleep are strongly inhibited by norepinephrine and serotonin. Thus, drugs that increase noradrenergic and serotonergic signaling suppress REM sleep and reduce cataplexy (",
"    <a class=\"graphic graphic_table graphicRef73910 \" href=\"UTD.htm?37/3/37949\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antidepressants that selectively inhibit the reuptake of norepinephrine or serotonin include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . Clinical experience suggests that they may substantially reduce cataplexy with relatively few side effects, although data from clinical trials are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/26\">",
"     26",
"    </a>",
"    ]. We have found extended release venlafaxine to be effective in many patients at a dose of 37.5 to 150 mg each morning, although fluoxetine and atomoxetine are also acceptable.",
"   </p>",
"   <p>",
"    For many years, cataplexy was treated with tricyclic antidepressants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"     protriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    that decrease the reuptake of aminergic neurotransmitters. These drugs are very effective, but many patients are bothered by anticholinergic side effects, including dry mouth and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abrupt withdrawal from any of these antidepressants can trigger status cataplecticus: severe, nearly continuous rebound cataplexy that can last up to several hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sodium oxybate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     Sodium oxybate",
"    </a>",
"    , the sodium salt of gamma hydroxybutyrate (GHB), is a metabolite of gamma amino butyric acid (GABA) that may act through GABA-B receptors. It also binds to specific gamma hydroxybutyrate receptors, but its precise mechanism of action in patients with narcolepsy is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     Sodium oxybate",
"    </a>",
"    markedly reduces cataplexy and, therefore, is a good choice for patients with severe cataplexy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. The reduction in cataplexy develops over several weeks of treatment so doses should be adjusted slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/32,35\">",
"     32,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     Sodium oxybate",
"    </a>",
"    can also decrease daytime sleepiness, perhaps by improving the quality of nighttime sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In one observational study, sodium oxybate was associated with a 30 percent decrease of subjective sleepiness, assessed by the Epworth Sleepiness Scale [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/32\">",
"     32",
"    </a>",
"    ]. Similarly, another observational study demonstrated improved sleepiness following the initiation of sodium oxybate, assessed by the Maintenance of Wakefulness Test [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link\">",
"     \"Quantifying sleepiness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     Sodium oxybate",
"    </a>",
"    is given as a liquid at bedtime, with a second dose 2.5 to 4 hours later; this second dose is necessary as the half-life is only two to three hours (",
"    <a class=\"graphic graphic_table graphicRef73910 \" href=\"UTD.htm?37/3/37949\">",
"     table 1",
"    </a>",
"    ). Patients may initially need to set an alarm clock to remind them to take the second dose, but after a few weeks, many learn to wake around the correct time. An appropriate initial dose is 3 g, twice per night. The dose can be increased up to 4.5 g, twice per night if cataplexy persists. The benefits of sodium oxybate are often apparent in the first few days, but it can take two to three months to achieve the full response; therefore, the dose should be increased slowly (0.75 g increases every two to four weeks), if needed.",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     sodium oxybate",
"    </a>",
"    are dose-dependent and are more common than with most other anticataplectic drugs. Sodium oxybate rapidly produces deep sedation, so household safety should be discussed (ability to respond to smoke alarms, care for children, etc). Additional adverse effects include nausea and dizziness, urinary incontinence, and worsening of sleepwalking [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/35\">",
"     35",
"    </a>",
"    ]. Overdosage can result in respiratory depression, coma, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Coadministration with alcohol and central nervous system depressants such as benzodiazepines and opioids increases risk for impaired consciousness and respiratory depression. Due to these risks, combined use with alcohol, sedatives, or hypnotics is specifically contraindicated in US licensing information [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gamma hydroxybutyrate gained notoriety as a &ldquo;date rape&rdquo; drug, and has potential for abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4071/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Thus, access to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     sodium oxybate",
"    </a>",
"    is restricted in the US, and prescribers are required to register with the Food and Drug Administration&rsquo;s Risk Evaluation and Mitigation Strategies (REMS) program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/19/27953?source=see_link\">",
"       \"Patient information: Narcolepsy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"       \"Patient information: Daytime sleepiness (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nearly half of patients report that their sleepiness and cataplexy substantially interfere with their daily lives, including jobs, marriages, or social lives. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with narcolepsy can benefit from a regular and adequate sleep schedule, scheduled daytime naps, avoidance of drugs that produce daytime sleepiness or insomnia, and a psychosocial support group. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many sleep disorders (eg, sleep apnea, periodic leg movements) can coexist with narcolepsy, thereby contributing to a patient's symptoms. Such disorders should be addressed before initiating narcolepsy-specific medications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the drugs available to treat narcolepsy target either daytime sleepiness or cataplexy. Therefore, many patients who have both symptoms require more than one drug to manage their disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Few patients with narcolepsy ever feel fully alert despite optimal therapy. The goal of therapy is to improve alertness to the point where performance and safety are not adversely affected. Once therapy has been optimized, the severity of residual sleepiness should be assessed with the Epworth Sleepiness Score or the Maintenance of Wakefulness Test, and persistently sleepy patients should be counseled to avoid potentially dangerous activities, such as driving. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Daytime sleepiness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with sleepiness severe enough to require medication can be treated with stimulant medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      , or amphetamines. We suggest an initial trial of modafinil, rather than methylphenidate or an amphetamine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The basis of this suggestion is that only modafinil has been studied in patients with narcolepsy using randomized, placebo-controlled trials, and modafinil seems to produce fewer adverse effects. However, modafinil can be more expensive and there is no reason to suspect that its efficacy is superior to other stimulants. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Modafinil'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Methylphenidate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Amphetamines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When prescribing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"       dextroamphetamine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/25/42390?source=see_link\">",
"       methamphetamine",
"      </a>",
"      , clinicians should alert patients about the risks of serious cardiovascular and psychiatric side effects. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Methylphenidate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Amphetamines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a REM sleep-suppressing medication (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"       atomoxetine",
"      </a>",
"      ) as first line therapy for cataplexy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We prefer extended release venlafaxine. For patients who do not improve with one of these medications,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"       sodium oxybate",
"      </a>",
"      may be of benefit. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'REM sleep-suppressing drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Sodium oxybate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/1\">",
"      Roy A. Psychiatric aspects of narcolepsy. Br J Psychiatry 1976; 128:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/2\">",
"      Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007; 30:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/3\">",
"      Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993; 16:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/4\">",
"      Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001; 24:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/5\">",
"      Goswami M. The influence of clinical symptoms on quality of life in patients with narcolepsy. Neurology 1998; 50:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/6\">",
"      Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994; 17:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/7\">",
"      Boivin DB, Montplaisir J, Petit D, et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993; 16:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/8\">",
"      Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep 1993; 16:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/9\">",
"      Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20:8620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/10\">",
"      Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/11\">",
"      Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009; 301:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/12\">",
"      Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/13\">",
"      Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000; 54:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/14\">",
"      Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/15\">",
"      Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of diphenhydramine and modafinil on arousal and autonomic functions in healthy volunteers. J Psychopharmacol 2007; 21:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/16\">",
"      Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000; 1:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/17\">",
"      Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/18\">",
"      Roth T, Schwartz JR, Hirshkowitz M, et al. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med 2007; 3:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/19\">",
"      Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005; 66:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/20\">",
"      Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354:1445.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Drug and Safety Management Advisory Committee Meeting, February 9 and 10, 2006. file://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202_00_TOC.htm (Accessed on July 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/22\">",
"      Mahowald MW, Bornemann MA. Stimulants and narcolepsy. Sleep 2005; 28:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/23\">",
"      Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol 1990; 7:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/24\">",
"      Shindler J, Schachter M, Brincat S, Parkes JD. Amphetamine, mazindol, and fencamfamin in narcolepsy. Br Med J (Clin Res Ed) 1985; 290:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/25\">",
"      Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997; 52:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/26\">",
"      Vignatelli L, D'Alessandro R, Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database Syst Rev 2005; :CD003724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/27\">",
"      Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003; 53:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/28\">",
"      Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB)--a neuroactive drug with abuse potential. J Toxicol Clin Toxicol 1997; 35:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/29\">",
"      Vienne J, Bettler B, Franken P, Tafti M. Differential effects of GABAB receptor subtypes, {gamma}-hydroxybutyric Acid, and Baclofen on EEG activity and sleep regulation. J Neurosci 2010; 30:14194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/30\">",
"      Gamma hydroxybutyrate (Xyrem) for narcolepsy. Med Lett Drugs Ther 2002; 44:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/31\">",
"      Tunnicliff G, Raess BU. Gamma-Hydroxybutyrate (orphan medical). Curr Opin Investig Drugs 2002; 3:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/32\">",
"      A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/33\">",
"      Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/34\">",
"      Alshaikh MK, Tricco AC, Tashkandi M, et al. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med 2012; 8:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/35\">",
"      A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/36\">",
"      Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009; 5:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/37\">",
"      Wang YG, Swick TJ, Carter LP, et al. Sodium oxybate: updates and correction to previously published safety data. J Clin Sleep Med 2011; 7:415.",
"     </a>",
"    </li>",
"    <li>",
"     Sodium oxybate (Xyrem) US licensed product information file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021196s013lbl.pdf (Accessed on December 28, 2012).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Warning against use of Xyrem (sodium oxybate) with alcohol or drugs causing respiratory depression file://www.fda.gov/Drugs/DrugSafety/ucm332029.htm (Accessed on December 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/40\">",
"      Kam PC, Yoong FF. Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia 1998; 53:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4071/abstract/41\">",
"      Mason PE, Kerns WP 2nd. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 2002; 9:730.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7681 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4071=[""].join("\n");
var outline_f3_62_4071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONPHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Daytime sleepiness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Modafinil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Methylphenidate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Amphetamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cataplexy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - REM sleep-suppressing drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sodium oxybate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7681\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7681|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/57/8086\" title=\"figure 1\">",
"      Neurochemical targets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7681|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/3/37949\" title=\"table 1\">",
"      Medications for narcolepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=related_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/19/27953?source=related_link\">",
"      Patient information: Narcolepsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_62_4072="Diagnosis and management of pleural causes of unexpandable lung";
var content_f3_62_4072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of pleural causes of unexpandable lung",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4072/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4072/contributors\">",
"     Richard W Light, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4072/contributors\">",
"     Peter Doelken, MD, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4072/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4072/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/62/4072/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/62/4072/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/62/4072/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unexpandable lung is present when the lung is unable to expand to the chest wall and achieve visceral and parietal pleural apposition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Full expansion of the lung can be prevented by inflammatory or fibrotic processes affecting the visceral pleura or by extrapleural processes such as endobronchial obstruction, chronic lung atelectasis, or lung parenchymal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unexpandable lung caused by disease of the visceral pleura usually comes to medical attention when removal of pleural fluid does not result in lung reexpansion or during the evaluation of a pleural effusion of undetermined etiology. &nbsp;",
"   </p>",
"   <p>",
"    The two types of pleural disease that result in unexpandable lung are lung entrapment and trapped lung. The diagnosis and management of these conditions will be reviewed here. The evaluation of pleural effusions, including those of undetermined etiology, the measurement of pleural pressures, and the physiology of excess pleural fluid production and accumulation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link\">",
"     \"Measurement of pleural pressure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=see_link\">",
"     \"Mechanisms of pleural liquid accumulation in disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88662168\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two types of pleural disease that result in unexpandable lung are lung entrapment and trapped lung. Both of these processes are associated with the presence of pleural fluid.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In lung entrapment, the lung is unexpandable due to visceral pleural restriction from active pleural disease, such as malignancy or infection.",
"     </li>",
"     <li>",
"      Trapped lung is a consequence of a remote inflammatory condition that has left behind a collagenous or fibrous peel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the absence of active pleural disease in patients with trapped lung, these entities can be differentiated by the particular patterns of pleural pressure and elastance (change in pleural pressure divided by the amount of pleural fluid removed) noted during thoracentesis. The key reasons to differentiate these entities are to identify active pleural processes that require specific treatment and to avoid unnecessary pleural procedures in patients with trapped lung. The technique of measuring pleural pressure and the interpretation of the results are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link\">",
"     \"Measurement of pleural pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LUNG ENTRAPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54982991\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung entrapment is most commonly caused by pleural malignancy, but can also be caused by pleural infection or inflammation (eg, rheumatoid pleuritis, postcardiac surgery pleuritis). Among malignant causes of lung entrapment, mesothelioma, primary lung cancer, and breast cancer are most common [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Lung entrapment complicates approximately 5 to 20 percent of malignant pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63531199\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a malignant pleural effusion is complicated by lung entrapment, fluid formation is due to a combination of increased capillary filtration (leakiness) due to tumor involvement and sometimes decreased clearance due to involvement of draining lymphatics. As the pleural pressure is typically slightly positive, the effusion is unlikely to be due to a hydrostatic effect of lung entrapment. Likewise, empyema or complicated parapneumonic effusion may be associated with lung entrapment but the mechanism of persistence of pleural fluid is largely dependent on the underlying condition. These mechanisms are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=see_link&amp;anchor=H11#H11\">",
"     \"Mechanisms of pleural liquid accumulation in disease\", section on 'Effusion formation by site'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63531420\">",
"    <span class=\"h2\">",
"     Clinical, radiographic, and laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a pleural effusion due to lung entrapment may be asymptomatic or may have shortness of breath, decreased exercise tolerance, or chest discomfort. Patients with pleural infection often have fever and may have cough or sputum production. Lung entrapment due to rheumatoid pleuritis may be associated with other clinical manifestations of rheumatoid arthritis, although pleural disease can be the presenting manifestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic lung entrapment may be identified during imaging studies obtained to evaluate a known malignancy. On computed tomography, the pleural surface may appear nodular and the pleural fluid loculated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link&amp;anchor=H13#H13\">",
"     \"Imaging of pleural effusions in adults\", section on 'Malignant pleural effusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A key feature of lung entrapment is that dyspnea typically improves minimally or not at all with thoracentesis. In addition, the underlying lung does not fully expand radiographically after thoracentesis or tube thoracostomy. Some patients, generally those with malignant effusions, develop chest discomfort during therapeutic thoracentesis despite having a considerable amount of residual pleural fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/6\">",
"     6",
"    </a>",
"    ]. It is thought that the chest discomfort is related to the negative pleural pressure created in the pleural space when the lung does not re-expand to fill the space created by fluid removal. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link&amp;anchor=H3#H3\">",
"     \"Imaging of pleural effusions in adults\", section on 'Conventional radiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pleural fluid is typically exudative [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/7\">",
"     7",
"    </a>",
"    ]. Malignant cells may be present on cytology when lung entrapment is caused by pleural malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of lung entrapment is not always obvious during the initial evaluation of a pleural effusion. However, the diagnosis should be suspected when a patient with known rheumatoid arthritis, empyema, or malignancy presents with a pleural effusion. Identification of lung entrapment in a patient with a malignant pleural effusion is important, as thoracentesis is less likely to relieve dyspnea and pleurodesis is rarely successful in treating a malignant pleural effusion when lung entrapment is present [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lack of lung reexpansion with thoracentesis is suggestive of lung entrapment, although other processes (eg, endobronchial obstruction by a tumor associated with a malignant effusion, significant underlying pulmonary fibrosis or consolidation) can have the same effect. Computed tomography of the chest can help exclude extrapleural causes of unexpandable lung.",
"   </p>",
"   <p>",
"    When lung entrapment is suspected, support for the diagnosis is provided by compatible pleural pressure and elastance findings, such as a normal to slightly increased initial pleural pressure, a decrease in pleural pressure to -20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O or lower after 1L of fluid is removed, and an increased pleural elastance measured at the end of thoracentesis when minimal pleural fluid remains (ie, the terminal elastance) (",
"    <a class=\"graphic graphic_figure graphicRef75040 \" href=\"UTD.htm?10/8/10382\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef59718 \" href=\"UTD.htm?13/11/13502\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The technique of measuring pleural pressure and the interpretation of the results are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link\">",
"     \"Measurement of pleural pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct visualization via thoracoscopy provides confirmation of the diagnosis, but is usually only necessary when the cause of lung entrapment is unclear or the patient has refractory symptoms. Occasionally, the diagnosis of lung entrapment only becomes apparent at the time of a thoracoscopy performed to evaluate a persistent undiagnosed effusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=see_link\">",
"     \"An overview of medical thoracoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42933?source=see_link\">",
"     \"Indications for diagnostic thoracoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the treatment of lung entrapment is focused on treating the underlying disease process (eg, infection, inflammation, malignancy). For patients with a treatable underlying condition such as infection or inflammation, lung entrapment often resolves with treatment of the underlying process (eg, antibiotics, anti-inflammatory drugs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link&amp;anchor=H12#H12\">",
"     \"Parapneumonic effusion and empyema in adults\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung entrapment due to pleural malignancy rarely responds to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, since the lung is entrapped and has limited ability to reexpand, attempted therapeutic thoracentesis may result in only partial or no relief of dyspnea. Other options for managing lung entrapment in this setting include placement of an indwelling pleural catheter, placement of a pleuroperitoneal shunt, and",
"    <span class=\"nowrap\">",
"     pleurectomy/decortication.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88662343\">",
"    <span class=\"h3\">",
"     Recurrent symptoms after partial relief of dyspnea with thoracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial symptomatic improvement with thoracentesis suggests that a component of pleural fluid production is due to the malignancy (eg, tumor infiltration causing leaky capillaries or impaired lymphatic function), rather than just lung entrapment by the tumor, and that efforts to reduce pleural fluid accumulation may provide symptomatic relief.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pleurodesis",
"      </strong>",
"       Pleurodesis is commonly used to treat recurrent and persistent malignant pleural effusions without lung entrapment. However, it is unlikely to be successful in patients with entrapped lung, as the lung is unable to expand adequately to achieve apposition between the parietal and visceral pleura. One study found that pleurodesis failed in all 19 patients with pleural malignancy and lung entrapment demonstrated by a pleural elastance greater than 19 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O after removal of 500 mL of pleural fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of malignant pleural effusions\", section on 'Pleurodesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Indwelling pleural catheter",
"      </strong>",
"       For those patients who have partial symptomatic improvement with removal of pleural fluid, the usual treatment is implantation of an in-dwelling pleural catheter for intermittent drainage at home [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]. This option has been successful in controlling dyspnea in a number of case series and in our clinical experience [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. In addition, it is less invasive than placement of pleuroperitoneal shunt and avoids frequent visits for therapeutic thoracentesis. In-dwelling pleural catheters are also used for patients with malignant pleural effusions without lung entrapment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link&amp;anchor=H8#H8\">",
"       \"Management of malignant pleural effusions\", section on 'In-dwelling pleural catheter'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Placement of in-dwelling pleural catheters is performed under conscious sedation with local anesthesia. In a series of 116 patients with lung entrapment due to pleural malignancy, placement of an in-dwelling pleural catheter resulted in symptomatic improvement in 48 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/10\">",
"       10",
"      </a>",
"      ]. Pain was the predominant complication occurring in 35 percent, but lasting less than three days. Pericatheter leakage occurred in 13 percent, but this was transient; occlusion or catheter displacement each occurred in 4 percent. No patients developed pleural infection.",
"     </li>",
"     <li>",
"      <strong>",
"       Pleuroperitoneal shunt",
"      </strong>",
"       Insertion of a pleuroperitoneal shunt is a rarely used option for patients with lung entrapment who do not want a chronic transcutaneous device with the accompanying need for special cleaning and drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/3,9,12,13\">",
"       3,9,12,13",
"      </a>",
"      ]. These shunts are placed via thoracoscopic guidance under general anesthesia. In the hands of experienced operators, placement of a pleuroperitoneal shunt is reasonably safe, although shunt-related complications (eg, infection, occlusion) occur in about 15 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of malignant pleural effusions\", section on 'Shunt'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In general, we prefer using an in-dwelling pleural catheter, rather than a pleuroperitoneal shunt, due to the frequency of shunt-related problems and the less invasive process for placing in-dwelling pleural catheters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103659118\">",
"    <span class=\"h3\">",
"     Inadequate improvement with pleural fluid removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with lung entrapment due to malignancy and inadequate or no improvement with pleural fluid removal, pleurectomy (resection of visceral and parietal pleura) with decortication (removal of pleural rind) is a potential option [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Typically, these patients have refractory shortness of breath, but are in good overall condition and have a primary tumor that is under control or progressing slowly. Pleurectomy controls the pleural effusion in over 90 percent of cases; however, it is a major operation with a mortality rate of about 5 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=see_link\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRAPPED LUNG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trapped lung occurs when the visceral pleura becomes encased with a fibrous peel or rind, but the inflammation that led to development of the rind has resolved. The incidence of trapped lung is unknown, but is probably much higher than is generally recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54982978\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The event producing the initial pleural inflammation is usually pneumonia or a hemothorax, but other causes include spontaneous pneumothorax, thoracic operations including coronary artery bypass surgery, uremia, and rheumatoid pleuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Trapped lung can also be a late consequence of nonmalignant lung entrapment, if the underlying inflammatory condition is successfully treated but the restricting fibrinous peel becomes organized into a fibrous peel with wide separation of the visceral and parietal pleurae. Rarely, patients with heart failure develop a trapped lung and a pleural effusion if they have a pleural effusion for many months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63531158\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In trapped lung, the fibrotic process affecting the visceral pleura prevents the lung from expanding to fill the thoracic cavity when pleural fluid is removed. In this situation, the negative pleural pressure prevents the absorption of excess pleural fluid by pleural lymphatics and, thereby, prevents apposition of the visceral and parietal pleura. Consequently, a steady state of fluid formation and removal is established, leading to persistence of a negative pressure pleural effusion of constant volume. The sole mechanism for the persistence of the pleural effusion is mechanical [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=see_link&amp;anchor=H9#H9\">",
"     \"Mechanisms of pleural liquid accumulation in disease\", section on 'Extrinsic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical and laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with trapped lung do not have symptoms referable to the pleural effusion; some patients, however, complain of shortness of breath due to restrictive ventilatory dysfunction. Symptoms of acute pleural inflammation such as pleuritic chest pain or fever are rarely present, but a careful history will often elicit these symptoms in the remote past.",
"   </p>",
"   <p>",
"    Over time, the size of an effusion due to trapped lung remains remarkably constant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/22\">",
"     22",
"    </a>",
"    ]. If thoracentesis is performed, the effusion recurs rapidly. The pleural fluid lactic dehydrogenase (LDH) is usually in the transudative or borderline exudative range, while pleural fluid protein may be either in the transudative or exudative range. Typically, the pleural fluid white blood cell count is relatively low and primarily consists of mononuclear cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25147598\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies such as upright and decubitus radiographs and chest computed tomography (CT) of trapped lung often show pleural thickening and loculation; partial shifting of fluid with positional changes may occur, but full relocation of free flowing fluid is not observed. The paradoxical finding that the hemithorax with the effusion is reduced in size compared to the contralateral side suggests that pleural pressure on the affected side is more negative than on the opposite side, providing further evidence for the diagnosis of trapped lung (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link&amp;anchor=H5#H5\">",
"     \"Imaging of pleural effusions in adults\", section on 'Loculated pleural effusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, the visceral pleural rind associated with trapped lung is difficult to visualize on routine CT. To improve visualization of the pleural rind, air contrast CT can be performed by injecting 200 to 400 mL of air at the termination of a therapeutic thoracentesis and obtaining a chest CT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. The air in the pleural space allows a clear demarcation on CT images of the thickness of the visceral pleura. In a case series, air contrast CT allowed visualization of visceral pleural rinds that were less than 3 mm, which is thicker than the minimally visible normal pleura, but difficult to visualize in the absence of air contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/20\">",
"     20",
"    </a>",
"    ]. After injection of air into the pleural space, travel and scuba diving must be avoided until the air is completely absorbed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of trapped lung should be suspected in any patient with a stable chronic pleural effusion, particularly if there is a history of pneumonia, pneumothorax, thoracic surgery, or hemothorax. If there is a suspicion of trapped lung, assessment of intrapleural pressure during thoracentesis can determine whether features of trapped lung are present [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/6,22,23\">",
"     6,22,23",
"    </a>",
"    ]. In patients with trapped lung, the initial pleural pressure is usually slightly negative, and the pressure decreases quickly as pleural fluid is withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/1\">",
"     1",
"    </a>",
"    ]. The pleural space elastance (change in pleural pressure divided by the amount of pleural fluid removed) exceeds 14.5 cm",
"    <span class=\"nowrap\">",
"     H",
"     <sub>",
"      2",
"     </sub>",
"     O/L",
"    </span>",
"    in the presence of trapped lung [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/20\">",
"     20",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef59718 \" href=\"UTD.htm?13/11/13502\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75040 \" href=\"UTD.htm?10/8/10382\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link&amp;anchor=H933967#H933967\">",
"     \"Measurement of pleural pressure\", section on 'Technique'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link&amp;anchor=H933974#H933974\">",
"     \"Measurement of pleural pressure\", section on 'Interpretation of pleural pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of trapped lung based on pleural pressures can be complicated in patients with more than one cause of pleural effusion. As an example, a patient may have heart failure with hydrostatic accumulation of pleural fluid in addition to trapped lung. In this situation, the initial pleural elastance is normal, correlating with partial lung reexpansion when fluid due to the hydrostatic component is removed, but the terminal elastance is abnormally high correlating with the presence of unexpandable lung [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link&amp;anchor=H934433#H934433\">",
"     \"Measurement of pleural pressure\", section on 'Pleural elastance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link&amp;anchor=H933974#H933974\">",
"     \"Measurement of pleural pressure\", section on 'Interpretation of pleural pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of characteristic pleural pressure changes is strongly suggestive of trapped lung and may be sufficient diagnostically in patients with minimal or absent symptoms. However, confirmation that visceral pleural thickening (a pleural rind) is present requires direct visualization via video-assisted thoracoscopy or air contrast computed tomography (CT). We typically obtain air contrast computed tomography (CT) when pleural manometry (ie, high elastance) suggests that the area of trapped lung is moderate to large. Air injected into the pleural space at the completion of thoracentesis allows a clear demarcation of the thickness of the visceral pleura and the proportion of the lung that is affected. This information is also helpful in subsequent management decisions. The technique of air contrast CT is described above. (See",
"    <a class=\"local\" href=\"#H25147598\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management of trapped lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a pleural effusion caused by trapped lung largely depends on the patient's symptoms. For patients who are asymptomatic, no further therapy is indicated, as performing further pleural drainage procedures will just lead to fluid reaccumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/22\">",
"     22",
"    </a>",
"    ]. Rarely, a patient&rsquo;s quality of life is limited by shortness of breath because the constricting fibrous rind involves a large portion of the lung. For these patients, decortication of the visceral pleura (removal of fibrous pleural rind) will usually allow reexpansion of the trapped lung [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/1,24\">",
"     1,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence in favor of decortication comes from case reports, small case series, and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/1,19,20\">",
"     1,19,20",
"    </a>",
"    ]. In a series of patients with trapped lung following coronary artery bypass grafting, three of the four patients who underwent decortication had successful lung reexpansion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/62/4072/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to decortication, other potential causes of dyspnea are excluded by noninvasive testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the patient with dyspnea\", section on 'Evaluation of chronic dyspnea'",
"    </a>",
"    .) As an example, a patient with rheumatoid pleuritis may have underlying interstitial lung disease (ILD) that may contribute to their dyspnea. High resolution computed tomography (HRCT) of the chest can be used to assess for ILD in the underlying lung parenchyma. Finally, candidates for decortication need to be acceptable surgical candidates who understand the risks associated with general anesthesia and thoracotomy or thoracoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13270434\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unexpandable lung is present when the lung is unable to expand to the chest wall and achieve visceral and parietal pleural apposition. The two types of pleural processes that cause unexpandable lung are lung entrapment and trapped lung; both are associated with the presence of a pleural effusion. (See",
"    <a class=\"local\" href=\"#H88662168\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103659462\">",
"    <span class=\"h2\">",
"     Lung entrapment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung entrapment refers to visceral pleural restriction caused by an active pleural process (malignancy, infection or inflammation). (See",
"      <a class=\"local\" href=\"#H88662168\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of lung entrapment is suspected when a patient with known rheumatoid arthritis, empyema, or malignancy presents with a pleural effusion and the lung does not fully reexpand with thoracentesis. (See",
"      <a class=\"local\" href=\"#H63531420\">",
"       'Clinical, radiographic, and laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with lung entrapment, direct measurement of pleural pressure at the time of thoracentesis reveals a nearly normal initial pleural pressure, but a gradual decrease in pressure as fluid is withdrawn, culminating in a steep decrease in pressure when minimal fluid remains in the pleural space. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link&amp;anchor=H933974#H933974\">",
"       \"Measurement of pleural pressure\", section on 'Interpretation of pleural pressures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compatible pleural pressure findings are strongly supportive of the diagnosis of lung entrapment. Direct visualization by thoracoscopy to confirm the diagnosis is performed when the cause of lung entrapment is unclear or the patient has refractory symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link&amp;anchor=H933974#H933974\">",
"       \"Measurement of pleural pressure\", section on 'Interpretation of pleural pressures'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the treatment of lung entrapment is focused on treating the underlying disease process (eg, infection, inflammation, malignancy). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with dyspnea due to a malignant pleural effusion with lung entrapment and a pleural elastance greater than 19 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L,",
"      </span>",
"      pleurodesis is unlikely to be successful. For such patients who obtain at least partial relief of symptoms after thoracentesis, we recommend implantation of an indwelling pleural catheter for intermittent drainage at home, rather than placement of a pleuroperitoneal shunt (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Placement of an indwelling catheter is preferred because shunt placement is more invasive and has a higher rate of complications. Despite these risks, some patients may prefer a shunt to avoid a transcutaneous device due to issues about appearance, cleaning, and drainage. (See",
"      <a class=\"local\" href=\"#H88662343\">",
"       'Recurrent symptoms after partial relief of dyspnea with thoracentesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For carefully selected patients with lung entrapment due to malignancy who have insufficient improvement in dyspnea after pleural fluid removal, are good surgical candidates, and have a slowly progressive malignancy, we suggest decortication (removal of pleural rind) with pleurectomy (resection of visceral and parietal pleura) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H103659118\">",
"       'Inadequate improvement with pleural fluid removal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103659470\">",
"    <span class=\"h2\">",
"     Trapped lung",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trapped lung occurs when the visceral pleura becomes encased with a fibrotic rind that renders the lung unexpandable. (See",
"      <a class=\"local\" href=\"#H88662168\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of pleural inflammation that eventually lead to trapped lung include pneumonia with parapneumonic effusion (bacterial and mycobacterial), hemothorax, spontaneous pneumothorax, thoracic operations including coronary artery bypass surgery, uremia, and rheumatoid pleuritis. (See",
"      <a class=\"local\" href=\"#H54982978\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with trapped lung do not have symptoms referable to the pleural effusion, although some patients complain of shortness of breath due to restrictive ventilatory dysfunction. Symptoms of acute pleural inflammation such as pleuritic chest pain or fever are generally absent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical and laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On chest radiography of trapped lung, the hemithorax with the effusion is reduced in size, indicating that the pleural pressure on the side with the effusion is more negative than that on the contralateral side. Computed tomography (CT) often reveals loculation and pleural thickening, although sometimes pleural thickening is only apparent on an air contrast CT. (See",
"      <a class=\"local\" href=\"#H25147598\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with trapped lung, direct measurement of pleural pressure at the time of thoracentesis usually reveals a negative initial pressure. With fluid removal, a rapid decrease in pleural pressure occurs, correlating with a pleural elastance (change in pleural pressure divided by the amount of pleural fluid removed) greater than 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L",
"      </span>",
"      (often greater than 25 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link&amp;anchor=H933974#H933974\">",
"       \"Measurement of pleural pressure\", section on 'Interpretation of pleural pressures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of characteristic pleural pressure changes is strongly suggestive of trapped lung and may be sufficient diagnostically in patients with minimal or absent symptoms. However, confirmation that visceral pleural thickening (a pleural rind) is present requires air contrast computed tomography (CT) or direct visualization via video-assisted thoracoscopy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link&amp;anchor=H933974#H933974\">",
"       \"Measurement of pleural pressure\", section on 'Interpretation of pleural pressures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have asymptomatic trapped lung, pleural drainage procedures are NOT indicated, as the pleural fluid will reaccumulate due to the negative pleural pressure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management of trapped lung'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are surgical candidates and have disabling shortness of breath due to trapped lung, we recommend decortication of the pleural rind on the visceral pleura (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management of trapped lung'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/1\">",
"      Doelken P. Clinical implications of unexpandable lung due to pleural disease. Am J Med Sci 2008; 335:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/2\">",
"      Huggins JT, Doelken P, Sahn SA. The unexpandable lung. F1000 Med Rep 2010; 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/3\">",
"      Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting. Cancer 1995; 75:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/4\">",
"      Rodriguez Panadero F. Lung cancer and ipsilateral pleural effusion. Ann Oncol 1995; 6 Suppl 3:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/5\">",
"      Milanez RC, Vargas FS, Filomeno LB, et al. Intrapleural talc for the treatment of malignant pleural effusions secondary to breast cancer. Cancer 1995; 75:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/6\">",
"      Feller-Kopman D, Parker MJ, Schwartzstein RM. Assessment of pleural pressure in the evaluation of pleural effusions. Chest 2009; 135:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/7\">",
"      Huggins JT, Doelken P. Pleural manometry. Clin Chest Med 2006; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/8\">",
"      Lan RS, Lo SK, Chuang ML, et al. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann Intern Med 1997; 126:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/9\">",
"      Pien GW, Gant MJ, Washam CL, Sterman DH. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest 2001; 119:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/10\">",
"      Efthymiou CA, Masudi T, Thorpe JA, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters. Interact Cardiovasc Thorac Surg 2009; 9:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/11\">",
"      Sioris T, Sihvo E, Salo J, et al. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol 2009; 35:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/12\">",
"      Schulze M, Boehle AS, Kurdow R, et al. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg 2001; 71:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/13\">",
"      Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000; 18:143.",
"     </a>",
"    </li>",
"    <li>",
"     Light RW. Pleural Diseases, 4th ed, Lippincott, Williams, and Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/15\">",
"      Sensakovic WF, Armato SG 3rd, Starkey A, et al. Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication. Acad Radiol 2011; 18:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/16\">",
"      Srivastava V, Dunning J, Au J. Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis? Interact Cardiovasc Thorac Surg 2009; 8:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/17\">",
"      Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin Thorac Cardiovasc Surg 2009; 21:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/18\">",
"      Kollef MH. Trapped-lung syndrome after cardiac surgery: a potentially preventable complication of pleural injury. Heart Lung 1990; 19:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/19\">",
"      Lee YC, Vaz MA, Ely KA, et al. Symptomatic persistent post-coronary artery bypass graft pleural effusions requiring operative treatment : clinical and histologic features. Chest 2001; 119:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/20\">",
"      Huggins JT, Sahn SA, Heidecker J, et al. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT. Chest 2007; 131:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/21\">",
"      Doelken P, Sahn SA. Trapped lung. Semin Respir Crit Care Med 2001; 22:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/22\">",
"      Light RW, Jenkinson SG, Minh VD, George RB. Observations on pleural fluid pressures as fluid is withdrawn during thoracentesis. Am Rev Respir Dis 1980; 121:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/23\">",
"      Villena V, L&oacute;pez-Encuentra A, Pozo F, et al. Measurement of pleural pressure during therapeutic thoracentesis. Am J Respir Crit Care Med 2000; 162:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/62/4072/abstract/24\">",
"      Heidecker J, Sahn SA. The spectrum of pleural effusions after coronary artery bypass grafting surgery. Clin Chest Med 2006; 27:267.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6697 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4072=[""].join("\n");
var outline_f3_62_4072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13270434\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88662168\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LUNG ENTRAPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54982991\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63531199\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63531420\">",
"      Clinical, radiographic, and laboratory features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88662343\">",
"      - Recurrent symptoms after partial relief of dyspnea with thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103659118\">",
"      - Inadequate improvement with pleural fluid removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRAPPED LUNG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54982978\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63531158\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical and laboratory features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25147598\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management of trapped lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13270434\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103659462\">",
"      Lung entrapment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103659470\">",
"      Trapped lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6697|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/8/10382\" title=\"figure 1\">",
"      Pleural pressure volume curves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/11/13502\" title=\"figure 2\">",
"      Pleural pressure volume curve in trapped lung and heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=related_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42933?source=related_link\">",
"      Indications for diagnostic thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=related_link\">",
"      Measurement of pleural pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=related_link\">",
"      Mechanisms of pleural liquid accumulation in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_62_4073="Tendinosis pathology summary";
var content_f3_62_4073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Summary of tendinosis pathology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 721px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histopathological features and corresponding biochemical abnormalities are presented from top to bottom in the order they are believed to develop. This postulated order is based upon pathology studies of human tendon and laboratory investigations of tendon overuse [see topic citations]. The pictures in the right column depict the histopathology in schematic form: Brown fibers represent collagen; blue material represents sulphated proteoglycan; black represents tenocytes; red represents blood vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Table created by Karim Khan, MD, PhD and Alex Scott, PhD, RPT",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4073=[""].join("\n");
var outline_f3_62_4073=null;
var title_f3_62_4074="C1 and C2 bone anatomy";
var content_f3_62_4074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    C1 and C2 bone anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 622px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Observe the occipital condyles that articulate with the superior articular surfaces (facets) of the atlas (vertebra C1).",
"    <br>",
"     (B) The atlas, on which the cranium rests, has neither a spinous process nor a body. It consists of two lateral masses connected by anterior and posterior arches.",
"     <br>",
"      (C, D) The tooth-like dens characterizes the axis (vertebra C2) and provides a pivot around which the atlas turns and carries the cranium. It articulates anteriorly with the anterior arch of the atlas (\"Facet for dens\" in part B) and posteriorly with the transverse ligament of the atlas (see part B).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4074=[""].join("\n");
var outline_f3_62_4074=null;
var title_f3_62_4075="Burn nutr curreri j";
var content_f3_62_4075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Caloric requirements for children based on the Curreri Junior formula",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calories (kcal/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        RDA + 15 kcal/TBSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        RDA + 25 kcal/TBSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 15",
"       </td>",
"       <td>",
"        RDA + 40 kcal/TBSA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      RDA: recommended daily allowance; TBSA: total body surface area.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Saffle, JR, Graves, C. Nutritional support of the burned patient. In: Total Burn Care: 3rd Edition, Herndon, DN (Ed), Saunders Elsevier, Philadelphia, PA 2007. p.398.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4075=[""].join("\n");
var outline_f3_62_4075=null;
var title_f3_62_4076="Therapy of acute type B aortic dissection";
var content_f3_62_4076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guidelines: therapy of acute type B aortic dissection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Medical therapy",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Surgical aortic replacement if signs of persistent or recurrent pain, early expansion, peripheral ischemic complications, rupture",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Surgical or endovascular fenestration and stenting if persisting mesenteric, renal or limb ischemia or neurologic deficits",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from Erbel, R, Alfonso, F, Boileau, C, et al, Eur Heart J 2001; 22:1642.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4076=[""].join("\n");
var outline_f3_62_4076=null;
var title_f3_62_4077="Major causes hypocalcemia";
var content_f3_62_4077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hypocalcemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low PTH (hypoparathyroidism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Genetic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abnormal parathyroid gland development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abnormal PTH synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Activating mutations of calcium-sensing receptor (autosomal dominant hypocalcemia or sporadic isolated hypoparathyroidism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-surgical (thyroidectomy, parathyroidectomy, radical neck dissection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Autoimmune",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autoimmune polyglandular syndrome (associated with chronic mucocutaneous candidiasis and primary adrenal insufficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Isolated hypoparathyroidism due to activating antibodies to calcium-sensing receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infiltration of the parathyroid gland (granulomatous, iron overload, metastases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation-induced destruction parathyroid glands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hungry bone syndrome (post parathyroidectomy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High PTH (secondary hyperparathyroidism in response to hypocalcemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vitamin D deficiency or resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Multiple causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Parathyroid hormone resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pseudohypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypomagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Loss of calcium from the circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperphosphatemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tumor lysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Osteoblastic metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute respiratory alkalosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sepsis or acute severe illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibitors of bone resorption (bisphosphonates, calcitonin), especially in vitamin D deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cinacalcet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium chelators (EDTA, citrate, phosphate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foscarnet (due to intravascular complexing with calcium)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin (due to conversion of vitamin D to inactive metabolites)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoride poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of magnesium metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypomagnesemia can reduce PTH secretion or cause PTH resistance and is therefore associated with normal, low, or high PTH levels",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Thakker RV. Hypocalcemia: Pathogenesis, differential diagnosis, and management. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, sixth edition, American Society of Bone and Mineral Research 2006; 35:213.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4077=[""].join("\n");
var outline_f3_62_4077=null;
var title_f3_62_4078="Contents: Gynecologic procedures";
var content_f3_62_4078=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gynecologic procedures",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gynecologic procedures",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/38/20070\">",
"           Barrier contraception: Diaphragm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33048\">",
"           Cervical intraepithelial neoplasia: Procedures for cervical conization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/14/24808\">",
"           Colposcopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/54/24420\">",
"           Culdocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11433\">",
"           Donor insemination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/131\">",
"           Endometrial sampling procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/27/3512\">",
"           Etonogestrel contraceptive implant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44071\">",
"           Evaluation and management of lower genital tract trauma in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/37/24150\">",
"           Hysterosalpingography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/56/37770\">",
"           In vitro fertilization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/25/20887\">",
"           Initial approach to the premenopausal woman with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34265\">",
"           Insertion and removal of an intrauterine contraceptive device",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30408\">",
"           Interventional radiology in management of gynecological disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42761\">",
"           Intraamniotic infection (chorioamnionitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/11/15546\">",
"           Intracytoplasmic sperm injection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36819\">",
"           Intrauterine fetal transfusion of platelets",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39065\">",
"           Multifetal pregnancy reduction and selective termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20499\">",
"           Pelvic examination under anesthesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/55/40823\">",
"           Saline infusion sonohysterography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/43/42681\">",
"           The gynecologic history and pelvic examination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22147\">",
"           Vaginoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/63/28659\">",
"           Word catheter placement for treatment of Bartholin cysts and abscesses",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-8F5950B0A2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_62_4078=[""].join("\n");
var outline_f3_62_4078=null;
var title_f3_62_4079="Aeroneb Go mesh nebulizer";
var content_f3_62_4079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F87397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F87397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Aeroneb Go mesh nebulizer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 296px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEoAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKzNb13TNDiEmq3sNsrfdDH5m+ijk1x178V9HhIFta3lwD/EVEYP5nP6UXGk2eiUV5Be/GWOH7mnRqD0LzZ/kKy3+NM+/KxW230wf50rhY9zorxe3+NYHEthC49VkK/wBK1bT4x6ZIB59hOnPJSVW/nii4WZ6nRXIad8RPDl9tH21rdm6LOhX9eRXT2d7a3se+zuYZ09Y3DD9KYixRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVDXb9dL0e9v3xtt4Wkwe5A4H51frgvjVqH2LwVJCGw13MkOM9vvH+VDBHgx1K51HUpNQ1aWSe4kfc7nnHsPQDsKtLborSXTTPIjH5doycVSsQhLCV3jDdSvQ/Ud6vLYXaYeykEsX/AEyPP4rWZsZsmnxzyFomBJOSB2qJ9PCkgEZ+grbhjuJmdJYI3ZRz5iFGp8lkifK8EkRYZ+ST+houFjnWsSOePyqM2WT0wfU5rpFsEIO15x9Yw1AtFU83Mg/7YmldhY5oW88b4t/Ob3j5A/CtSzurvTgJY55I7hTncpKk+3FaJSJGJ+03GcY+SHmoGaJB8kNxI3UNLRcLHb+G/inqNh5Q1QG+tTjercTR+4PRvoefevaNF1Sz1nTIL/TZlmtZlyrD9QR2I9K+VGimmZ2WN2dupA4H417f8CT5fhi7tSRmK6LYHbcoP881cXciUbanpVFFFUQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXj3x+uQ76PZYyMSTH9AP617AxAGSQAOSTXz38V9Yh1jxUr2rM1vDEIkfsxBJJHtz+lJlR3OVtUtTZtHLI8Uo5Riu5T7E9RVAC5ilzCSSOhQ81NcZSOqfngH0qDQ1I9b1CDC3G9lHaWPP61cj1yC4x59pC5HcMRWda6pcQ48uZseh5H61fTWlLKLqysZlPUmAA/pigLl+2vLAMGW3ljPTh8/zqzDFprnJW65Ofv0kE+kyAE2FuM/3d6/yNaEDaTuBFmo/wC2r0DCKz0wjmGd/wDekNTrBYREmGxi3di/zH9asxvYY/d26r/wNjUcz26oxAY/TigDK1RmZQG2ovYAYH5V23wTdlbVYSCFby3GfxBrk5mj8sbIlBwCWPJrqvhE3/E61FQc/uFP/j1Nbky2PVKKKKsyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiig0AcD8WfEB0/TU022kK3F0MyEdVj/APrnj868WupMqrEA47HpW54/1b+1vFF9cI2YlbyYvTavH6nJrn7wKqIFz05+tQzRaEdxJazABS8Z/utyPzrJurFySY/mHtU8nU1GowfkJU+xxS5R3KIEsZ+YEY9RQLk7wDWujSNw7Bx/tDNPFnBIctCmfbimBMJo4NgILbgORWhaXiH+Fqg+ypMyl404GBV62soxyI1/M0hmhBcLt4U/iadczyNG3lRhm9M1JBaL/dUfrVuKxjzk5oGYc8s/lgOQDjof8K7/AODlvcrqV/PcrsVoVVARgkbutZNtZ28JBSJd3qRk12PgH/kJ3f8A1xH/AKFTREtjuqKKKszCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuT+JWty6H4Zke1O26uXFvE393OSzfgoP411leafG4r/ZWmZbDee2F9fl6/59aTGtzxyU5cdevc0Xhy5ojVZLhFblSefpTbkjeak0KL9aRBSv3pU5NMRPFVyEVVhq5EKYF2EcCtC3HIqhAOlaEHUUmM0YB0q5HVOGrcY6UgLSV1Xw/wD+Qld/9cR/OuUTpXWfD/8A5CN3/wBch/OhEvY7miiirICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvHvjhdb9T020ByI4mkI9Cxx/SvYa8C+K9x9o8aXg7RIkQ/AZ/maTHHc5C1H7/AD2AJqK461Nbcea3tiq83WpsaFV6cgpGHNPjFUSWIhzVyIVViHNXIqBluEdKvwDpVGEVoQdqljL0VW0qpDVuPpQBOp6V1vw//wCQjdD/AKZD+dcildZ8Pv8AkJ3X/XH/ANmoQnsd5RRRVmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV83+OZPO8Vau4II+0uvykHGOO1fSFfnXqV1f6XrmoSadez27G5lJw/X526+v40mNOx7VCMQMfU1Vl71neB9RuNU8KQXN7Kkt15jrIUULjB4yB3xWjIetIsgPWpYxUfep4xTETxirUI6VXjFWohQMtwir8PUVShq7D2qWMuRVcj6VTi61cioAmTius+H3/ACE7r/riP/Qq5VF4rqvh6QdSuyOR5QGfxoW4nsd5RRRVmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV+e3jq1Nn4s1q3I4jvZlwP9819+6vqdlo+mXOoapcx2tlbIZJZZDgKBXwV8QtUstd8Xazqml+YbS7u3mi3jawUnuO3rikNHTfDOzY+FZbiGQxytdOMjuAAOa3pJL6InzLeO4X+9G21vyqr8NU2+CLc/wB+eVunvW1IPmNDWpa2Mn+0I1P723uY/wDgG4fpU0ep2PeWRP8AejIq4BzUsag9QPypAQxajYH/AJe0H1B/wq3HqNj/AM/SH6A/4VJGi/3V/IVbhUDoqj6CkMji1Cz/AIZWb/djY/0q7Beo3+rhupD7REfzp8TEAc1ZVzjqaQCwyXTH5bJwPWR1X/GtG2ivJWA3QR+yguf14qpb5kfaPzrZt5ViQKvHqe5oC5NFp4GDLI8rf7Z4/IVveG7xNLuppJkdldAoEYHHNYa3HvUi3Axk9Ka0E9Tu18TWRGWWdR7p/wDXpD4o00fxTH/tma4j7SO5zSrMrN0H5U7i5UdqPFFiT8qXDf8AAB/jT08SWhPzRTqPUqP8a5KKItjauKsLC47Z+houFkdtaaha3f8AqJkZv7p4P5VargPLwcspBHetKz1a6tcBz58Q7MeR+NO4uU62ivnf4nfGvxh4X1X7Da+FbWJJP+Pe6kkedZh6qFAwfY1wp8WfHLxeFOnw6nbwNkqbSyFuuP8AfYc/nTFY+wqq3GoWdspNzd28QHUySKv8zXyOfhP8Y9aXfqOoXCh+q3WrMfzVSRViD9mXxZOoN3rulxZ6rmVz/IUBY+m5/GXhm3BM3iLR0x1zeR5/nWPd/FjwJaHE/irSwf8AZl3fyzXh9p+ytcMc3fia3U/9MrQt/NhWxZ/stabGwN14mvJF/uxWqp+pJoEegXvx2+Htr0137R/1wt5H/wDZaxrr9o/wPE2IRqlwP7yW4Uf+PMKqWn7M/g6I5ub3Wbj2MyJ/Ja04/wBnX4foObO/c+rXr/0oAqxftI+CXPzx6qg9TAp/k1Xo/wBoXwA6km9vkIGcGzc5/LNNP7PPw9x/x4Xo9/tsn+Nct49+Bfw80XQ7i6bUrzSZ9jeQ0tz5is+OBtIJYZ9OaaV3ZCbUVduwRftQaMYk83w9fiZpimyOdGAT+9njn2x+Na1n+0l4UmaJJtO1mOSSTaAkKyYT++drdPYZNfL+neFokCNfSmRgMFI+B+fWuhtreG2QJbRJEoGMKMV108HKWstDyK+c0oaU1zP7kfULfG3wmbA3ETag8m4qLc2xVz788AfjXKap8fJSSNJ0JAOzXU//ALKo/rXh9Ia6Y4Smt9Ty6mb4ie1l6Hpl98a/FtwzeQ1haKegjg3EfixNY8nxQ8ZSMS2uTL7LFGB/6DXGCitVRpr7KOSWNxEt5v7zs4/id4yjbI12dv8AejjP/stdV4f+OGt2jqmtWltfw92jHlSD+h/KvIh7UdKUqFOW6Kp4/EU3dTfz1PrLwx8T/DWvlIkvPsd03/LG6+Qk+x6H867dSGAKkEEZBFfC+ea63wr8QPEPhtkWyvnltV628/zpj2zyPwrlqYLrBnrYfO1tWXzR9eUV5V4S+M2i6oY4NZRtMujxvJLRE/73UfjXqFvcQ3MCTW8qSxOMq6MCD+IrilCUHaSPapVqdZc1N3RLRRRUmoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAee/Hjw3ceKPhnqtnZMwuYQt3Gg6SGM7tp+oz+OK+E3jkDHyjh+6HrX6WkA9a+JfjX4OTw546v7NIzHbTZurNx2Rjkr74bIx9KTGbPw7DDwJppkGGYyMR/wI1rSDJzVPwdG0XgrSEY5byiScYzljVx6HuWhlSx1GBU0YoAsR1ZiqvHVqOkxk6cCnPLt4B5NMLBVyazjcbnLetIDchnCKADip1u8d655Z/epFuPegDoVvOlPa8wQM9s1zouMnGaU3XJ5oA6L7afWpYLolgSa5kXdXbCUyvjOF7mgDtbC/8AMwhPzVrQynqWArlba7igUKm3J75rQaSIRhpb2zGf4Q5Zv0FAjoReRIMPIp+pqvLewE5jAHr3zWH9ssl/5et3+7Ef60n9oWAOTJO30QCi4krGzbagsN9BOq5EbZ+726HGfUVuN4rB4is3J7bnAriJdWswD5SS5x1ZhUcOqxwQXN03KwRl6L2K5bnazeJLpRzHbw/7xJrLu/GYiyJNRgU+iKM/1rxS91O6v7h5rqV2ZznGeB7UyN6xde+xapI9XuPHIP8Aq7m5kP8As/KKov4snlYlTIPdpDXn8cpqzHOR3pe0bK5Ej2LwV4ke7uVtLly2/hdxyQfrXclgASeAO9fP3hi9eHWbWRCflcGtD9oPxRq0MEemacssGjuMXV7GeHf/AJ5Ej7q+p75xXTRXtGkceKqewg6lr27Gl8Q/jJaaY8un+FxHe3q5V7puYYj/ALP98/p9a8D1jVb/AFm/e91W7lu7puskhyQPQDoB7CqS8ADsOlBOOvSvapUYU1ofGYrG1cS/eenYKKs6XbrdS/vpI4oegdmHJ9/SjVYBZ3QSB0uI84LRsGC++R1p+3hzcnUPqNb2XtraFY0UvFH0rU4xK1tC0G91qRltEAjX78rnCr/9esoda9K8AanZppMVojqs6MxZWOCST1rmxdaVGnzQR6OWYWniq3JVdl+fkQ23w4TaPtWpNu9Iov6k0tz8Nhtza6nz2EsXH5g13KTqRwRUolHqOa8X69XvfmPqf7Iwdrcn4v8AzPFdc8M6nouXu4d1v2miO5fx9PxrGr3u/uLeO1kN0yLAVIff0I9DmvB5gvnSbPubjt+meP0r1cHiZV0+ZbHzma4CGEknTej6dUMBxXReFfGOt+F5w+lXjrHn5oH+aNvqv+Fc7igV2SipKzPLp1JU3zQdmfTXgj4vaTrZS21dRpt8eBubMTn2bt9DXpsciyIHjYMh5BU5Br4ZHFdx4I+I2r+GnSEzPc2PeFzkqP8AZJ/lXBVwdtYHv4TOU/dxH3/5n1hRXH+FfHuleILQSwyhSPvjuh/2h1H8q66N1kQMjBlPIIOQa4mmnZnvRkpLmi7odRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFIzBQSTgDkn0rxj4kftAeHPDEktloY/t7VEJVhA+23ib/AGpOckei5/CgD2iuf1nxp4a0bI1TXdOt2H8DTqW/75HNfJ8eofFL4w3MxsmvJdOLYKwyfZLOP2znLkfVjXY+HP2ZLyUrJ4m8QRwL1MGnR5Oe+XbH/oNAHpGsfH7wDppwuo3N7/162zN/PFeLfF74r+GviLFYQaTpuox31rIxjupQgXYR8ykAk8kA+2K908N/BDwJoe1l0cahMv8Ay1v3Mx+u0/L+ldfqWiaVa6DqMdvpNosTW0itFAiQ7wVOV3ADbnpntQM+b9CXZ4a0tMdLdf605+tReHyp8M6WUQxr9nXCF9xUdhu746Z71M/Wk9yxgqeOolqZBQBYTrViMVBGKsJQMh1GTbBgdW4rM3elaF+uStVTHSsBCGNODGpPLpRHTAYrnI5pFYn1NTCL2oSHG4c8GpYEeW9DVuCSRF4BpgjNW7VAwCt17UWAaLqQdjR9tk9DV0WYNH2AUhlE3kmOhpDdy+hrQ/s/jpSf2eaAM/7TL6GrfmSS+H9VX+LYp/DdzUv2CrumWYzNBJ/q50MZPpmk1dWGtzh40z0qzHHV19Omt53hlQiRDg8VetdIupv9XC7fhXIkzcy0jqVIWYgCujt/DN0w/eBIx/tEVvab4XbIwjyn/pmhP61pGDZDkjB8Oaa4uVlYfKgyTXTxbJoWjdVdGGGVxkMPQg9ah1KdLLzLKJCsqnbJnqPaqttPjFdEY2Rm3c4zxX8NVkZ7rwwUhfq1jK3yN/1zb+H/AHTx9K8yu7We1uXtbyCW3uE+/FKu1h+Hp7ivpWCRZBjPNUtd0TTtctRb6rarMq/ckHyyR+6sOR/KuyjipQ0lqjx8blFOv79P3Zfgz5oawbcTHO0Y9BVmODyl++0jDux/kK7rxL8PdS0sPNphbU7Ic4Vf38Y91/i+o/KuKBz05wcEdwfQivSpyhPWJ81iqWIoPkqq35EW8hsbV9uetOU5yCCD9acF4wTx6UvatUcjYgp6MVYFSQR0I4xTKXNAjUtte1O3AEV5LjsGOf51YbxTrJXH2xgPZV/wrDorL2FJu7ivuOhYzEJWVR/eyzeX11eMTd3Esv8AvtkflVU0vejFapKKsjGU5Sd5O42gjinUlMm4lApSKTFIZa06/utNulubGeSGdTwyn9D6ivafh/8AEsXMkdrdulrfHjaxxDMfb+63tXhlKKxq0I1VruduEx9XCv3dV2PtPTNZgvSI2zFP/cbv9D3rVFfLvgXx61qYtP16Qvbfdjujy0XoG9R79RXuWk+IJIURbk/aLdgCsqkE47H3FeVVpSpO0j63DYmnioc9P5rsdhRUVvcRXMSyQOHQ9xUtZm4UUUUAFFFFABRRRQAUUUUABrG8XeJtL8JaFcavrtytvZQjk4yzt2VR3Y9hWzXy78W4734s/Gmz8GafcNFpWk/8fEi8hHwDK+PUAqg96AOX8T+O/Hvxt1abRvCFlc2uiA7Xt4X25XP3riXoP90HH1r0z4afs56No6wXfi911W9UbhaJkW0Z9+hc/XA9q9l8J+GtJ8J6JBpWhWcdrZwjoo+Zz3Zj1Zj6mtmgCK2t4bWCOC1ijhgjG1I41Cqo9ABwKloooAK4n40a/F4b+GPiC+l8gu1s1vFHMCVkeQbQuByc5rtq+P8A9q/4gprmsReGdHmEljpjs908cmVlnxjYR/sDP4sfSgC/4cXZ4W0hcYxaRjHp8oqw1QeHjnwxpJwRm0j6/wC6KsHrSe5oIoqZBUK1OlAE8fUVYSoFHpU6dKQxsybgKYIfarBGafHjgGgCuIPalEHtV4R04R0XAoC39qVYcP04PH41oCOl8oHjBpAUxb09YParojPTv/OniI+lFwI4dy8Hke9Wo2XulNVPUVKiUAPGz+5+tSokbfwNn61LZWU104S3jeRieijNdnovhILiXUyD3ESn+Z/wosDdjA0Tw++qyHYGjgX70p5GfQetbP8AwgxB+W9H4p/9eu0ijSKNUiUIijAUDAFPqrEczOUh8JkFfPuUfbwD5WSPxNaUPh2zQDzWll9i2B+QrZooshXZVg06zg/1VvEp9duT+Zq1jGAKKRvunHWmI8P1GY3Go3Ux/jmZv1NMR8d6ztbvhpdvLcOpdBIQV79ealtbmK6t47i2cPFINyken+NTc3sbVtOQRzzWlHMHXk81zscmD1q7DNjvQBtK20ggnIrC8R+EdJ8Q5kuojBe44uoMK/8AwIdG/GtKGcHqasI/pVRk4u6InTjUjyzV0eKeJPAusaIGlWP7fZDnz7dSSo/2k6j8MiuWXBGQQR6g19Oxyehx9K57xF4K0XXWaWW3Nren/l5tsKx/3h0b8RXdSxrWk0eDisijL3qDt5PY8DxSYrs9f+Hmt6WHltUTU7Uc77cYlUe8Z6/gTXHf8tGjOVkQ4ZGXay/UHmu6FWNT4WfPV8LWw7tVjb8hMUUtFaHPcb3paU0UBcbRinUYoC43FGKdiigBuKQDFOx7UhoGHSu8+HPjJtKmTTNUctprnEcjHPkMf/Zf5VwdBrOpTjUjyyN8NiZ4aoqkD6mtLieymEltJgnn1DD3rrNJ1iK+AjfEVx/cJ4P0rxD4TeImv7B9Ju3LXNqu6FmPLRen1H8q9AxyCOo5BHGK8apB05OLPucPWhiaSqx6nolFczpOvFSIb85HQS/4/wCNdKrBlBUgg8gjvUFtWFooooEFFFFABRRRQAjZCnaMnHAr5Q+C/iW10L44a/Fr7rDPqs00CSyHAWUyZAJ7Zxj64r6wPSvm34+fBjUNX1S41/wtB9oac+ZcWqNiQP3dM/ez1x1z0oA+kVPFLXx34J+OvizwNImi+MdOl1S2gGxfOzDdxAdiWHzAf7Qz716xp37SvgO5hVrttUspO8ctoWx+KEigD2yjNeK3/wC0p4BghZrWTVL2QdI4rMqT+LYFeZ+NP2mtZvont/CmkxaUr/KLq7YTSj/dQfKD9c0Ae7/Fb4oaJ8O9N3Xr/atVlXNtp8TfvJPdv7qe5/DNfDVj4d1/xXdX82g6NeaiDIZJktImcQs7EgZ/zxXpfgD4PeLfiJqp1fxBJdWNhcP5k2oXuTcXGf8Anmrcn6nAHbNfX3g/wvpPg/QoNI0G1FvZxc9ctIx6u7d2Pr/SgD5x0ywudL0aysL+Iw3lrAkM0ZOSjgcinN1rovG67fFmsr/08sfzAP8AWudYUjToC9anQcCoVqdKAJ1HFSpUa9KfHxSGSgU4CgdKcKQEkZI71ZQ+1VVHNWI6BpFuFVY8iu/8P+E9OvNKt7m4WYySgsQHwOtcHbjvXsuhxCHR7JB2hX+VNEy0MxfCGjr/AMu7N9ZDU8fhnSUHFop+rE/1rZoqrGdzMXQNKXpYw/iM1Imj6chyljbA+vlir9FAXGRRRxDEUaIPRQBT6KKACiiigAooooAKDzRRQB5R410Y6dqbuEDWlwS6ccAnqprkLa0i08y+UCsUrhsdlP8A9evetW0+HU7GS1uR8jjgjqp7EV4/runTaTdywXK4KjIYDh19RUtGsZXVjOJxUkcmKr42D5OV9P8ACkDcZHSgo1Ip8d6uxT5xzWEkmDVmOf3oA3o5fQ1aSXPesOGfpzVuKYetMDZU1m63oGla7GBqtjDcOBgS42yL9HHNSRT+9W45AR1pp9UJxUlZnmOs/CmRcyaDqQYf8+96P0Ei/wBRXB6xoWr6KT/amm3EEf8Az2VfMiP/AAJeB+OK+jwacCQCAeCMEdjXTDF1I76nlYjJsNV1iuV+X+R8uRssi5jYOPVTmlxzwDXv+s+CfDusMXu9MijnP/La2Pkv+a9fxrjdU+E8gy2jaycdor2Ld+G9ef0rqhjYP4lY8atkNeGtNqX4HmJHNGK6LUfBPijTsmbSGuol/wCWllIJf/HeDXOXEi20my7WW1ccbbiNoz+orpjVhLZnmVcHXo/HBoUUYoR0kGY3V/8AdOafsPofyrQ5ttxmOKTFPxSYoC43FJipApPQGmnAcKfvHgKOSfoByaHoNXbsjZ8E3smn+KdMnjznzhGwHdW4I/Wvogjkj0ryf4b+Cr46lBq+sQPbWsPzwQSjEkrdmI7KPfmvWiDn3ryMXOM5+6faZNQqUcPaorXd7DCKv6Xqk2nkLzJb90PUfSqeOKTiuY9Vq53Vndw3kIlgcMO/qPY1YrgLW4ms5/Ot22t0IPRh6Gux0vUYdQg3R/K6/fQ9R/8AWoM5RsXqKKKCQooooAKMUUUAY/iLwxofiS38nXtKs7+PGB58QYj6HqPwrzrU/wBnrwFeOzQ2l9ZljnEF02B+DZr12igDxO2/Zs8ExPukm1eYf3WuVH8lBrtvCvws8GeGJUn0rQrUXS9LifM0g+jPnH4V21FABRRRQB4D8RU8vxnqg/vOr/morlzXX/FQY8bXnvHEf/Ha5A0jToKtTp1qBanjoAsJ0p61EtTL2oGSDpTxTFp9QCJFqzGKqJVuKgo0bNNzqo6kgV7VCoSJEHRVArx/QY/N1K0T+9Mg/WvY6qJnPcKKKKogKKKKACiiigAooooAKKKKACiiigArK8RaNb61YtBP8sg5jkA5Q/4e1atFAHhGp6fc6Xdva3abJk/75cf3h9aonklkOG7g9/r/AI17h4h0S11uzMNyNsi8xyqPmQ/1HtXj2uaTdaRfNbXi7XHKyD7si+oP9O1TY1jK5mhwxxyCOop6SYqKQB8BuG7EVGXZOJenZ+34+lBRoRzY71biuPesfeR0qRJcUwN+K4q3Fc+9c7FPVuK496YHSRXAPFWkkzXOxXFXYbn3oA2Qc0tU4rgHvVlXBxQBIOORUc8UVwmy5ijmT+7KgcfrTsjFKKAOdv8AwN4WvyWuNCsg5/iiUxn81xWRN8LPDLnMK6hb+0d22P1zXd0VSnJbMynQpT+KKfyPPD8KNH6rqGqr7eYp/pT4/hVoykb7/U3/AO2ij+legUAZNV7ap/MzH6jhv+fa+4462+GvhqIgvbXNx/11uGx+QxVi4gtfCzCWx0vRrO3dljhYBjczSH+FQBkn8a2pNZ09Ibx47mOd7QN50UTbpAV6jb1zXLXGrrrmrWc2m2UT3NvG5WUbZZArLg+S3QOuQSCOegNS5Sl8TNqdCnT+CKXojqIri4t4jca5LaWitwsYPIPux6n2FUdS8U6faSSxRMJZUCsD1Rs+hHJHqQCB3qlH4auZ5tPN5PhLYFmlErtI8mPldQ3+rYHk9R2rdTR7AFme1hkd8F2ZB8x7tjoCe+OtSamKms3d0kcAt3jup3A8pCSYR1wzYxhgOHBIyRVi3u9Ql1ue2XCRwxxukUhG4oSQWfqc8Ecenoa6JRtUKvCgYAHQD0pojUMzKihm5Y7Rk/U0ANI54ot55LS4WeA4dfyI9DTiKjYcUAdzp15He2qTRdDwQeqnuKtVxnhy8NpqAiY/upztPs3Y12dBjJWYUUUUCCiiigAooooAKKKKACg0UGgDw34vLs8ZMf79vGf5iuI716F8bbWWPXrK7MZ+zyQeWJO28MTj8iK86zSNFsTJU6GqyGpkNAFlTUy9KrqamU0mMlWng9KiVqUNUjROhq1Ec4qkrVZhPNAzq/BkZl1+yUfwsXP4A16yK8w+HUfma7u/55xM354H9a9PFXHYyluFFFFMkKKKKACiiigAooooAKKKKACiiigAooooADVHWNKtNXs2tr2Peh5UjhkPqD2NXqKAPFPFHhq70KQtKPOsifkuFHT2Ydj+hrnmBHB5FfRMsSTIySorowwysMgj3FedeKfARXfc6FyvVrVj/wCgH+hpWNFLuealCgzEQV/uHp+HpQkgLYGQ3dT1qaaNopXSRWilU7WRgQQfQioZFVxiQc9j0x9DSLJBIRUqTEDrVEmSP72XX1H3h9R3qRJAwypBHqKYGnFce9W4risRXOetSpNg8mmB0UN105q/Dd+9cvFce9W4rnpzQB1MdyD3qwkma5uG66c1diu6AN1TkUorNjuh61YW4HrQBbFLjFV1uAaf54IoAyJvDVlNrdzfzIrx3EYEkBGB5g48wEchscVq2dlbWcYS2gjjAG3IUZI9z3p/mjFIZR60ATYowKi87ik83PegRNwKMiofM96aZBRcCUmmMRimeZTC+aBiOxU7h1HIr0W3fzYI5P7yhvzFecE5Fd9ozFtKtSevligiZdooooMwooooAKKKKACiiigAooooApaxplpq9hJZahCs1vJ1B6g9iD2I9a8Z8UfDHVdOdpdFJ1G0HIjyFlUfTo34flXudFA07HynMk1rKY7qKSCQHlJVKH8jUkcgxX1BeWVrex+Xe20Nwn92VAw/WuZvPh14Zusn+zhCx5JhkZP60rD5jwtZKmV69bn+FOit/qLq/h/7aK38xUB+FFj/AAaneD6qp/pSsPmR5cHpwevUE+FViPv6ndn6Ko/pV+2+GehxY85ryc/7Uu0H8gKVmNSR5GsgB5IFb+haHqWryr9jtX8rvK/yoPx7/hXrWn+FdE09g1rptuH/ALzrvP5nNbQGAABgCnyiczF8L6BDodqVDebcyYMkuMZ9h6CtuiiqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMPxF4a0/XYj9qjKXAGEuIxh1/xHsa8o8SeGdQ0JyblBLaE4W4jB2/8AAv7pr3OmyIsiMjqrIwwQwyCKClJo+b9pH3eR6VG0as25SVk9R1/+vXqfij4fJIHudA2xSdWtXPyN/un+H6dPpXmN3DJbXb213E8Fwv3o5BtIpGikmQF3T/Wjj++o/mO1SKcgFSGX1FLyB6iozEpO6MlH9u/1HSgZKHxUySniqhZkP71Mj+8nP5jtT1IK7kIZfUUwNCOfHerUdz71jhsc5p6SmmBux3XvVlLv3rn1m96lWf0NKwHQpd+9Srd+9c+k5qVZzQBui5z3p4uPfNYqzVKs5pgbAnz3p4m96ykmNSCXipA0/No8ys9ZDUgc0wLvmUBs1VVjUqnmgCbPBr0XSk8vTbZfSMfyrzqMb2C9ckD869MiXZGiDooAoM5j6KKKCAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACszXNC07W7fytRt1lx9yQcOn+63UVp0UAeO+IfAOpaZvl0wtqNqOdgAEyj0x0b8OfauPBViQcq6nDAjBU+hFfSWKwfEXhTStfBa8g2XOMLcQnbIPx7/jmgtT7nhY3L7j9ajZEZty5R/UcH/69dZr3gXWdJzJar/adoP4ohiUD3Tv+H5VyySxyFkPEinDKwwVPpjqKC00xvzr95Q49V4P5UsZVjhW+b0PBqTaR0OR6GkIBGJF49xkUDF2kU8DpSIgx+7Zh7A5FSASDrsb8MUXAValXjvTUz/FGfwOamG3uHH4UwFQmplNMBUDr+lPXae+aAJkbJxU65qGPaO5/AVMp/2T/KkBMlSrUSk9gKkJCrukYKo7k4oAmXA6mpQQFLMQqjuaordBji3QzEfxdFH4/wCFamiaNcavdLvbMaH53AwifQdzSB6bmr4Ssnvr5bl1ItYDkZH3m7f413lQWVtFaWyQQLtjUcep9z71PTMW7sKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAGsPxB4V0jXxnULNTMPu3EfySr/wIc/geK3KKAPH9a+HGr2JaTRrlNQh6+VNiOUfQ/db9K4+7lk0+5+z6pbzWU3TZOm3P0PQ/ga+kKr3tlbX0BhvbeG4hPVJUDD8jQWps+ekaKTkYNShQPuuw/WvTdT+F2gXRZrEXOnSHkfZpPkz/utkfgMVzV58MNbtmP8AZ2r2l0gGQtxGY2P4rkfpQUpo5pd46Mh+oxUitIOqp+DVdm8IeLrY4bS45x6wXCH+eDVSTSvEMDbZNA1An1jj3j9DQO6HB3PWLP8AwMU5WkDDEbEf74qsw1KI4m0rUEI65t24p8LX0n+r02+f6W7f4UBcuCSTtEv4vUgac9oh+ZpkOn63KwCaJqPPdoSo/M1rWnhTxHcY3WcVup7zTKP0XNILozgJTw85A9EAWnJHAHHy+ZIemcux/Cuy0vwDtIfVr9pT/wA87ddi/mea63TtJsdNXFlbRxHuwGWP1J5oJc0cZoPhq5vSst8r21r1CHh3/D+EfrXeWlvFawLDbxrHEowFAqWimQ3cKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGKKKKACiiigAoxRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Aeroneb Go (Aerogen) is a type of mesh nebulizer that is portable, battery-operated, and has a small residual medication volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission. Copyright &copy; 2012 Aerogen. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_62_4079=[""].join("\n");
var outline_f3_62_4079=null;
